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Summary 
Nanoparticles offer an ideal platform for the delivery of small molecule drugs, subunit 
vaccines and genetic constructs. Besides the necessity of a homogenous size 
distribution, defined loading efficiencies and reasonable production and development 
costs, one of the major bottlenecks in translating nanoparticles into clinical application 
is the need for rapid, robust and reproducible development techniques. Within this 
thesis, microfluidic methods were investigated for the manufacturing, drug or protein 
loading and purification of pharmaceutically relevant nanoparticles. 
 
Initially, methods to prepare small liposomes were evaluated and compared to a 
microfluidics-directed nanoprecipitation method. To support the implementation of 
statistical process control, design of experiment models aided the process robustness 
and validation for the methods investigated and gave an initial overview of the size 
ranges obtainable in each method whilst evaluating advantages and disadvantages of 
each method. The lab-on-a-chip system resulted in a high-throughput vesicle 
manufacturing, enabling a rapid process and a high degree of process control. 
 
To further investigate this method, cationic low transition temperature lipids, cationic 
bola-amphiphiles with delocalized charge centers, neutral lipids and polymers were 
used in the microfluidics-directed nanoprecipitation method to formulate vesicles. 
Whereas the total flow rate (TFR) and the ratio of solvent to aqueous stream (flow rate 
ratio, FRR) was shown to be influential for controlling the vesicle size in high transition 
temperature lipids, the factor FRR was found the most influential factor controlling the 
size of vesicles consisting of low transition temperature lipids and polymer-based 
nanoparticles. The biological activity of the resulting constructs was confirmed by an in-
vitro transfection of pDNA constructs using cationic nanoprecipitated vesicles. Design 
of experiments and multivariate data analysis revealed the mathematical relationship 
and significance of the factors TFR and FRR in the microfluidics process to the 
liposome size, polydispersity and transfection efficiency. Multivariate tools were used to 
cluster and predict specific in-vivo immune responses dependent on key liposome 
adjuvant characteristics upon delivery a tuberculosis antigen in a vaccine candidate. 
The addition of a low solubility model drug (propofol) in the nanoprecipitation method 
resulted in a significantly higher solubilisation of the drug within the liposomal bilayer, 
compared to the control method. The microfluidics method underwent scale-up work by 
increasing the channel diameter and parallelisation of the mixers in a planar way, 
resulting in an overall 40-fold increase in throughput. Furthermore, microfluidic tools 
were developed based on a microfluidics-directed tangential flow filtration, which 
allowed for a continuous manufacturing, purification and concentration of liposomal 
drug products.  
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Abbreviations  
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1.1 Liposomes 
Liposomes were discovered by Bangham in 1965, initially being used as a model of cell 
walls to investigate receptors (Bangham et al., 1965). In 1974, Gregoriadis first 
described liposomes as a delivery vehicle for drugs and suggested their effectiveness 
as vaccine delivery systems (Allison and Gregoriadis, 1974). To date, liposome-based 
research and developed technologies have led to several candidates on the market 
and in clinical trials. 
 
By definition, liposomes are vesicles comprised of lipids. The amphiphilic structure of 
lipids combines a polar head groups and a hydrophobic carbon tail, leading to 
spontaneous formation of lipid bilayers when suspended in an aqueous medium (Lasic, 
1998). The orientation of the lipids triggers the assembly into vesicles with a closed-off 
aqueous core (Figure 1A). As the core component of the liposomes, lipids strongly 
influence the physicochemical parameters of the resulting liposomes, including surface 
charge and membrane rigidity (Watson et al., 2012), whereas the resulting size of the 
vesicles is not only dominated by the lipid composition but also dictated by the 
manufacturing method (Perrie et al., 2013).  
 
Liposomes are categorized by their vesicle size (diameter) and numbers of lipid 
bilayers usually ranging within 25 nm to 2.5 µm in size (Figure 1B) (Taylor et al., 2005). 
i) Small unilamellar vesicles (SUV); size ≤ 0.1 µm; single bilayer 
membrane. 
ii) Large unilamellar vesicles (LUV); size > 0.1µm; single bilayer 
membrane. 
iii) Multilamellar vesicles (MLV); size > 0.1µm; multi-bilayer membrane. 
iv) Multivesicular vesicles (MVV); size > 0.1µm; multi-bilayer membrane, 
incorporation of several vesicles into a singly bilayer. 
 
The bilayer vesicle structure of liposomes allows for the entrapment of hydrophilic 
components in the core of the vesicles as well incorporation of hydrophobic 
components incorporated within the lipid bilayer. Furthermore, components can be 
attached to the surface of the vesicles, based on electrostatic interaction or covalent 
bonding to lipophilic anchors incorporated into the lipid bilayer (Watson et al., 2012). 
The flexibility in different lamellarity structure and sizes of the vesicles, along with a 
range of lipid choices influencing the surface potential of the vesicles, liposomes 
comprise a flexible drug delivery method.  
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Figure 1.1: A) Schematic representation of a liposome, comprised of a bilayered lipid 
membrane. B) Schematic representation of liposome structures. 
 
1.1.1 The importance of liposome size 
The size of the liposomal vesicles dictates clearance and targeting in-vivo. A liposome 
with a diameter greater than 400 nm is quickly captured by the reticuloendothelial 
system (RES), whereas smaller vesicles (< 200 nm) are circulating longer after 
systemic administration (Liu et al., 1992; Maruyama et al., 1992). Due to greater 
capillary permeability in tumours, small liposomes accumulate and retain in well-
vascularized tumours, as described by the enhanced permeability and retention effect 
(EPR) (Maeda, 1992). In the design of liposomal adjuvants, the vesicle size is well 
known to affect the immune responses towards a Th1 or Th2 cytokine profile via a 
range of routes (Brewer et al., 2004; Brewer et al., 1998b; Carstens et al., 2011; Mann 
et al., 2009; Manolova et al., 2008). Where smaller particles promoted enhanced Th2 
responses, larger vesicles promoted typical Th1 responses (Brewer et al., 1998a; 
Mann et al., 2009), linked to differences in particle trafficking to local lymph nodes and 
uptake by antigen presenting cells (APCs).  
 
1.1.2 Liposomes as immunological adjuvants 
It was Gregoriadis in 1974 who first described liposomes to act as immunological 
adjuvants, despite little being known about the immune system (Allison and 
Gregoriadis, 1974). Since then, liposomes have been extensively developed and 
investigated for the delivery of a wide range of disease antigens (Christensen et al., 
2007b; Gregoriadis et al., 1987). The effectiveness of liposomes acting as 
immunological adjuvants is linked to their flexibility in delivering an antigen, which may 
be incorporated (Perrie and Gregoriadis, 2000) or associated into the bilayer (May et 
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al., 2000; McNeil et al., 2010). The ability to act as adjuvants for protein-based 
vaccines is further strengthened by the flexibility in formulation, the particulate nature 
and the versatility, all promoting a range of immune responses (May et al., 2000; 
McNeil et al., 2010).   
 
A successful subunit vaccine requires the delivery of the non-immunogenic antigen 
along with an immunstimulatory compound. In subunit vaccines, antigens are often 
highly purified proteins or peptides derived from pathogens, which lack an 
immunstimulation if delivered alone, and additional immunstimulatory compounds like 
lipids, proteins, peptides, DNA or RNA are required. As mentioned, liposomes allow for 
a range of designs, sizes, surface charges, and the incorporation of these 
immunstimulatory compounds in the interior, the bilayer, or the particle surface 
comprises a powerful delivery system of these components to APCs. Such 
immunstimulatory or –potentiating compounds are often (synthetic) pathogen 
associated molecular patterns (PAMPs), which are ligands for the pattern recognition 
receptors (PRRs). These are often specific to natural ligands from specific pathogens 
(Hafner et al., 2013). 
 
Cationic lipids interact with negatively charged molecules like nucleic acids (Karmali 
and Chaudhuri, 2007), proteins and peptides (Christensen et al., 2009). In comparison 
to encapsulation methods, the charged-based interaction between liposomes and 
target molecules is less time and cost consuming. Compared to neutral or negatively 
charged liposomes, cationic liposomes account for an enriched protection of anionic 
antigens as well as promoting the formation of a depot at the injection-site (Kaur et al., 
2012b). Furthermore, the positive charge enhances antigen uptake by dendritic cells 
and macrophages and antigen presentation (Lonez et al., 2008).  
 
It was Gall and colleagues who first described the immunological properties of cationic 
lipids in 1966 (Gall, 1966). The quaternary ammonium compound 
dimethyldioctadecylammonium bromide (DDA) is a synthetically derived amphiphilic 
molecule that consists of a hydrophilic positively charged dimethylammonium head–
group and a tail of two hydrophobic 18-carbon alkyl chains. DDA spontaneously form 
bilayer vesicles once exposed to an aqueous environment. The adjuvant effect was 
first described by Gall in the 1960s (Gall, 1966) and has to date been used as a  
liposomal subunit vaccine to trigger immune responses. DDA itself was shown to 
trigger a weak Th1 type immune response (Olsen et al., 2001). DDA-liposomes deliver 
the antigen to the cell surface and trigger efficient antigen uptake and presentation 
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(Smith Korsholm et al., 2007). Liposomes based solely on DDA were shown to 
efficiently induce humoral and cell mediated immune responses; however, physical 
instabilities has limited its use in adjuvants (Davidsen et al., 2005). For example, salt 
addition leads to aggregation observed in aqueous environment over time (Davidsen et 
al., 2005). In order to address considerations, a range of additional lipids have been 
investigated and evaluated to both improve stability and enhance efficacy of DDA 
liposomes. In particular, trehalose 6,6-dibehenate (TDB) has been used as an 
immunstimulatory compound in DDA-liposomes to enhance the immune response and 
vaccine efficiency (Smith Korsholm et al., 2007). TDB glycolipid consists of a 6,6’ -
diester of α-α’ trehalose with two 22-carbon acyl chains (behenic acids). TDB is a 
synthetic analogue of trehalose 6,6 -dimycolate (TDM); often referred to as cord factor; 
a component in the mycobacterial cell wall. TDM has a strong immunstimulating effect; 
the shorter fatty acid chains of TDB are associated with its lower toxicity (Davidsen et 
al., 2005). Without the addition of TDB, the liposomes were found not able to induce an 
immune response, while its incorporation induced strong immune responses (Nordly et 
al., 2011; Rosenkrands et al., 2005). 
 
Cationic DDA-TDB liposomes were shown to stimulate cell mediated immune response 
as well as an antibody response and TDB serves as a stabilizing agent for the DDA 
vesicles (Davidsen et al., 2005). The size of DDA-TDB vesicles was shown to influence 
the cell-mediated immune response (Henriksen-Lacey et al., 2011a). The cationic head 
group of DDA allows to target the negatively-charged cell membrane of APCs, 
stimulating the uptake of an associated protein antigen (Smith Korsholm et al., 2007). 
The incorporation of TDB furthermore enhances the immune response against a range 
of subunit vaccine antigens (Ishikawa et al., 2009; Werninghaus et al., 2009). 
 
The induction of the immune response strongly depends on the association between 
the adjuvant and the antigen. Studies have shown that DDA-TDB together with a 
negatively-charged tuberculosis antigen, Ag85B-ESAT-6 (H1 antigen) significantly 
increased the immune response once compared to the same antigen not associated to 
the adjuvant (Andersen and Doherty, 2005; Kamath et al., 2012). Furthermore, the 
combination of the cationic delivery system together with the negatively charged H1 
antigen remained localized at the site of injection, whereas an antigen, not able to 
electrostatically associate with the delivery system, was found in the draining lymph 
nodes (Henriksen-Lacey et al., 2010b). For the delivery of peptides similar results were 
observed. Peptides encapsulated in a vesicle or associated on the surface induced a 
Th1 immune response, whereas free peptide did not raise any immune response 
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(Guan et al., 1998). The adsorption onto the surface of the liposome further induced 
humoral immune response, opposed to peptide encapsulated within the vesicles (Guan 
et al., 1998). The combination of DDA-TDB liposomes with the H1 antigens is a 
promising candidate for a new TB vaccine currently in clinical trials (NCT 00922363); 
accompanied by strong protective immune responses (Andersen and Doherty, 2005; 
Henriksen-Lacey et al., 2011b). 
 
1.1.3 Liposomes as transfection agents 
Other than the delivery of proteins and peptides, liposomes have been extensively 
investigated as particulate systems for non-viral gene delivery (Allison and Gregoriadis, 
1974). Felgner showed in 1987 that cationic liposomes promote gene expression in-
vitro (Felgner et al., 1987). The incorporation of DNA into cationic liposomes resulted in 
high levels of gene expression (Karmali and Chaudhuri, 2007). The fusion of a cationic 
liposome with a negatively charged nucleic acid is referred to as lipoplex. Cationic 
lipids are the core of these gene delivery systems, which led to many cationic liposome 
mediated transfection studies (Fumoto et al., 2004; Majeti et al., 2004; Perrie et al., 
2002). Lipoplexes typically range within 80-400 nm, which strongly depends upon 
cationic lipid/DNA ratio, type of lipids used and method of preparation. 
 
The delivery strategy is based on the intracellular liposome mediated gene transfer, 
where DNA or other polynucleotides are translated to a protein or peptide. The cationic 
surface charge of lipoplexes mediates electrostatic interaction with the negatively 
charged cell wall. The incubation of lipoplexes with cultured cells triggers the release of 
the DNA into the cytoplasm after the uptake based on a vesicular pathway based on 
clathrin-mediated endocytosis, caveolae-mediated endocytosis or macropinocytosis 
(Uyechi-O Brien and Szoka, 2003; Wasungu and Hoekstra, 2006). DNA trafficked into 
the nucleus is transcribed and translated into the protein encoded by the DNA. The 
size of the DNA and the time of transfection was shown to influence the transfection 
outcome (McNeil and Perrie, 2006). Furthermore the charge and lipid/DNA ration have 
previously been shown to effect transfection efficiency (Aljaberi et al., 2007; Caracciolo 
et al., 2007). The commercially available LipofectinTM has been extensively used to 
transfect a wide variety of cells (Fortunati et al., 1996; Malone et al., 1989); made of 
1,2-dioleoyl-sn-glycero-3-phsphoethanolamine (DOPE) and N-[1-(2,3-
dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) (Felgner et al., 1987).  
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1.1.4 Liposomes for the solubilisation 
Besides the use of liposomes for the delivery of nucleic acids and aqueous soluble 
moieties, they are also well placed to act as solubilisation agents for drugs with low 
aqueous solubility. With currently more than 40% (Williams et al., 2012) of all new 
chemical entities in discovery having low solubility, this is of considerable interest. 
Drugs with low aqueous solubility effects bioavailability and efficacy (Savjani et al., 
2012; Williams et al., 2012). The therapeutic application of a drug with low aqueous 
solubility is associated with poor absorption, potentially leading to aggregates formed 
upon intravenous administration of the low solubility drug, leading to embolisation of 
blood vessels and potential failure of the respiratory system (Lukyanov and Torchilin, 
2004). Aggregation may further lead to local toxicity and lowered systemic 
bioavailability (Lukyanov and Torchilin, 2004). Poor aqueous solubility has been listed 
as one of the main challenges in the formulation industry (Muller and Keck, 2004). 
Therefore, solubilisation strategies are urgently required. Approaches to enhance the 
solubility include the adjustment of the pH of ionisable drugs, a function of the aqueous 
media conditions. Nevertheless, drugs without any ionisable moiety cannot be ionized 
by altering the pH. Co-solvents have been used to aid the solubility of drugs (Seedher 
and Bhatia, 2003) and polyethylene glycol has been described to enhance the solubility 
of sparingly soluble drugs (Nandi et al., 2003). Furthermore, solid dispersions maybe 
used to improve the oral bioavailability of poorly water soluble drugs using melting or 
evaporation methods (Vasconcelos et al., 2007). Solubilizing a low solubility drug in the 
bilayer of liposomes allows the solubilisation in aqueous media, protection from 
degradation and control of the drug distribution profile along with aiding the therapeutic 
efficacy. The advantage of using liposomes as solubilisation vesicles is linked to their 
particulate nature, the ability for targeted delivery and the flexibility in range of lipids 
incorporated. Research on using liposomes as solubilizing agents has shown that drug 
incorporation and release rates were strongly linked to the properties of the drug as 
well as the lipid concentration and the choice of lipids (Ali et al., 2010; Ali et al., 2013; 
Mohammed et al., 2004). The molecular weight of the drug, as well as the log P, were 
important factors influencing the effective loading of liposomes (Ali et al., 2013). 
Furthermore, the lipophilic volume was shown to enhance the loading of a low solubility 
drug into liposomes by using longer alkyl chain lipids (Mohammed et al., 2004; Ali et 
al., 2013). Other than the chain length, the charge of the lipids was shown to impact the 
loading efficiency, as like-charged lipids result in electrostatic repulsion of drugs 
(Mohammed et al., 2004). Given cholesterol being well known to enhance the stability 
of vesicles, it was further shown to reduce bilayer drug loading, giving its space-filling 
action in the bilayer membrane (Ali et al., 2010). Furthermore, the incorporation of 
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cholesterol into the lipid bilayer shifted the drug release profile from a zero-order (when 
no cholesterol was present) to first order (when 11 to 33 mol% of cholesterol was 
incorporated). Following, the membrane could be associated more porous without the 
incorporaion of choleterol, whereas the incorporation of cholesterol rendered the 
membrane into a more condensed and less-permeable bilayer (Ali et al., 2010).   
 
1.1.5 Traditional liposome manufacturing methods 
The method of vesicle manufacturing can be a dominating factor influencing the 
resulting particle size (Table 1.1). All methods rely on the assembly of the vesicles 
based the exposure of the amphiphilic lipid molecules to an aqueous buffer system 
(Taylor et al., 2005). Generally, traditional manufacturing methods rely on a “top-down” 
method, comprising the manufacturing of initially large vesicles, which are sequentially 
reduced in size and lamellarity by mechanical methods.  
 
For example, the lipid film hydration method (first described in 1961 by Alec Bangham 
(Bangham, 1961; Bangham et al., 1965)) involves a mixture of lipids being dissolved in 
a solvent, often chloroform or a mixture of chloroform and methanol. Solvent removal 
via rotary evaporation results in the formation of a dried lipid film on the wall of the 
round bottom flask. Nitrogen is further used to remove any residual solvent left prior to 
addition of the aqueous phase. This hydration step is key in forming the vesicles, aided 
by mechanical agitation and performed above the transition temperature of the lipids 
(Bangham et al., 1965; Szoka Jr and Papahadjopoulos, 1980). Mechanical stresses, 
such as vortexing result in the rearrangement of the lipids and budding into MLV by 
swelling lamella from the flask bottom. The resulting vesicles are generally quite 
polydisperse and relatively large, ranging up to several microns in size. The resulting 
size is primarily dictated by the choice of lipids, the aqueous hydration buffer and the 
temperatures adopted during vesicle formation (Bangham et al., 1965; Gregoriadis et 
al., 2002). A molecule of interest may be added into the aqueous hydration buffer or in 
the solvent phase, leading to encapsulation in the aqueous core or into the lipid bilayer 
respectively. Nevertheless, reported encapsulation efficiencies are usually low (Riaz, 
1996) and the hydration time was found as a contributing factor controlling the 
encapsulation efficiency time (Bangham et al., 1965). Other methods used that result in 
the formation of large vesicle structures include reverse-phase evaporation and 
depending on the size range required, injection methods may also produce a range of 
liposome sizes as required (Table 1.1). To reduce vesicle sizes, subsequent 
mechanical methods are used. These methods often rely on shear or pressure forces, 
including a microfluidisation, high-pressure homogenisation or other shear force-
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induced homogeniser (Szoka Jr and Papahadjopoulos, 1980; Wagner and Vorauer-
Uhl, 2010). Those methods introduce a high and controlled pressure, disrupting the 
MLV and leading to the formation of SUV in a continuous and scalable process setup 
(Wagner and Vorauer-Uhl, 2010).  Pressures are as high as 20 000 psi, where forcing 
MLV thorough a small gap and collision with a stainless steel wall results in smaller 
vesicles generated (Barnadas-Rodrı́guez and Sabés, 2001; Bergstrand et al., 2003). 
Often, several cycles are required to yield a homogenous and final size distribution; the 
option of continuous processing accomplishes this. During an extrusion method, MLV 
are lead through a membrane, filter or mesh with desired pore size. The pressure can 
be adjusted to yield the final size distribution, which is often dictated by the pore size 
and the number of recirculation runs (Riaz, 1996). The sonication method is another 
frequently applied method, mainly used in research and development processes. A 
probe or a bath sonicator breaks up larger vesicles into smaller ones, and the process 
runs at temperatures above the transition temperature of the lipids (Wagner and 
Vorauer-Uhl, 2010). The main disadvantages of these methods is the lack of scalability 
and relatively low encapsulation efficiencies and drug loading (Riaz, 1996). 
Furthermore, lipids subjected to the sonication power might degrade and the direct 
contact with the probe tip results in a contamination with metal residues. The high-
energy input is required for breaking up larger vesicles into smaller ones. Heat 
developing during the process might be a further problem for heat sensitive material. A 
bath sonication process circumvents the contamination by metal residues, maintaining 
the sterility in the formulation (Kataria et al., 2011). In contrast to the mechanical top 
down method, methods around fluidic control can be summarized as bottom-up 
methods (Table 1.1). The ethanol injection method was the first one reported in the 
1970s by Batzri and Korn (Batzri and Korn, 1973). Lipids are initially dissolved in a 
solvent, followed by rapid injection of the solvent into an aqueous buffer stream. The 
precipitation of the lipids leads to the formation of vesicles. The method itself is 
relatively simple; however, results are dictated by the solubility of the lipids in the 
water-miscible solvent, which strongly influences resulting homogeneity. Furthermore, 
solvent residues remain. These are removed by heating in the similar ether-injection 
method. Using this type of method, encapsulation efficiencies within liposomes may be 
relatively high for hydrophobic drugs, where the encapsulation of a hydrophilic drug is 
generally relatively low due to the high volumes of aqueous phase and resulting dilution 
(Jaafar-Maalej et al., 2010). However, this type of methods can generally be 
considered scalable, simple and highly applicable for a large-scale process. Indeed, 
the control of lipid sizes has been reported in an adaptive method, called inkjet method 
(Hauschild et al., 2005). 
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Table 1.1: Overview of traditional methods of liposome manufacturing, adapted from (Kastner et al., 2015). 
 
Method Advantages Disadvantages Vesicles Sizes reported Ref. 
M
e
c
h
a
n
i
c
a
l
 
m
e
t
h
o
d
s
 
Rotary evaporation Easy 
Simple 
Organic solvent residue 
No control over vesicle size 
Additional method for size 
reduction required 
Heterogeneity 
Low encapsulation  
MLV Up to several 
microns 
 
(Bangham, 1961) 
“Top-
down” 
methods 
Homogenization, 
extrusion, high 
shear mixing 
Easy 
Simple design 
Bulk production 
Continuous 
High pressures 
Heat generation  
Filter clogging (extrusion 
method) 
SUV Dependent on 
no of cycles and 
pressure 
(Bally et al., 1991) 
Sonication Easy 
Relatively quick  
 
Sterility 
Degradation 
Low encapsulation 
Limited scalability 
SUV > 90 nm (Wagner and Vorauer-Uhl, 
2010) 
Reverse phase evaporation High encapsulation efficiencies  Contact with organic phase 
Time intensive 
Limited scalability 
LUV Intermediate nm 
to um 
(Meure et al., 2008) 
F
l
u
i
d
 
c
o
n
t
r
o
l
 
“
b
o
t
t
o
m
 
u
p
”
 
m
e
t
h
o
d
s
 
Injection Ethanol injection Rapid, easy 
No special equipment required  
High encapsulation of 
hydrophobic drugs 
Solvent residue 
Dilution 
 
 
SUV Dependent on 
needle diameter 
pressure and 
concentration < 
100 nm 
 (Batzri and Korn, 1973) 
 (Jaafar-Maalej et al., 2010) 
Ether injection Size controlled SUV 
Higher encapsulation 
efficiencies 
SUV 100-300 nm (Deamer and Bangham, 
1976) 
(Deamer, 1978) 
Inkjet Small unilamellar SUV 
Loading in combination with 
liposome formation 
High reproducibility 
SUV 50 – 200 nm  (Hauschild et al., 2005) 
Supercritical fluid Very small particles reported High costs 
High pressures 
Encapsulation lower than with 
conventional methods 
SUV >25 nm  (Frederiksen et al., 1997) 
(Karn et al., 2013) 
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1.2 Microfluidics  
1.2.1 Background  
Despite all the advances in the application of liposomes they are limited by their 
manufacturing methods and new systems for reproducibly vesicle manufacturing are 
needed. 
 
Microfluidic devices comprise fluid handling in a constrained volume, achieving 
millisecond mixing at the nanoliter scale (Demello, 2006; Song et al., 2008). The area 
of microfluidics and its associated development of novel lab-on-a-chip based devices 
considerably gained attention over the past decades (Nguyen and Wu, 2005). 
Microfluidics is a complex area; besides the fundamentals of physics and chemistry, 
mass transport, heat and mass transfer, fluid flow, thermodynamics, elasticity, 
electrostatics are important areas incorporated (Squires and Quake, 2005). 
Characterisation of the fluid flow in micromixing is essential for understanding its 
impact to the mixing performance. It is important to understand that a micromixer is not 
just a copy of a mixer at larger size. The design has to leverage physical characteristics 
as far as possible (Capretto et al., 2011). With an increasing number of liposomal 
products in clinical trials and development (Chang and Yeh, 2012) the demand for 
rapid process development tools rises, emphasised by several microfluidic-based 
methodologies in drug development (Dittrich and Manz, 2006; Hood et al., 2014a; 
Weigl et al., 2003; Whitesides, 2006). Microfluidic-based technologies offer an 
enhanced control over processing conditions, thus yielding a set-up for reproducible 
and robust manufacturing, which is required to achieve uniform liposome size 
distributions; at the same time, the miniaturisation makes efficient use of materials. 
Whilst reducing volumes during development processes, costs can be diminished 
whereas throughput is increased (Jensen, 2001; van Swaay, 2013; Weibel and 
Whitesides, 2006). 
 
1.2.2 Microflow physics  
1.2.2.1 Dimensionless numbers  
Dimensionless numbers describe fluid flow patterns and physical phenomena for flow 
characterisation. The Reynolds Number (Re) is one the most frequently used 
dimensionless numbers in fluid flow. Describing the ratio of inertia to viscous forces it is 
used to determine whether fluid flow is categorised as laminar or turbulent (Figure 1.2). 
Determination of the Re number includes the assessment of the characteristic length 
  Chapter 1: Introduction 
43 
 
L0, which differs according to system studied; for mixing in a channel or pipe, the 
characteristic length is described by the channel diameter (Equation1.1).  
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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  Equation 1.1 
With  
L0 Characteristic length  
u Fluid velocity  
Dh Hydraulic channel diameter  
ν Kinematic viscosity  
µ Dynamic viscosity  
ρ Fluid density  
 
 
Figure 1.2: Flow profile around a cylinder for increasing Re numbers. 
 
Due to small characteristic length in micromixing devices, Re numbers are usually 
small (< 100) and generally fall into laminar flow regime (Capretto et al., 2011). At such 
low Re numbers, mixing is dominated by diffusion, considerably taking a long time. 
Besides diffusion, advection dominates mixing performance in microchannels (Das and 
Chakraborty, 2009) indicated the difference transition number from laminar to turbulent 
applicable for microfluidic mixing. The Peclet number (Pe) expresses ratio of 
convection to diffusion and is used to characterize the nature and strength of diffusion. 
The Pe number is used to calculate the approximate number of channel widths in 
length that is required for achieving diffusive mixing. At high Pe numbers, advection is 
dominant in a fluid (Equation 1.2). The characteristic mixing length grows linearly with 
Pe (Stroock et al., 2002).  
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With  
L0 Characteristic length  
u Fluid velocity  
w Channel diameter  
D Diffusion coefficient  
 
1.2.2.2 Micromixer characterisation  
Both Re and Pe numbers are strongly influenced by the channel diameter; which 
underlies its significance in microfluidic mixing and mixer characterisation. The channel 
geometries significantly affect diffusion and are hence a key point of interest for the 
design of a microfluidic channel. The aim is to decrease the mixing path and increase 
the contact surface area (Capretto et al., 2011). As described above, the Re numbers 
in microfluidic channels are generally laminar and typically smaller than 100. Hence, 
mixing in microchannels is mainly dominated by passive molecular diffusion and 
advection. Diffusion describes a transport phenomena based on the Brownian motion 
of molecules; molecules spread from higher to lower concentrations and within a 
certain time achieve equilibrium. Diffusion hence results in gradual mixing of molecules 
and can be described by Fick's Law (Equation 1.3) (Capretto et al., 2011). 
 = −


  Equation 1.3 
With 
 Molecule concentration 
x Molecule position 
D Diffusion coefficient 
 
For the assumption of simple spherical particles, Einstein-Stokes equation is used to 
derive the diffusion coefficient (Equation 1.4). 
 =	


  Equation 1.4 
With 
 Viscosity of the medium 
k Boltzmann constant 
T Absolute temperature 
R Radius of the particles 
 
A molecule requires a certain time to diffuse, whereas the diffusion process itself is a 
nonlinear which is modelled into Equation 1.5 (Capretto et al., 2011). 
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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   Equation 1.5 
 
With 
t Average time for a molecule to diffuse over the distance x 
x Stream width in channel 
 
Equation 1.5 indicates the importance of the channel width in microfluidic mixers. As 
the stream width varies with squares power, an increase in channel width drastically 
affects the diffusion process and hence leads to an increase in time till mixing can be 
sufficiently achieved. Hence, diffusion actually becomes a variable in microfluidic 
mixing (Capretto et al., 2011).  
 
1.2.3 Classification active passive micromixers  
In order achieve complete diffusive mixing, devices have been developed to decrease 
mixing length. Developed micromixers can be classified into active and passive 
micromixers (Capretto et al., 2011). Active micromixers require an input from an 
external energy source; this can be pressure-driven, temperature-induced or ultrasonic-
driven. Active micromixers are categorized by their energy input or disturbance, 
meaning pressure, electrokinetics, dielectrophoretic, electrowetting, magneto-
hydrodynamic or ultrasound (Nguyen and Wu, 2005). Despite high mixing efficiencies 
in active micromixers, their engineering setup can be quite complex. The incorporation 
of the external power source into the microfluidic mixing chamber or device is cost and 
time intensive, with resulting restricted application in industry. Besides, high 
temperatures or ultrasonic applications might lead to damage of biological materials 
(Capretto et al., 2011).  
 
So called passive mixers (Table 1.2) do not require an additional external energy 
source to achieve mixing, but use the fluid flow and specially designed micro-structures 
that enhance diffusion and advection processes (Nguyen and Wu, 2005). In order to 
maximize diffusion by decreasing the diffusion path and increasing the surface area 
between different fluids, passive micromixers often undergo extensive channel 
engineering to modify the flow pattern. Engineering activities, including the splitting of 
fluid flow streams, introduction of bubbles or gas, alterations in channel design, width 
and shape by introduction of grooves, lead to a number to extensively altered 
micromixing chambers. Their integration to lab-on-a-chip based devices is easier; as 
no external power source has to be incorporated (Capretto et al., 2011).  
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Table 1.2: Selection of common passive micromixers 
 
Passive 
Micromixer 
Mixing principle Type References 
T- and 
Y-shaped 
To stream are guided in one 
flow path; mixing solely by 
diffusion and hence generally 
slow 
 (Gobby et al., 2001) 
Parallel 
lamination 
Split of inlet stream into a 
number of sub-streams and 
their rejoin.  Enhanced mixing 
by increased surface area and 
decreased diffusion length 
Bifurcation-type feeds, 
Interdigital-type feeds, 
Chessboard micromixer, 
Circular micromixer 
(Erbacher et al., 1999) 
Sequential 
lamination 
Sequential splitting and 
recombination and 
rearrangement of fluid streams 
Split-and-recombine 
micromixer, crossing 
manifold micromixer 
(Lee et al., 2003) 
Flow 
focusing 
Hydrodynamic focusing of the 
middle inlet stream by two 
outer fluids, leading to 
decreased lamination width of 
the inner stream 
Horizontal and vertical flow 
focusing devices 
(Wu and Nguyen, 
2005) 
 
Chaotic 
advection 
Increase in interfacial area by 
altering channel shapes (split, 
stretch, fold, break) to alter 
flow direction and induce 
whirls and chaotic flow, 
grooved pattern in channel 
design 
Slanted groove micromixer, 
staggered herringbone 
micromixer, connected-
groove micromixer, 
circulation disturbance 
micromixer ,3D serpentine 
micromixers, zig-zag 
micromixer 
(Stroock et al., 2002) 
Droplet Microdroplet generation by 
electric fields, micro-injectors 
or needles or multiphase  
flows, droplets lead to 
reduction in diffusion length 
and generation of recirculating  
flow in the droplet 
T-junction droplet generator, 
planar serpentine 
micromixer  
(Quevedo et al., 2005) 
 
 
1.2.3.1 Staggered herringbone micromixer  
The low Re numbers, as described earlier, have been the basis for engineering of 
novel micromixers. Stroock et al described a method for introducing chaotic flow even 
at low Re numbers (0 < Re < 100). The staggered herringbone micromixer (SHM) is a 
micromixer based on patterns of grooves in the channel floor (Figure 1.3A). The design 
introduces a chaotic flow in a microchannel by subjecting the fluid to repetitive series of 
a rotational flow profile, which is achieved by alteration of the grooves as a function of 
the axial position in the channel. Characterisation work by Stroock et al. (2002) 
determined the orientation of grooves in the floor changing after a half cycle in the 
design. This “centre of rotation” is hence changed along with the local extensional flow 
in the transverse flow (Stroock et al., 2002). 
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A B 
 
 
C 
 
Figure 1.3: A) Schematic zoom into the microfluidic chip of a SHM. B) Schematic of six 
grooves per half cycle of a SHM. C) Schematic streamlines in the cross section of the 
channel with the angle ∆φm as the angular displacement of the fluid volume along the 
wide arms of the herringbones. h= height of chamber, w= width of chamber, dg = depth 
of grooves, wg = width of grooves, p = asymmetric factor, c = centre of rotation, θ= 
angle of grooves, pw = asymmetry factor over the width of the long herringbone arms. 
 
The mixing efficiency is characterised and controlled by the asymmetry of the 
herringbones as well as the rotational amplitude (Figure 1.3 B and C). The asymmetry 
of the herringbones is determined as p. p approaches one-half for symmetric 
herringbones, which results in a non-chaotic flow. Ideally, p approaches 2/3, which 
involves the majority of the cross sectional area in the chaotic flow. The rotation 
amplitude of the fluid at half a cycle is determined as ∆φm (Figure 1.3C). This angular 
displacement is controlled by the design and number of the grooves per half cycle. A 
non-chaotic flow results for ∆φm approaching zero. Ideally, ∆φm= 60° C; involving the 
majority of the cross sectional area in the chaotic flow (Stroock et al., 2002). 
 
The flow in the SHM design was found independent of Re for Re<100 (Stroock et al., 
2002). When mixing two streams, the design allows for a rapid increase in the number 
of filaments, and the respective decrease in the filament thickness as a function of 
mixing cycles. Confocal micrographs showed the distribution of fluorescent molecules 
in the cross sectional area of the channel; the increase in number of filaments as well 
as the decrease of the thickness of fluid layers correlates with increases in mixing 
cycles. With increase in cycles the fluid layers are folded on top of each other, aiding 
mixing (Stroock et al., 2002). The design from Stroock et al. showed that even at high 
Pe numbers (9x105) mixing occurs.  
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1.2.4 Microfluidics for liposome manufacturing 
The application of microfluidic tools for liposome manufacturing is based on the theory 
of a nanoprecipitation reaction. Nanoprecipitation produces nanoparticles in a one-step 
process (Bally 2012). The process has been described as the formation of particles 
sub-micron size at right polymer concentration and high enough ratio between aqueous 
to solvent flow (Stainmesse et al., 1995). This work was taken further, defining the 
nanoprecipitation process relying on a nucleation process, based on chemical 
instability (Mora-Huertas et al., 2011). The solvent needs to be miscible with the non-
solvent phase, which is usually a buffer. Due to the mixing process of the two streams, 
molecules dissolved in the solvent phase are diluted, and this drastic dilution in the 
aqueous phase leads to the formation of precipitated molecules (Zook and Vreeland, 
2010). With less solvent available for solubilisation of the hydrophobic chains, the 
closure time for the vesicle decreases, triggering the precipitation process and the 
formation of nanoparticles. With more solvent remaining present during the mixing 
process, hydrophobic components remain stabilised for a prolonged time. A dialysis 
tubing can be used to drive the nanoprecipitation method (Figure 1.4A) (RemziáBecer, 
2009). The method was used in a larger-scale format (volumes of 20 mL per batch) 
where solvent phase was added dropped into an aqueous phase, stirred magnetically, 
after which evaporation of the solvent was conducted (Govender et al., 1999) (Figure 
1.4B). Opposed to the top-down methods, no further disruption of the resulting 
nanoparticles is required and the method is categorized as a bottom-up method. 
 
Figure 1.4: Schematic depiction of the nanoprecipitation method by A) dialysis method 
and B) dropping method. 
 
Recently, the method has been transferred onto microfluidic platforms taking 
advantage of the high-throughput systems. Opposed to the initial larger scale methods, 
microfluidics allows for a controlled input of fluid streams in micro-sized flow channels. 
Given the theory of nanoprecipitation, an aqueous volume is required in order to trigger 
the precipitation of the amphiphilic molecules. Microfluidic mixing allows for a controlled 
mixing of solvent and aqueous phase in a rapid process. The alteration of the flow 
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channel, e.g. by aiding the diffusion process in a chaotic advection micromixer further 
enhances this mixing process. Using a microfluidic-sized flow channel allows for a tight 
control of flow rates, and opposed to the ethanol injection method (Batzri and Korn, 
1973), gives a controlled precipitation method on a small footprint, well suited for a 
high-throughput screening. Compared with process optimisation on a larger scale, 
process development with microfluidic devices allows for a better control of mixing 
efficiencies, which at this scale is predominantly based on molecular diffusion. The 
increased surface-to-volume ratios generate fast mixing times by minimizing 
dimensions and diffusion lengths (Lee et al., 2011; Mengeaud et al., 2002) 
accompanied with a reduced time for sample handling (Weigl, 2003).  
 
Figure 1.5: Overview of the chaotic advection SHM method and the flow focusing 
method. 
 
Early work focused on the use of a flow-focusing technique on a microfluidic platform. 
This platform resulted in successful formation of liposomes in size ranges from 35 – 
180 nm (Jahn et al., 2007; Valencia et al., 2010). Here, the lipid-solvent stream was 
centred between two streams of aqueous buffer, where mixing occurs at the interfaces 
primarily dominated by diffusion (Figure 1.5). The nanoprecipitation method was 
adapted into a multilamination micromixer for the production of polymer nanoparticles 
(Bally et al., 2012). A chaotic advection micromixer has been initially described for the 
nanoprecipitation of liposomes, now commercialized by Precision Nanosystems Inc. A 
SHM mixer resulted in limit-size synthesis of lipid based nanoparticles. Variations in 
flow rate and flow rate ratios led to the engineering of liposomes in the range of 20-80 
nm for small interfering RNA (siRNA) delivery (Belliveau et al., 2012; Zhigaltsev et al., 
2012).  
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1.3 Statistical tools for reproducible manufacturing 
In addition to new methods for vesicle manufacturing, systems can be more effectively 
developed using statistical tools. In the traditional one-factor-at-a-time (OFAT) method 
only one factor is optimised while all other factors remain constant (Figure 1.6), overall 
a very time intensive method, which might lead to overlooking the optimum process or 
factor-interactions (Montgomery et al., 1997).  Design of experiments (DoE) is a 
statistical optimisation method applied in pharmaceutical and biopharmaceutical 
process development and optimisation (Lawrence, 2008; Singh et al., 2011; 
Vandervoort and Ludwig, 2002). The difference to the OFAT method lies in a 
systematic approach of creating structured experiments, where the effect of changes in 
a factor is related to a response (Figure 1.6). Here, a minimum number of experiments 
performed leads to enhanced process understanding and overall aiding the process 
robustness and product quality. Factors and responses are the basis of a DoE, defining 
the variables in the process and the outcome that is measured qualitatively or 
quantitatively. The selected factors manipulate the system and effect the responses. In 
a DoE, the variation in a factor is mathematically linked to the resulting responses. 
Besides assessing the statistical significant factors (main effects), a possible interaction 
between the factors is identified (Eriksson, 2008; Mandenius and Brundin, 2008).  
 
Figure 1.6 Schematic depiction of screening of two factors; left: screening one factor at a 
time resulting in 5 experiments. Right: Designed experiment with only one experiment. 
  
Multivariate analysis (MVA) is a tool used to analyse more than one statistical variable 
at a time. The dimensionality in a data set is reduced, allowing for identifying patterns 
and relationships between several variables (Wold et al., 2001a; Wold et al., 2001b). 
MVA is frequently used for data analysis, mining, classification (e.g. cluster analysis or 
outlier detection), regression analysis and predictive modelling and allows to link the 
effect of alteration in one variable to other variables (Eriksson, 2006; Pasqualoto et al., 
2007; Rathore et al., 2011).  
 
The accumulation of large data sets is linked to advances in analytical high-throughput 
methodologies being developed. The challenge lies in the extraction of valuable 
information from such large data quantities in a reasonable timeframe. Besides 
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analysing only one variable at a time, MVA allows to incorporate the analysis of several 
variables simultaneously, representing a flexible and multipurpose data analysis 
method. The analysis allows generating an overview in a data set and classifies and 
compares groups of data by regression modelling. Similar to DoE, variables (X) and 
responses (Y) are defined. MVA handles several variables simultaneously, extrapolate 
from limited data sets and is robust to noise in the responses or variables (Eriksson, 
2006). The analysis commences with fitting a principal component (PC) through the 
multidimensional space in order to approximate the best data fit (Figure 1.7 A and B). 
Usually at least two PCs are computed orthogonal to each other. A principal 
component analysis (PCA) allows for grouping of the data, generating an overview and 
identifying trends, groups and outliers (Jackson, 2005; Wold et al., 1984). The PCA 
results in a correlation between the observations and identifies sudden shifts or trends 
in the data set and the relationship between the X-variables is identified (Figure 1.7 C). 
The addition of the Y-variables in a partial least square (PLS) analysis includes the 
responses in a system or measurement, aiming to predict Y from X. PLS links the 
influence of the factor variation to the responses and identifies the controlling or most 
influential factors that are desired to achieve a certain response (Wold et al., 1984; 
Wold et al., 2001a; Wold et al., 2001b). 
A B C 
 
 
 
 
Figure 1.7: Overview over a MVA process with A) data scattered in a multidimensional 
space, B) two PCs are fitted and C) projection of the data and the PCs onto a plane. 
 
The combination of such theoretical models with experimentally obtained data provides 
extra information and overall leasing to an enhanced confidence level. Both statistical-
based tools, DoE and MVA, allow building knowledge around a specific research 
application, aiming to enhance the robustness of a process with generally fewer 
experiments required for identifying the local optima. Identified factor interactions can 
be used for process simulation and predictions in an overall cost-effective method 
(Singh et al., 2005). Generally, the combined application of multivariate methods with 
experimental design allows identifying process optima by accelerating the developing 
process. 
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1.4 Aim and Objectives 
Given the need to support the translation of liposomal products into the clinical 
application in a cost-effective manner, the overall aim of this thesis was to explore 
methods for manufacturing SUV and investigate the potential of microfluidics for the 
manufacturing and purification of liposomes and nanoparticles. Microfluidics was 
assessed as a bottom-up method in drug and protein delivery to better understand the 
link between manufacturing method and formulation outcome.  
 
To achieve this aim, the main objectives of this thesis were to: 
1. Compare and evaluate three different methods for manufacturing SUV 
(sonication, high shear mixing and microfluidics) and assess the resulting 
physicochemical particle characteristics using statistical process modelling by 
DoE. 
2. Investigate the microfluidics-based nanoprecipitation method for the 
manufacturing of liposomes comprised of low transition temperature lipids for 
gene transfer and in-vitro transfection efficiencies. 
3. Investigate the microfluidics-based nanoprecipitation method for the 
manufacturing of DQAsomes comprised of cationic bola-amphiphiles 
(dequalinium) for gene transfer and in-vitro transfection efficiencies. 
4. Investigate the microfluidics-based nanoprecipitation method for the 
manufacturing of polymer-based nanoparticles for the delivery of protein.  
5. Investigate the microfluidics-based nanoprecipitation method for the 
manufacturing of liposomes comprised of low transition temperature lipids for 
the solubilisation of a drug with low aqueous solubility. 
6. Investigate the scalability of the microfluidics-based nanoprecipitation method 
by alteration of the channel geometries and mixer parallelisation in a continuous 
flow setup. 
7. Investigate the microfluidics-based nanoprecipitation method for the 
manufacturing of liposomes comprised of high transition temperature lipids DDA 
and TDB in an adjuvant formulation. 
8. Investigate and implement MVA to statistically relate the physicochemical 
adjuvant characteristics of DDA-TDB liposomes to in-vivo derived immune 
responses upon delivery of a tuberculosis antigen. 
9. Design and implement a microfluidics-based purification method based on 
tangential flow filtration and combination into a continuous manufacturing setup.  
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2.1 Materials 
Material / Chemicals Supplier 
1,1'-(decane-1,10-diyl)bis(9-amino-
1,2,3,4- tetrahydroacridinium) diiodide 
(CM2)  
Procarta Biosystems Ltd., Norwich, UK 
1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP) 
Avanti Polar Lipids, Alabaster, AL, USA 
1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate) 
(DilC) 
Sigma-Aldrich, Poole, Dorset, UK 
1,2-dioleoyl-sn-glycero-3-
phsphoethanolamine (DOPE) 
Avanti Polar Lipids, Alabaster, AL, USA 
1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) 
Avanti Polar Lipids, Alabaster, AL, USA 
12 % Tris-glycine gels Invitrogen, CA, USA 
12-well plates Greiner Bio-One Ltd, Gloucestershire, 
UK 
2,2’-azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid) 
Sigma-Aldrich, Poole, Dorset, UK 
2,6-Bis(isopropyl)phenol (Propofol) Sigma-Aldrich, Poole, Dorset, UK 
3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H tetrazolium (MTS) 
Sigma-Aldrich, Poole, Dorset, UK 
96-well plates Greiner Bio-One Ltd, Gloucestershire, 
UK 
Acetonitrile Fisher Scientific, Leicestershire, UK 
African green monkey kidney cells (COS-
7) 
European collection of cell cultures 
(ECACC), Salisbury, UK 
BALB/C mice Charles River, Margrate, UK 
Capillary I.D. 100 µm Postnova Analytics GmbH, Lech, 
Germany 
Capillary I.D. 50 µm VICI AG International, Schenkon, CH 
Capillary I.D. 63 µm IDEX Health & Science, WA, USA 
cell harvester Titertek Instruments, Alabama, USA 
Cell IQ CM Technologies OY, Finland 
CellTiter 96® AQueous
 
One Solution Cell Promega, Madison, WI, USA 
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Proliferation Assay 
Centrifuge  Universal 32 Hettich Lab Technology, Tuttlingen, 
Germany 
Centrifuge MSE Mistral 3000i DJB Labcare Ltd,. Buckinghamshire  UK 
Chloroform Fisher Scientific, Leicestershire, UK 
Cholesterol Sigma-Aldrich, Poole, Dorset, UK 
CO2 laser Synrad Inc., Mukilteo, WA, USA 
Colouring agent 2,2’-azino-bis (3-
ethylbenzthiazoline-6-sulfonic acid) 
ABTS; Sigma, Dorset, UK 
Column Jupiter 300 C18(2)  Phenomenex, Cheshire ,UK 
Column Luna C18(2)  Phenomenex, Cheshire ,UK 
Concanavalin A Sigma-Aldrich, Poole, Dorset, UK 
Continous Flow pumps Flash 100  Scientific System Inc (SSI), PA, USA 
Cytometer FC500 Beckman-Coulter, High Wycombe, UK 
Delbecco’s Modified Eagles Medium 
(DMEM) 
Biosera, Leicestershire, UK 
Dialysis tubing Medicell, London, UK 
Dihydroxyvitamin D3  Enzo Life Sciences, Exeter UK 
Dimethyldioctadecylammoniumbromide 
(DDA) 
Avanti Polar Lipids, Alabaster, AL, USA 
DuoSet ELISA development kit R&D Systems, Oxfordshire, UK 
Ethanol Fisher Scientific, Leicestershire, UK 
Evaporative light scattering detector 
(ELSD) 
Sedere, Alfortville, France 
Foetal bovine serum (FBS) Biosera, Leicestershire, UK 
Fusion protein Ag85B-ESAT-6-Rv2660c 
(H56 antigen) 
Statens Serum Institut, Copenhagen, 
Denmark 
Gas Chromatography (GC) CSi 200 Cambridge Scientific Instruments Ltd, 
Witchford, UK 
Gasket TFF Sylgard 184 Dow Corning, Midland, USA 
GC column TRACE, 15 m x 0.25 mm x 
0.25 µm 
Fisher Scientific UK Ltd , 
Loughborough, UK 
GeneFlash gel photoimager Syngene bioimaging, Cambridge, UK 
Goat anti-mouse IgG, IgG1, IgG2b AbD Serotec, Oxford, UK 
gWizTM Luciferase Aldveron Freiburg GmbH, Freiburg, 
Germany 
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High shear mixing apparatus, 
SilentCrusher M 
Heidolph instruments, Schwabach, 
Germany 
HPLC YoungLin Instruments, Korea 
Human cervical carcinoma cells (HeLa)  European collection of cell cultures 
(ECACC), Salisbury, UK 
Hydrogen Peroxide Sigma-Aldrich, Poole, Dorset, UK 
IL4 & GM-CSF Enzo Life Sciences, Exeter UK 
Illuminometer Spectra Max Gemini XPS Molecular Devices, CA, USA 
L-glutamine/Penicillin-Streptomycin Biosera, Leicestershire, UK 
LipofectinTM reagent Invitrogen Life Technologies, UK 
Loading buffer Promega, Madison, WI, USA 
Luciferase assay system Promega, Madison, WI, USA 
Malvern Nano ZS Malvern Instruments, Worcestershire, 
UK 
Marvel milk Premier Int. Foods Ltd, Lincs, UK 
MES buffer  Sigma-Aldrich, Poole, Dorset, UK 
Methanol Fisher Scientific, Leicestershire, UK 
Microfluidic fittings P-221, Upchurch Scientific, Oak Harbor, 
WA, USA 
MilliGAT pump VICI Valco, Valco Instruments Co., 
Schenkon, CH 
Milling machine Folken IND, Glendale, USA 
Modulyo bench top freeze dryer Edwards, West Sussex, UK 
Mouse DuoSet capture ELISA  R & D Systems, Abingdon, UK 
NanoAssemblr™ Precision Nanosystems Inc., 
Vancouver, Canada 
Nanosight LM20 NanoSight, Amesbury, UK 
Ovalbumin Sigma-Aldrich, Poole, Dorset, UK 
Phosphate buffer saline tablets (PBS) Sigma-Aldrich, Poole, Dorset, UK 
Phosphatidylcholine (PC) Avanti Polar Lipids, Alabaster, AL, USA 
Plastic syringes (1mL, 2mL, 5mL, 10mL, 
20mL) 
Becton, Dickinson and Company, New 
Jersey, USA 
Plate reader ThermoFisher Scientific Inc., MA, USA  
Plate washer MTX Lab Systems, INC., Virginia, USA 
Poly(lactide-co glycolide) (PLGA) Sigma-Aldrich, Poole, Dorset, UK 
Polylactic acid (PLA) MW 1,600-2,400 Polysciences Inc., PA, USA 
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Pressure sensor 40PC100, Honeywell, NJ, USA 
Probe sonicator Soniprep150plus MSE Ltd., London, UK 
Propan-1-ol Fisher Scientific, Leicestershire, UK 
Propan-2-ol Fisher Scientific, Leicestershire, UK 
Quartz filter mats Skatron/Molecular Devices, Berkshire, 
UK 
Rotary evaporation rotavapor-R Buchi Labortechnik GmbH, Essen, GE 
RPMI 1640 Biosera, Leicestershire, UK 
Scintillation vials Sarstedt, Leciester, UK 
SDS PAGE Apparatus Bio-Rad Laboratories Inc., CA, USA 
Serum free and antibiotic free medium  
(Opti-MEM) 
Gibco, Invitrogen, Paisley, UK 
Spin columns Sartorius AG, Goettingen, Germany 
Sscintillation cocktail Ultima Gold, PerkinElmer, 
Cambridgeshire, UK 
Stop solution R & D Systems, Abingdon, UK 
Syringe pump Harvard Apparatus, MA, USA 
Syringe pump Nemesys, Cetoni GmbH, Germany 
Syringe pump KDS 200 CE Cole-Parmer-Instruments Co. Ltd., 
London, UK 
Thiazolyl Blue Tetrazolium Bromide (MTT) Sigma-Aldrich, Poole, Dorset, UK 
Trehalose 6,6′-dibehenate (TDB) Avanti Polar Lipids, Alabaster, AL, USA 
Trifluoroacetic acid (TFA) Sigma-Aldrich, Poole, Dorset, UK 
TRIS buffer ICN Biomedicals Inc, US 
Ultrafiltration membrane PBMK06210, 
100kDa 
Merck Millipore, Darmstadt, Germany 
Ultrafiltration membrane U3630, 10kDa Sigma-Aldrich, Poole, Dorset, UK 
 
Software Version Supplier 
GraphPad Prism 6.0 GraphPad Software, Inc,. USA 
MODDE 10 Umetrics, Sweden 
SIMCA 13.0 Umetrics, Sweden 
Clarity 2.4.1.91 DataApex, Czech Republic  
Clarity 4.0.3.876 DataApex, Czech Republic 
NanoAssemblr™  3.0 Presicion NanoSystems Inc., Canada 
Labview  National Instruments, TX, USA 
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2.2 Methods in liposome manufacturing 
2.2.1 Lipid film hydration 
MLV were prepared using the lipid film hydration method (Bangham et al., 1965). 
Weighted amounts of lipids were dissolved in chloroform:methanol (9:1, v/v). The 
organic solvents were subsequently removed by rotary evaporation under vacuum, 
followed by flushing of the dried lipid film with N2 for removal of solvent residues. The 
thin lipid film on the bottom of a round bottom flask was rehydrated with the aqueous 
phase at 20°C above the transition temperature of the lipids. Each formulation was 
vortexed every 5 minutes for a total time of 20 minutes, incubating the suspension 
between vortexing in a water bath, which heated above the transition temperature of 
the lipids. The suspension was left to cool for 15 minutes before further work was 
conducted. 
 
2.2.2 Sonication 
A probe sonicator was used for subsequent size reduction of MLV produced by the lipid 
film hydration method. Sonication time varied from 1 to 2 min at an amplitude ranging 
of 1 to 10. A titanium probe was emerged into the required volume of MLV 
formulations. Temperature during the process was maintained above the transition 
temperature of the lipids. A change from a milky MLV suspension to a clear suspension 
was observed throughout the sonication process. The suspension was left to cool for 
15 minutes before further work was conducted. To remove metal residues from the 
probe tip, the suspension was centrifuged for 10 minutes at 500 x g.  
 
2.2.3 High shear mixing 
A high shear mixing (HSM) apparatus was used subsequent size reduction of MLV 
produced by the lipid film hydration method. High shear mixing time was varied from 1 
to 10 min at a rotational speed from 1000 to 25000rpm. The mixer tip was immerged 
into the required volume of MLV formulations. Temperature during the process was 
maintained above the transition temperature of the lipids. The suspension was left to 
cool for 15 minutes before further work was conducted. 
 
2.2.4 Microfluidics 
2.2.4.1 Setup 
The micromixer was obtained from Precision NanoSystems Inc., Vancouver, Canada. 
The mixer was a staggered herringbone micromixer (SHM) with moulded channels in 
poly(dimethylsiloxane) (PDMS) (Figure 2.1A), which were 200 µm x 79 µm (width x 
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height) with herringbone features of 50 x 31 µm (Figure 2.1B). Disposable syringes 
(1mL, Luer Lock) were used to cnnect to the inlet streams by fluid connectors. 
Formulations were performed on a NanoAssemblrTM bench top instrument (Precision 
NanoSystems Inc., Vancouver, Canada). 
A B 
 
 
Figure 2.1: A) Chip in PDMS for size comparison next to a penny. B) Detailed flow path 
including two full cycles of herringbones. 
 
2.2.4.2 Nanoprecipitation 
Lipids in solvent and aqueous buffer (Table 2.1) were injected in 1 mL disposable 
syringes into separate chamber inlets. Syringe pumps were used to drive the fluids into 
the chamber. The total flow rate (TFR) as well as the flow rate ratio (FRR, rate of 
solvent to aqueous stream) was set in the user interface. The heating block was used 
to maintain the lipid solubility above the transition temperature of the lipids, if required 
(Table 2.1). The system was primed with the respective solvent and aqueous phase 
prior to making the formulation. The first droplets (30% of the total sample volume) 
were collected as the waste and the remaining 70% of the formulation was collected as 
the core of the sample (steady state). After each run, the system was flushed with 
ethanol for cleaning. 
 
Table 2.1: Lipids and polymers used throughout this thesis. IPA = Isopropanol, n/a = not 
applicable. 
 
Compound* Solvent Aqueous Phase Concentration Heating block 
DDA IPA TRIS, 10 mM, pH7.2 1.25 mg/mL 60°C 
 
TDB IPA TRIS, 10 mM, pH7.2 0.25 mg/mL 60°C 
 
DOPE Ethanol TRIS, 10 mM, pH7.2 5.9 mg/mL n/a 
 
DOTAP Ethanol TRIS, 10 mM, pH7.2 5.5 mg/mL n/a 
 
PC Ethanol TRIS, 10 mM, pH7.2 6.06 – 36.48 mg/mL n/a 
 
Chol Ethanol TRIS, 10 mM, pH7.2 0.77 – 4.62 mg/mL n/a 
 
CM2 Methanol MES, 100mM, pH 5.5 0.6 – 5 mg/mL 60°C ≥ 3 mg/mL 
 
PLA Acetonitrile TRIS, 10 mM, pH7.2 10 mg/mL n/a 
 
PLGA Acetonitrile TRIS, 10 mM, pH7.2 10 mg/mL n/a 
 
* DDA = Dimethyldioctadecylammoniumbromide, TDB = Trehalose 6,6′-dibehenate,  DOPE = 1,2-dioleoyl-sn-glycero-3-
phsphoethanolamine, DOTAP =1,2-dioleoyl-3-trimethylammonium-propane, PC = Phosphatidylcholine, Chol = 
Cholesterol, CM2 = 1,1'-(decane-1,10-diyl)bis(9-amino-1,2,3,4- tetrahydroacridinium) diiodide, PLA = Plylactic acid, 
PLGA = Poly(lactide-co glycolide). 
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2.3 Methods for quantification 
2.3.1 Solvent quantification by gas chromatography 
Solvent concentration was quantified by gas chromatography (GC) using a flame 
ionization detector with detector temperature 230°C, injector temperature 200°C and 
an injection volume of 1 µL. Carrier gas was helium at 15 psi inlet pressure. An internal 
reference standard (propan-1-ol) was chosen in order to account for variations in 
injection volumes. A calibration curve (6 standards ranging from 0.5-50% v/v) was 
established and used for quantification using an internal reference standard (propan-1-
ol). All analysis was made in Clarity DataApex version 2.4 
 
2.3.2 Lipid and drug quantification by liquid chromatography and evaporative 
light scattering 
Quantification was performed by reverse phase high performance liquid 
chromatography (HPLC) using a C18 column (Luna 5µ for lipids and drug, Jupiter 5µ 
for protein) with a UV detector set at wavelength described in Table 2.2. Lipids were 
quantified using an evaporative light scattering detector (ELSD), which required 
separation of lipids by reverse phase (RP) high performance liquid chromatography 
(RP-HPLC). UV wavelength, flow rate, analysis time, gradient flow, gain value was 
adjusted and optimised for each method (Table 2.2). Lipids injected were dissolved in 
chloroform:methanol (9:1 v/v). Loop volume was 100 µL, tubing volume 15 µL and, 
injection volume was 30 µL in partial loopfill injection mode. Flush volume as 10 µL with 
a wash between vials (wash solution 50:50 IPA:water). Auto sampler analysis time was 
adjusted dependent on each method (Table 2.2). Column temperature was controlled 
at 35°C. Carrier gas in the ELSD was nitrogen at 3.5 bar inlet pressure. All analysis 
was made in Clarity, DataApex version 4.0.3.876. Each method was validated by 
assessing the linearity, reproducibility, robustness, accuracy and level of detection and 
level of quantification. For quantification, established calibration curves were used. 
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Table 2.2: Detailed HPLC methods for compounds used in this study, mobile phase 
comprised A (0.1%TFA in water) and B (100% methanol) in all runs.  
 
Compound Detector Elution time  
(min) 
Flow rate 
(mL/min) 
Method 
Chol ELSD 
Gain 6 
12.2 1 t (min) A% B% 
0 15 85 
4 0 100 
13 0 100 
13.1 15 85 
15 15 85 
 
PC ELSD 
Gain 8 
15.2 1 t (min) A% B% 
0 15 85 
6 0 100 
25 0 100 
26 15 85 
35 15 85 
 
DOPE ELSD 
Gain 8 
13.5  1 t (min) A% B% 
0 15 85 
6 0 100 
25 0 100 
26 15 85 
35 15 85 
 
DOTAP ELSD 
Gain 8 
8.9 1 t (min) A% B% 
0 15 85 
6 0 100 
25 0 100 
26 15 85 
35 15 85 
 
DDA ELSD 
Gain 8 
7.1 1.5 t (min) A% B% 
0 15 85 
6 0 100 
25 0 100 
26 15 85 
35 15 85 
 
TDB ELSD 
Gain 8 
19.5 1.5 t (min) A% B% 
0 15 85 
6 0 100 
25 0 100 
26 15 85 
35 15 85 
 
Propofol UV 
268 nm 
6.4 1 t (min) A% B% 
0 95 5 
3 0 100 
8 0 100 
8.1 95 5 
10 95 5 
 
Ovalbumin  ELSD 
Gain 10 
11.5 1 t (min) A% B% 
0 100 0 
10 0 100 
15 0 100 
15.1 10 0 
20 10 0 
 
CM2 UV  
254 nm 
5.3 1 t (min) A% B% 
0 95 5 
3 0 100 
6 0 100 
6.1 95 5 
9 95 5 
 
 
  Chapter 2: Materials and Methods 
62 
 
2.4 Liposome purification 
2.4.1 Dialysis 
Liposome samples were dialysed (3500Da membrane) over night against buffer at 
room temperature to remove residual solvent (nanoprecipitation method) and 
unentrapped drug (nanoprecipitation method and sonication method). The dialysis 
tubing was cut into the desired length and soaked under running water for at least 2 
hours to remove contaminants. The buffer volume was exchanged every hour to 
optimize the dialysis protocol to a total dialysis time of 4 hours.  
 
2.4.2 Spin columns 
Disposable spin columns (Hydrosart® membrane 30kDa, 50kDa, 100kDa) were used 
for liposome purification. The membrane was wetted with 1 mL of distilled water 
through the membrane (2000 x g, 2 minutes). The required volume of liposome sample 
was placed on the concentrate side, followed by centrifugation at 2000 x g for 5 
minutes in a swing bucket rotor. For washing steps, the filtrate was weighted after and 
respective volume of fresh buffer was added to the concentrate side. For washing the 
liposomes, three centrifugation cycles were performed. For concentration, no buffer 
was added to the concentrate side and only the filtrate was removed. 
 
2.5 Liposome characterisation 
2.5.1 Dynamic light scattering 
Characterisation of the vesicles was performed by dynamic light scattering (DLS) 
(Malvern Zetasizer Nano-ZS). If not stated otherwise, the z-average (intensity based 
mean particle diameter) was reported for monomodal size distributions. For multimodal 
distributions, average diameter reported was based on intensity- and volume-based 
distribution. Recording time was automatically determined by the system and three 
runs were performed for each measurement. Vesicles were diluted in distilled water to 
obtain the best attenuator (6-9) and measurements took place at 25°C. Polydispersity 
measurements (Malvern Zetasizer Nano-ZS) were assessed based on the width of the 
particle distribution. 
 
2.5.2 Nanoparticle tracking analysis 
Nanoparticle tracking analysis (NTA) was performed with a Nanosight LM20, 
connected to a 20x magnification microscope. Liposomes were diluted 1:10 to 1:100 in 
distilled water, to achieve an optimal particle concentration of 107 – 109 particles/mL 
during measurement. NTA analysis was used for determination of the particle size 
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concentration (particles/mL) and as a visual confirmation of particles. Recording time 
was 60 seconds and camera settings (shutter and gain) were adjusted manually to 
obtain the best resolution.  
 
2.5.3 Zeta potential 
Characterisation of the liposomes included zeta potential measurements using particle 
electrophoresis (Malvern Zetasizer Nano-ZS) with vesicles diluted 1:100 in distilled 
water. 
 
2.5.4 Recovery of lipids and drug  
Recovery in the microfluidics process was expressed as in Equation 2.1, relating the 
determined concentration in the steady state of the process to the concentration in the 
stock prior to the manufacturing by microfluidics, incorporating the dilution by the FRR. 
Recovery in the lipid film hydration, sonication and HSM process was expressed as in 
Equation 2.2. If the formulation contained more than one compound, the individual 
recovery was assessed as in Equation 2.1 or Equation 2.2 and the overall recovery 
assessed according to Equation 2.3. All concentrations were assessed by HPLC-ELSD 
as described in Section 2.3.2. 
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2.6 Liposome Imaging 
2.6.1 Transmission electron microscopy  
Images were taken on a Jeol 2011 with a 200kv beam using minimal dose protocol; 
scanned at low magnification and jumped to high magnification without exposing the 
sample to the beam first. Camera used was a Gatan ultrascan (2k by 2k pixels). Grids 
were lacey carbon, 200 mesh and were prepared by adding 8 µL of sample to a glow 
discharged grid, blotting from both sides for approximately 5 seconds then plunging 
into nitrogen cooled ethane propane mix (70% ethane). CryoTEM pictures were taken 
at Warwick University, UK with the help of Mr. Hands-Portman.  
 
  Chapter 2: Materials and Methods 
64 
 
2.6.2 Freeze fracturing electron microscopy 
The liposome suspension (2 µL) were placed in a ridged gold specimen support, frozen 
rapidly by plunging into a briskly stirred mixture of propane:isopentane (4:1) and cooled 
in a liquid nitrogen bath. Fracturing was performed with a cold knife, and replication 
used a Balzers BAF 400D apparatus (Forge et al., 1978; Forge et al., 1989). Prior to 
mounting the replicas on grids for electron microscopy, replicas were floated off on 
water, cleaned in domestic bleach, diluted 1:1 in distilled water and then washed 
several times in distilled water. Replicas were viewed in a transmission electron 
microscope (JEOL 1200EXII), which operated at 80 kV and digital images collected 
with a Gatan camera. Images of the freeze-fractured samples were presented in 
reverse contrast, where the shadows appear black. Imaging was performed with help 
of Prof. Andrew Forge at UCL Ear Institute, London, UK. 
 
2.6.3 Fluorescent imaging of liposomes 
Vesicles were manufactured as described in Section 2.2.2 and 2.2.4 with 1 mM 
carboxyfluorescein (CF) included in the aqueous buffer (Tris, 10 mM, pH 7.2). Vesicles 
were subjected to dialysis over night against 1 L fresh TRIS buffer, pH 7.2 to remove 
unentrapped CF, prior to imaging under a confocal microscope SP5 TCS II MP, Leica 
Microsystems, Leica TCSSP5 II, 63 x objective (HCX PLAPO 63 x/1.4-0.6 oil CS). 
 
2.7 Loading of protein 
2.7.1 Adsorption of protein 
Vesicles were performed as described in Section 2.2.2, 2.2.4, and were mixed with 
various concentrations of protein / antigen (ovalbumin, lysozyme, H56). Adsorption of 
the protein onto the particle surface was performed by adding the required amount of 
protein to the particles. Frequent mixing of the eppendorf tube over a period of 45 
minutes was performed. Protein adsorption took place at room temperature. 
 
2.7.2 Gel electrophoresis for qualitative protein detection 
Semi-qualitative protein detection was performed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) with 12% Tris-glycine gels. Tris/ 
Glycine/ SDS running buffer was made by the mixing of Tris (15 g), glycine (72g) and 
SDS (5g) made up to 1 L with deionised H20. All samples were heated at 90°C for 3 
minutes to denature the protein present in the sample. The samples containing the 
proteins of interest were separated on a 12 % Tris-glycine gel in the running buffer 
using Novex Mini Cell gel apparatus. 10 µL each sample was loaded into the gel, with 
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a total run time of 90 min at constant 30 mA per gel.  All samples were compared 
against 10 µL of a protein marker. The gel was subsequently stained overnight using 
Coomassie Blue, followed by destaining for several hours (4-5 hours). The gels were 
imaged using a photoimager. 
 
2.8 Loading of a low solubility drug 
2.8.1 Solubilisation of low solubility drug 
The low solubility drug (propofol) was dissolved with the lipids in the solvent phase at 
concentrations ranging from 0.5 – 3 mg/mL. Liposome formation and encapsulation of 
the drug was performed simultaneously using the lipid film hydration method (Section 
2.2.1 followed by sonication Section 2.2.2) or the nanoprecipitation method (Section 
2.2.4). 
 
2.8.2 Determination of drug loading into liposomes  
The drug loading was quantified after removal of non-entrapped drug by dialysis (sink 
conditions) against 1 L of Tris buffer, 10 mM pH 7.2 (Section 2.4.1) after which 
quantification was performed by HPLC as described in Section 2.3.2. Validation 
assessed the rate of propofol removal by dialysis. 
 
2.8.3 Drug release study 
Drug-loaded liposomes were incubated at 37°C in a shaking water bath (150 
shakes/min) in 1 L Tris buffer (10 mM, pH 7.2) after removal of the non-incorporated 
drug. Drug-loaded liposomes were manufactured by the nanoprecipitation method 
(Section 2.2.4) and lipid film hydration followed by sonication (Section 2.2.2). 3 mL per 
formulation were incubated and samples of 200 uL were withdrawn at time intervals of 
0.5 h, 1 h, 2 h, 4 h, 8 h and 16 h. Drug quantification was performed as described in 
Section 2.3.2 and expressed as % cumulative release relative to the initial amount of 
drug encapsulated. 
 
2.9 Stability Studies 
SUV were stored at 4 °C, 25 °C (60%RH) and 40 °C (75%RH) in pharmaceutical grade 
stability cabinets over the required period of time. Samples were taken at specific time 
points for measurement of particle characteristics (Section 2.5). For assessment of the 
drug loading, samples were dialysed against 500 mL Tris buffer (10 mM, pH7.2, sink 
conditions) at each time point to remove non-entrapped drug after which quantification 
was performed as described in Section 2.3.2. 
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2.10 Solvent evaporation of polymer-based nanoparticles  
Polymer (PLA or PLGA) was dissolved in chloroform by magnetic agitation over 2 
hours, followed by emulsification in phosphate buffer solution over 15 minutes by using 
a tip sonicator. To form the second emulsion a 2% PVA solution was added to the first 
emulsion over a 30 minutes sonication process. The emulsion was mixed with a 0.2% 
PVA solution by magnetic stirring overnight prior to centrifugation by using spin 
columns (Section 2.4.2). Nanoparticles were collected on the retentate side and 
characterisation was performed as described in Section 2.5. 
 
2.11 In-vitro studies 
2.11.1 Culture and maintenance of continuous cell lines  
African green monkey kidney cells (COS-7) and human cervical carcinoma cells 
(HeLa) were cultured in DMEM media supplemented with 10 % foetal bovine serum 
(FBS) and 1 % penicillin-streptomycin-58 glutamine (PSG). Cells grew as an adherent 
monolayer in T75 flasks and were passaged at 70-90% confluence. Media was 
removed and cell monolayer was washed three times with PBS to remove any residual 
media. Trypsin (1:4 diluted) was added to the monolayer and flasks were incubated for 
approximately 5 minutes at 37°C in a shaking incubator. Cell detachment was 
confirmed by microscopy. 5 mL of fresh media was added to cell suspension, which 
was transferred into a 15 mL flacon tube. Cells were separated from the supernatant 
by centrifugation (200 x g, 5 minutes) at room temperature. Supernatant was carefully 
removed and cell pellet was resuspended in pre-warmed media. Cells were then 
seeded at desired concentration into new flasks. All cell lines were maintained at 37°C, 
5 % CO2 and 95 % relative humidity and were feed with fresh media every 2-3 days.  
 
2.11.2 Determination of cell number  
During routine cell passage, the approximate cell number was estimated from the level 
of confluence. The exact cell number was determined prior to freezing cells for a cell 
bank, and determined by a tryphan blue exclusion. 20 µL of resuspended cells was 
mixed with an equal volume of tryphan blue, and cells were counted using a 
hemocytometer. Cells were quantified and the number of cells/ml was calculated using 
the average of 10 squares in the hemocytometer, the dilution factor and the 
multiplication factor related to the volume of the hemocytometer grid, Equation 2.4.  
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2.11.3 Cryopreservation 
Adherent cells were brought into suspension and quantified as described Sections 
2.11.1 and 2.11.2. Cells were centrifuged at 200 x g for 10 minutes at 15 °C and the 
pellet resuspended in ice-cold media containing 10 % DMSO with a cell concentration 
of 4 x 106 cells/mL. 1 mL aliquots of cell suspension were stored in cryopreservation 
ampoules and frozen at -70 °C overnight prior to transfer into a liquid nitrogen storage 
container. 
 
2.11.4 Transfection of COS-7 Cells 
COS-7 cells were maintained at 37 °C and 5% CO2 in Delbecco’s modified Eagles 
medium (DMEM), which was supplemented with 4 mM L-glutamine, 10% (v/v) FBS, 
penicillin (100 mg/mL) and streptomycin (100 mg/mL). Cells were plated at a 
concentration of 1 x105 cells/mL in 1 mL of medium in a 12-well plate 24 h prior to the 
transfection and incubated overnight. SUV (16 µmoles) were incubated with 0.35 mL 
Opti MEM and incubated for 40 min at room temperature after which 0.35 mL of Opti-
MEM containing 3.5 µg plasmid DNA (luciferase plasmid (gWiz-Luc) and a GFP 
plasmid (pEGFP-C3) was added and incubated for a further 15 min at room 
temperature. The resultant lipoplex mixture was diluted to a final volume of 3.5 mL with 
Opti-MEM. Before the lipoplexe solution was added, cells were washed with 1 mL of 
Opti-MEM. 0.0078 µmole total lipid content containing 1 µg plasmid DNA was added to 
each well and each transfection performed in triplicate. Incubation time was 5h at 37 °C 
in 5% CO2, after which the medium was replaced with growth medium (DMEM) 
containing 10% FBS and the cells were incubated for further 48 h.  
 
2.11.5 Luciferase Assay 
The transfection efficiency was assessed by a luciferase assay system. The 
transcriptional activity of cells transfected with the DNA, emitting light which can be 
quantifiedby a illuminometer. Transfected cells were exposed to 80 µL/well of lysis 
buffer and detached from the well using cell scrapper. Detached cells were centrifuged 
at 12,000 x g for 15 seconds at room temperature to remove cell debris. 10 µL of the 
supernatant was removed onto a new 96-well plate. The plate was read using 
illuminometer with 30 reads/well, prior to addition of luciferase reagent in order to 
quantify the luciferase activity. 100 µL/well of the luciferase assay reagent was added 
and the plate was read again. The luciferase activity was related to the activity 
achieved with Lipofectin™, which acted as the control transfection reagent. 
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2.11.6 Detection of fluorescent protein expression  
Cells were transfected with the GFP plasmid as described in Section 2.11.4. 
Transfection was qualitatively assessed under a fluorescent microscope (DMI400B, 
Leica Microsystems). 
 
2.11.7  Cytotoxicity study 
COS-7 or HeLa cells were seeded at 1x105 c/mL on a 96-well plate and incubated for 
24 h at 37 °C, 5%CO2 in DMEM medium. The medium was replaced by 200 µL of 
supplemented DMEM (containing the lipoplex formulation as described in Section 
2.11.4 or Section 2.8) and incubated for 5 h, after which 20 µL of Thiazolyl Blue 
Tetrazolium Bromide (MTT) reagent, was added to each well. The MTT gets 
bioreduced by the cells into a red formazan product, indicative of metabolically active 
cells. Cells were incubated for 4h at 37°C, in a 5% humid CO2 atmosphere, after which 
medium was removed. 100 µL DMSO was added in each well to lyse the cells. The 
absorbance of the produced formazan was measured on microplate reader at A490. 
The absorbance was, directly proportional to the number of living cells in the medium. 
cell viability was calculated and expressed as a percentage to the positive control (i.e., 
cells and medium). 
 
2.11.8 In-vitro association assay 
Liposomes were manufactured and labelled with 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate) (DilC) (0.1 mol %) by inclusion of the lipid 
(dissolved in solvent) in the solvent evaporation stage of liposome production (as 
described in Section 2.2.1 and 2.2.4). Un-entrapped dye was removed by dialysis as 
described in Section 2.4.1.  
 
Phagocytes at 1 x 106/ml and fluorochrome tagged liposomes (1mg/ml) were mixed at 
1:1 and incubate at 37°C until sampled (5, 15, 30, 60 and 120 min). At each time point, 
samples were gently mixed and 200 µL of the phagocyte-liposome mix was extracted.   
The extracted cell culture was washed by addition of 200 µL PBS/BSA (1% w/v) and 
centrifuged at 1200 rpm for 3 min. Cell pellets were resuspended in 500 µL PBS/BSA 
(1% w/v). Cell samples were analysed immediately on flow cytometer by taking 5000 
events minimum in ‘cell’ region. For the analysis, MFI (mean fluor intensity - amount of 
fluorescence per cell) and % positive cells (% of MØ or DC that are positive for 
liposome) were considered. This assay was performed by Vinod Nadella at Aston 
University. 
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2.11.9 In-vitro migration assay 
Liposomes were manufactured as described in Section 2.2.1 and 2.2.4. 1 mg/mL of 
liposome formulation was placed in 24 well trans-well plates. 8µm transwells (BD) were 
inserted in each well in the correct position to make sure no air bubble were left 
between the transwell and the medium. THP-1 cells (monocyte cell from human blood) 
at 1 x 106/mL were stimulated with VD3 or with IL4 & GM-CSF (differentiation into 
macrophages or iDCs respectively) and were loaded at 300 µL into each trans-well. 
Empty wells or empty spaces between adjacent wells were partly filled with distilled 
water to maintain humidity within the plate. Trans- well plate was sealed with thermal 
tape and placed in plate holding chamber of Cell IQ unit while connecting to the CO2 in-
let. The migration of macrophages or iDC towards liposomes placed in the trans-well 
plate was assessed using the Cell IQ automated cell tracking system. This assay was 
performed by Vinod Nadella at Aston University. 
 
2.12 In-vivo studies immunisation study 
All experiments mentioned under “in vivo studies” were performed by Jubair Hussain. 
 
2.12.1 Vaccination of mice 
Work was undertaken in accordance with the 1986 Scientific Procedures Act (UK), 
(project license number PPL 30/2743). Female C57BL/6 mice, 6-8 weeks old were 
obtained from Charles River, UK. Lipsomes were prepared according to Section 2.2.1, 
increasing levels (25, 50, 75 mol%) of the saturated phosphatidylcholine, 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC) was incorporated into the DDA-TDB 
formulation, at a locked DDA-TDB molar ratio of 8:1 with the addition of Ag85B-ESAT-
6-Rv2660 (H56) antigen to a final concentration of 0.1 mg/mL (5 µg/vaccine dose). All 
mice, (exception of the naive group), were immunised intramuscularly (i.m.) with 0.05 
mL/dose three times, with two week intervals between each immunisation. 
 
2.12.2 Sera collection 
The seven-week immunisation study included five scheduled bleeds, blood samples 
were taken at regular intervals prior to termination. A small incision the tail vein was 
used to draw blood (50 µL) with micropipette capillary tubes lightly coated in heparin 
solution (0.1% w/v in PBS). The blood was subsequently added to 450 µl PBS and 
centrifuged using a centrifuge (13,000 RPM, 5 minutes). The supernatants were stored 
at -20 °C for further analysis.  
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2.12.3 Mice termination and in vitro spleen cell culture  
Suspensions of spleen cells were produced into 10 mL RPMI 1640 cell culture medium 
(w/o Glutamine) containing 10% (v/v) FBS and 1% (v/v) PSG. Each suspension was 
centrifuged twice (1000 RPM, 10 min, 15 °C) and the final pellet was resuspended in 5 
mL RPMI. Single cell suspensions assessed the splenocyte proliferation and antigen 
specific cytokine responses. To assess splenocyte proliferation, H56 was added to 
sterile 96 well cell culture plates at various concentrations (0-5 µg/mL), using 
concanavalin A (2 µg/mL) as a positive control. 100 µL of the spleen cell suspensions 
were added and incubated at 37 °C, 5% CO2. After 72 hours incubation, 40 µL of [3H] 
thymidine at 0.5 (µCi) in supplemented RPMI was added to each well and incubated for 
further 24 hours. A cell harvester was used to harvest onto quartz filter mats and 
solutions were transferred to 20 mL scintillation vials containing 5 mL scintillation 
cocktail. A scintillation counter measured the incorporation of [3H] thymidine in cultured 
cells. 
 
2.12.4 Assessment of H56 specific antibody isotype titres 
Antibody isotypes (IgG, IgG1 and IgG2b) were measured in serum samples using a 
enzyme-linked immunosorbent assay (ELISA). The ELISA plates (96 well, flat 
bottomed, high binding) were coated with 3 µg/mL H56 antigen, after which plated 
were incubated at 4 °C overnight. Plates were washed three times with PBST wash 
buffer (40 g NaCI, 1 g KCI, 1 g KH2PO4, 7.2 g Na2HPO4, (2H20) per 5 litres of ddH20, 
incorporating ~0.4 mL of Tween 20) using a plate washer, any unbound antigen was 
removed by blotting. Each well was coated with 100 µl of Marvel in PBS for blocking 
and incubated for one hour at 37 °C, after which plates were washed three times with 
PBST buffer. 140 µl of serum sample was serially diluted in PBS (70 µl sequentially), 
and added to the plates for one hour incubation at 37 °C. Plates were washed five 
times with PBST buffer, after which 60 µl/well of horseradish peroxidise (HRP) 
conjugated anti-mouse isotype specific immunoglobulins of IgG, IgG1 and IgG2b was 
added to each well, diluted to 1/750, 1/4000 and 1/4000 in PBS respectively. Plates 
were washed five times with PBST buffer, after which 60 µL/well substrate solution 
(colouring agent: 6x 10 mg tablets of 2,2’-azino-bis (3-ethylbenzthiazoline-6-sulfonic 
acid) in citrate buffer (0.92g Citric Acid + 1.956g NA2 HPO4 per 100 mL) was added to 
each well, incorporating 10 µL of hydrogen peroxide (30% H2O2/100 mL). Plates were 
incubated for further 30 min at 37 °C prior to measuring the absorbance at 405 nm 
using a microplate reader. Positive and negative controls incorporated Known positive 
serum and pooled naïve mice sera respectively. 
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2.12.5 Quantification of cytokine production by the sandwich ELISA 
Splenocyte cell suspensions were harvested and plated onto 96 well cell culture plates 
as described in Section 2.7.3. The cells were incubated for 48 hours (37 °C, 5% CO2), 
after which supernatant was removed and stored at -70 °C for further analysis. 
Cytokines (IL-2, IL-5, IL-6, IL-10 and IFN-γ) were quantified within cell culture 
supernatants using a specific DuoSet ELISA development kit. Each well was coated 
with 100 µL capture antibody and incubated at room temperature overnight. Prior to 
blocking, the plates washed three times with PBST buffer. The plates were incubated 
(room temperature, minimum of one hour) after which plates were washed three times. 
100 µL/well of sample or standards was added to each well and incubated for two 
hours (room temperature.) after which plates were washed three times. 100 µL of 
cytokine specific detection antibody was added per well and incubation for two hours 
(room temperature). Plates were washed for three times and 100 µL of Streptavidin- 
HRP was added per well (diluted 1/200). The plates were covered to avoid exposure to 
direct light and incubated for 20 min (room temperature). Plates were washed for three 
times and 100 µL substrate solution was added to each well (1:1 mixture of colour 
reagent A and B: stabilised hydrogen peroxide and stabilised tetramethylbenzidine 
respectively) after which the covered plates were incubated for a further 20 min (room 
temperature). 50 µL stop solution (2N H2SO4) was added per well and the optical 
density was immediately determined at 450 nm. 
 
2.13 Scalability assessment of the nanoprecipitation method 
2.13.1 Scale-up by increase of channel diameter 
The channel diameter was increased in a scale-up format in order to assess the 
scalability by increasing the throughput through the mixer. The mixer was obtained 
from Precision NanoSystems Inc. and included a SHM with moulded channels in 
PDMS, which were 300 µm x 130 µm (width x height), the herringbone features remain 
IP protected. 
 
2.13.2 Scale-out by mixer parallelisation  
All experiments were performed at Precision Nanosystems, Inc. in Vancouver, Canada. 
The 300 µm design as described in Section 2.13.1 was used in a scale-out platform for 
further scalability assessment, using a 2x and 4x syringe driven platform (Figure 2.2A 
and B) and a 1x and 4x continuous flow system (Figure 2.2C and D). 
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The syringe driven system operated with syringe pumps for the solvent and aqueous 
stream respectively and disposable syringes between 5-20 mL. Aqueous and solvent 
phase was split into the 2x or 4x system using two fluid manifolds. For the 2x syringe 
driven system, a total sample volume of 10 mL was collected, with 5 mL was collected 
as waste and 5 mL as the core of the formulation. For the 4x system, a total sample 
volume of 12 mL was split into 8 mL waste and 4 mL of core sample. 
 
The continuous flow system operated with two continuous flow pumps for the solvent 
and aqueous stream respectively, a glass reservoir was used for each phase. The 
tubing for the solvent phase was manually purged over the pump heads and recycled 
back into the solvent reservoir prior to operation. Aqueous and solvent phase was split 
using two fluid manifolds for the 4x system. For the 1x continuous flow system, a total 
sample volume of 55 mL was collected, with 5 mL was collected as waste and 50 mL 
as the core of the formulation was split in 5 batched of 10 mL. For the 4x continuous 
flow system, a total sample volume of 135 mL was split into 10 mL waste and 125 mL 
of core sample was split into 5 batched of 25 mL. The total sample volume was split 
into consecutive batches, verifying variation throughout the continuous process. Low 
solubility model drug was solubilised (Section 2.8), and after dialysis (Section 2.4.1) 
samples were analysed as described in Section 2.3.2 and 2.5. 
 
Figure 2.2: Schematic of the scale-out layout for A) 2x syringe driven, B) 4x syringe 
driven, C) 1x continuous flow and D) 4x continuous flow. 
 
2.14 Tangential flow filtration for liposome purification 
2.14.1 Filtration unit manufacturing 
Poly(methylmethacrylate) (PMMA) was used to manufacture the rigid parts of the 
filtration unit, as previously reported (O'Sullivan et al., 2012); also the clamping system 
for the SHM chip using a micromilling machine. The gasket for the filtration unit was 
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manufactured from PDMS, according to the manufacturer’s instructions and cast in 
PMMA moulds, manufactured as described above. Interconnect ports (milled from 5 
mm PMMA), with two holes tapped with an M3 thread, were used for connection to the 
filtration unit; an M6 threaded hole was used for standard connection fittings (P-221). 
 
2.14.2 Filtration device 
The filtration system was designed to seal membranes in place by means of clamping 
(O'Sullivan et al., 2012). Two PMMA plates, with a straight channel (1 mm width, 1 mm 
depth, 45 mm length) and a 1 mm hole milled at each end were clamped together 
using M3 screws along the edges (Torque 10 Ncm). A 1 mm wide and 0.75 mm deep 
cutting was used to hold the PDMS gasket in place, which was used to secure the 
membrane in place. Different commercially available membrane sheets were cut to the 
required size using a CO2 laser marking head. The membrane used in this set of 
experiments had a cut-off of 10kDa or 300kDa, for drug or protein filtration, 
respectively. The membrane was cleaned after each experiment by back-flushing with 
water and stored inside the TFF system in 0.8M saline solution. Thus the device was 
ready to use in another experiment. 
 
2.14.3 Backpressure regulation 
Constricting capillaries (internal diameters of 50, 63 and 100 µm, length 2.5 – 5 cm) 
were attached to the retentate outlet of the filtration device. Backpressure was related 
to the dynamic viscosity (µ) of medium at 25°C, length (L) and diameter (d) of the 
restricting capillary and the volumetric flow rate (Q) using Hagen-Poiseuille Law, 
(Equation 2.5). 
 
∆- = 	 ".	/		01	+    Equation 2.5 
 
Verification of the calculated backpressure was performed by measuring the pressure 
with an inline pressure sensor (40PC100) on the retentate side and the data logged 
with a LabVIEW virtual instrument. 
 
2.14.4 Membrane fouling 
Membrane fouling was assessed by comparing the cumulative permeate volumes of a 
filtered liposome formulation (concentration 5x1010 p/mL) to a normalized water 
permeability, NWP, (cumulative permeate volume of filtered water) for 150 minutes. 
Membrane fouling during filtration of the liposome sample was indicated by deviation of 
the slope of the accumulated permeate volume from the NWP over time.  
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2.14.5 Integrity testing 
For the integrity testing, backpressure was set at 80 psi (0.1 mL/min, 50 um capillary 
ID, 0.05 m). Ovalbumin at 1 mg/mL and 0.5 mg/mL was filtered through the TFF and 
permeate and retentate were analysed by SDS - PAGE, Section 2.7.2.  
 
2.14.6 Liposome formulations for spiking the filtration system 
Multilamellar vesicles (MLV) were prepared using the lipid film hydration method 
(Bangham et al., 1965) as described in Section 2.2.1. Cationic liposomes comprised 
DDA-TDB (8 : 1 molar ratio) and anionic liposomes comprised DPPG, DPPC, Chol 
(1:1:1.3 molar ratio). Small liposomes were formed via probe sonication, Section 2.2.2.  
(5 min at an amplitude of 5). Vesicles were freeze dried (pre-freezing at -70°C for 4h, 
followed by drying in two stages, -50 °C for 48 h and at -30 °C to a final temperature of 
20 °C for 6h) (Mohammed et al., 2010) and stored at -20°C until use. The vesicles 
were rehydrated with distilled water prior to filtration experiments. Ethanol was 
manually added to the liposome formulation to a final concentration of 20% (v/v). 
Aqueous model protein (ovalbumin, 100 µg/mL) and model drug (propofol, 1 mg/mL) 
were manually added to the liposome formulation in order to mimic the conditions post 
liposome manufacturing by microfluidics, Figure 2.3. 
 
2.14.7 Filtration  
Filtration was performed in a diafiltration mode. Liposomes (Section 2.14.6), spiked 
with drug, protein or solvent were introduced into the filtration device by means of 
syringe pumps (Figure 2.3). Retentate and permeate volumes were assessed (by 
weight), collected in eppendorf tubes and used for further analysis. 10 mM pH 7.2 TRIS 
buffer, equivalent to the permeate volume, was added manually to the remaining 
retentate allowing for a washing process (diafiltration cycle). For particle concentration, 
no buffer was added on the retentate side. 
 
Figure 2.3: Filtration mode with a syringe pump driving the sample through the TFF. 
Retentate and permeate were collected manually. 
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2.14.8 Micromixer for liposome formation in combination with TFF purification 
To achieve liposome formation and purification a SHM and a TFF device were 
connected in line (Figure 2.4). The SHM was as described in Section 2.2.4.1.  
 
Luer-lock fitting and polytetrafluoroethylene (PTFE) tubing (1/16 in. x 0.031 in., Sigma- 
Aldrich Int.) were used to link disposable 1 mL syringes with the two inlet ports of the 
chip; flow rates and flow rate ratios were controlled by a syringe pump and the whole 
system was primed with Tris buffer (10mM, pH 7.2) prior to operation. Organic phase, 
weighed amounts of lipids in ethanol, was injected into the first inlet of the SHM device, 
while in the second inlet aqueous phase (TRIS buffer, 10mM, pH 7.2) was injected. 
The micromixer was clamped in place using a PMMA holding device. 
 
It was connected to the tangential flow filtration (TFF) unit (Figure 2.4A) via an 
intermediate collection vial (1.5 mL Eppendorf) to allow for a direct input of 
microfluidics-manufactured liposomes into the filtration system for purification. Bi-
directional milliGAT pump was connected in-line with the retentate loop of the TFF. 
Two different liposome formulations were produced using this set-up. For the 
preparation of neutral liposomes, PC and Chol (4:1 molar ratio) in ethanol were 
injected into the micromixer at 2 mL/min at a FRR 1:3, including 1 mg/mL of propofol in 
the solvent stream (Figure 2.4B). For the preparation of a cationic liposome 
formulation, DOPE and DOTAP (1:1 molar ratio) in ethanol were injected into the 
micromixer at a TFR of 2 mL/min at FRR 1:3. After formulation, the required amount of 
protein (ovalbumin, 100 µg/mL) was manually added to the collection vial, Figure 2.4C.  
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Figure 2.4: A) Schematic overview over the continuous manufacturing setup with B) 
loading of the low solubility drug and C) loading of the protein. 
 
2.15 Statistical analysis 
If not stated otherwise, results were reported as the mean ± one standard deviation 
(SD). One- or two-way analysis of variance (ANOVA) was used to assess statistical 
significance, followed by Tukey’s multiple comparing test and t-test was performed for 
paired comparisons. Significance was acknowledged for p values lower than 0.05 
(marked with *). All calculations were made in GraphPad Prism version 6.0 (GraphPad 
Software Inc., La Jolla, CA, US). 
 
2.16 Design of experiments 
Chosen model depended on required outcome; screening design were used for initial 
testing and response surface modelling was used for optimization testing. Factors in 
selected ranges as well as desired responses were selected before the worksheet was 
produced. All runs were performed randomized. For evaluation, summary plot was 
evaluated for goodness of fit (R2), goodness of prediction (Q2) as well as model validity 
and reproducibility. Responses, which gave a poor model were removed and not 
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further investigated. Outliers were detected and removed if required using normal 
probability plot, observed vs. predicted and normal plot of residuals. Coefficients were 
assessed for significance and removed if required. Prediction plots (response surface 
or contour plot) were used for model interpretation and assessment of optimal regions 
in the model prediction. Sweet spot analysis determined the optimal region with pre-
selected criteria (Eriksson, 2008).  
 
2.16.1 Model evaluation  
The first column presented the R2 value, the fraction of the variation for the responses 
as explained by the model. 
23 = 4456744  
With  
SSREG    The sum of squares of Y corrected for the mean, explained by the model 
SS   The total sum of squares of Y corrected for the mean 
 
The second column displayed Q2, which represented the fraction of the variation of the 
response predicted by the model according to cross validation, expressed in the same 
units as R2. 
83 = 1 −	;2<4444  
With 
PRESS  The predicted residual sum of squares 
SS   The total sum of squares of Y corrected for the mean 
 
R2 and Q2 range between 0 and 1; values close to 1 indicate a very good model with 
excellent goodness of fit and predictive power. Furthermore, the predictive power 
should ideally be approaching the goodness of fit to a maximum of 100%, will however 
never outreach R2. The third column represented a measure of the validity of the 
model. A bar larger than 0.25 represents no lack of fit in the model, where the model 
error is similar to the pure error. A bar less than 0.25 indicates a lack of fit where the 
model error is significantly larger than the pure error. The fourth column represented 
the reproducibility of the model, comparing the total variation of the response under the 
same conditions (pure error), measured at the replicates (e.g. center points). A bar of 1 
presents a perfect model for both, model validity and reproducibility. 
 
2=>?@ABCDEDFDGH = 1 −	 I4		>B?=	=??@?I4		G@GJF	44	C@??=CG=A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With 
MS   Mean squares (or variance) 
SS   The total sum of squares of Y corrected for the mean 
 
2.16.2 Normal probability and replicate plot 
The normal probability plot displayed the residuals plotted on a normal probability 
scale, which allowed detecting the normality of the residuals. If the data follows a 
normal distribution, the residuals follow a straight line (in a 45° angle); outliers can be 
determined if residuals deviate from the normal probability line, i.e. larger than 4 
standard deviations as indicated by the red line in the plot. 
 
The replicate plots (residuals vs run number) compared the response values against 
the experimental runs. This displayed the variation in the responses for the replicated 
experiments. This was especially important if experiments have been performed over a 
prolonged time period where any effect on environmental change (e.g. temperature 
change in the lab) could impede the output measurements. 
 
2.16.3 Coefficient plot 
The coefficient plot (or regression coefficient plot), displayed the model terms, main 
effect and interaction terms, ranging from 0 to high, for a selected response with the 
confidence intervals as error bars. Confidence intervals cross zero in non-significant 
model terms. The most important factor had the highest range (positive or negative). 
Similar coefficients plots patterns were indicative of correlated responses.  
 
2.16.4 ANOVA 
An ANOVA was performed, as the basis for regression model evaluation. Here, two F-
tests examined the probability value p; firstly the significance of the regression model 
was assessed and determined as statistically significant for p< 0.05. The second test 
compared the model error and replicate error, with a sufficient low model error the 
model showed good fit to the data with no lack of fit (LOF). Hence, the LOF test was 
fulfilled for p> 0.05. 
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2.17 Multivariate Analysis 
Studies using multivariate data analysis were made in SIMCA version 13.0 (Umetrics). 
Scaling and transformation of the data set prior to analysis was performed 
automatically.  
 
2.17.1 Principal component analysis 
Initially, all data was pre-processed in Principal Component Analysis (PCA). PCA 
included the assessment of scores (t) and loadings (p), representing the position of an 
observation on the model plane (score) and expressing how the original variable 
correlates to the model (loading). The goodness of fit (R2) and goodness of prediction 
(Q2) assessed the model fit, which was regarded as good for R2 > 0.5.  The score 
scatter plot was used to assess situation of the x observations with respect to each 
other. Possible outliers, groups or patterns were identified with using the tolerance 
ellipse around the observations.  
 
2.17.2 Partial least square analysis 
PCA was followed by Partial Least Square (PLS) as the quantitative modelling tool, for 
prediction of Y, correlation of X to Y matrix and regression. PLS modelled the 
relationship between X- and Y- variables and identified the importance of the X-
variables (Eriksson, 2006). The X/Y Overview plot was used to evaluate the cumulated 
R2 and Q2 values for each variable of the data set. The number of components required 
were assessed and added or removed manually if required in order to avoid overfitting. 
DModX analysis was used for determination of the Dcrit in order to detect moderate 
outliers. The loading plot displayed the relation between the X-variables and the Y-
variables. Weights were selected to maximize the correlation. The loading scatter plot 
identified relationships between the variables and the responses, and the relationships 
between the variables and the responses themselves. For interpretation, a line from a 
selected variable was drawn though the origin and X- and Y-variables were projected 
on the line. Variables opposite to each other were determined as negatively correlated, 
positive correlation was determined with variables adjacent to each other. The variable 
importance for the projection (VIP) plot was used to summarize the importance of the 
variables for explanation and prediction. The specific regression coefficients plots 
evaluated the X–Y relations in the computed PLS model. Correlated responses 
demonstrated similar coefficient profiles, uncorrelated responses showed different 
profiles in the regression coefficient plots (Wold et al., 2001a).  
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2.17.3 Validation 
The model was validated using a permutations plots, which assessed the validity of the 
PLS model by evaluating the risk of invalidity and verified the validity not only for the 
current data set, but for new observations and predictions of Y. The X-data was left 
unchanged while permuting the Y-data, which was arranged it in a different order. new 
PLS models were fitted using the permuted data set and new R2 and Q2 verified the 
derived models by cross-validation, which were compared with real R2 and Q2 values of 
the model after random shuffling. Parallel models were generated over 40 permuations 
per model, assessing the validity of the initial PLS model (van der Voet, 1994) by 
comparing R2 and Q2 of the current model to the ones of the randomly permuted Y-
observations at constant X-variables. A respective correlation line between permuted 
Y-vector to the original X-vector was shown and model validity was pre-set as the 
intercept of the Q2 regression line at or below zero.  
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3 Method development and evaluation: 
 Quantification, particle sizing and microfluidics 
 
 
 
Papers relating to this chapter: 
Kastner E., Schmidt S. T., Wilkinson A., Christensen D. and Perrie Y. (2015). The 
Application of Liposomes as Vaccine Adjuvants. In Foged C., Rades T., Perrie Y. and 
Hook, S. Eds Subunit Vaccine Delivery Springer New York. pp. 77-94. 
 
Kastner E. and Perrie Y. (2015). Particle size analysis for micro- and nanoparticles. In 
Analytical Methods in Pharmaceutical Sciences (submitted) 
 
Kastner E., Lowry D. and Perrie Y. (2015). Rapid quantification of lipid concentrations 
within liposome systems (in preparation) 
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3.1 Introduction 
Amongst all the methods available for liposome manufacturing, the lipid film hydration 
was the first described (Bangham, 1961; Bangham et al., 1965), and has since become 
one of the most commonly adopted methods for the manufacture of multilamellar 
vesicles (MLV). In addition to this method, sonication and high shear mixing (HSM) are 
used as down-sizing methods, categorised as “top-down” methods. In contrast, the 
microfluidics-based nanoprecipitation method has been described as a novel “bottom-
up” method for vesicle manufacturing (Belliveau et al., 2012; Zhigaltsev et al., 2012) 
(Figure 3.1). The microfluidics-directed vesicle formation is based on a 
nanoprecipitation process; the controlled introduction of an aqueous phase to a solvent 
phase triggering the precipitation of lipids into liposomes.  
 
 
Figure 3.1: Schematic overview over the range of vesicle manufacturing methods 
investigated in this study. 
 
It is well recognised that the size of drug delivery particles can dictate drug loading, 
drug release, biodistribution, cellular interactions and uptake, and biological function 
(Allen, 1994; Brewer et al., 1998b; Kirby et al., 1980; Mann et al., 2009). For example, 
in the design of vaccines, the vesicle size of liposomal adjuvants has been shown to 
influence the development of the immune responses towards a Th1 or Th2 cytokine 
profile via a range of routes (Brewer et al., 2004; Brewer et al., 1998b; Carstens et al., 
2011; Mann et al., 2009; Manolova et al., 2008). Studies suggest that smaller particles 
promoted enhanced Th2 responses whilst larger particles promote IFN-γ and typical 
Th1 responses (Brewer et al., 1998a; Mann et al., 2009). This may be linked to 
differences in particle trafficking to local lymph nodes and uptake by antigen presenting 
cells (APCs). Improved antigen processing upon delivery in large (560 nm) vesicles, as 
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opposed to smaller (155 nm) vesicles, has been shown (Brewer et al., 2004). Similarly, 
uptake of particulates by dendritic cells was only observed at the injection site when 
large (0.5 – 2 µm) particles were used rather than small (20 – 200 nm) particles 
(Manolova et al., 2008) and significantly higher amounts of smaller liposomes were 
found at the popliteal lymph node 6 hours after injection (Henriksen-Lacey et al., 
2011a) making the vesicle size a factor crucial for liposome exposure in the lymph 
nodes and recruitment of the innate immune system (Henriksen-Lacey et al., 2011a). 
 
For particle characterisation light scattering techniques were used in the studies 
reported within this thesis. These methods are currently the most widely used 
techniques available to size micro- and nanoparticles. Based on the non-destructive 
methods, protocols can be adopted for a range of sample and molecules with a 
relatively quick analysis time. Here, two of the main light scattering techniques were 
compared, namely DLS and NTA. With methods highly applicable to determine the size 
liposome, typically SUV and LUV sizes ranging between 30 nm to 500 nm, each 
method was described first to consider the correct interpretation of measurement data. 
DLS (also known as photon correlation spectroscopy (PCS) and quasielastic light 
scattering (QELS)) determines the hydrodynamic diameter of particles typically below 
the micrometer range and down to a few nanometers in size. DLS assesses the time-
dependent intensity scattering fluctuation of a particle in suspension. The method is 
based on determination of the diffusion constant (D) in order to derive the 
hydrodynamic diameter (dH) of a particle; the measurement depends on the viscosity of 
the suspending media (µ), the absolute temperature (T) and the Boltzmann constant 
(k) as based on the Stokes-Einstein relationship, (Equation 3.1). 
 
 =	 		
     Equation 3.1 
 
Based on collision between particles moving under the Brownian motion, the 
suspended particles scatter a light beam hitting on the suspension. A detector analyses 
the scattered light intensity, which strongly depends on the size of the particles. The 
measurement results in a correlation curve, which links the diffusion of the particles to 
the scattered light fluctuations over time (Figure 3.2) (Chu and Liu, 2000; Pecora, 
2000). Measurements determine the hydrodynamic diameter (Stokes-Diameter), 
determining the translational diffusion coefficient of the measured particle by relation to 
a hypothetical sphere (Chu and Liu, 2000). 
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Figure 3.2: Schematic of a correlation function as obtained from a DLS measurement 
with indicated qualitative properties of suspended particles. Adapted from (Kastner and 
Perrie, 2015). 
 
A monomodal size distribution is represented by an ideal single exponential decay 
correlation function, which fits the decay to the particle diffusion allowing derivitisation 
of the diffusion coefficient (D). The correlation function is assessed by the steepness 
and the gradient of the decay function, reflecting the heterogeneity of the sample and 
the Y-intercept, a qualitative indication of the signal-to noise ratio, ideally located at 1 
and acceptable within the range of 0.6-0.9. The z-average size (cumulants mean) is 
the primary and most accurate measurement obtained. By definition, the z-average 
represents the intensity averaged particle diameter, which is difficult to directly 
compare with a number-based size as obtained by e.g. microscopy imaging. For a 
monomodal size distribution the z-average is highly applicable as it is defined in ISO 
standards (ISO, 2008). Nevertheless, the presence of a small number of larger 
aggregates will substantially influence the measurement outcome, which generally 
makes the z-average value less applicable in a multimodal size distribution. A 
measurement typically results in an intensity-based distribution, which can be 
converted into a number and volume distributions using the Mie theory (Fu and Sun, 
2001). This aids in approximation of the relative proportions of the particles in a sample 
(Chu and Liu, 2000; Ito et al., 2004), given the distribution bias towards larger particles. 
The intensity of the scattered light is proportional to the molecular weight of the particle 
squared and the diameter of the particle to the power 6. Given this bias towards larger 
particles, the conversion into a volume-based distribution is often more applicable as 
the volume is proportional to the diameter of the particles cubed. Besides using DLS 
for particle size determination, the heterogeneity of the particle suspension is 
simultaneously determined and reported as the polydispersity index (PDI), ranging to a 
maximum of 1 for a very heterogeneous sample. Generally, any value > 0.7 is 
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representative of a very broad size distribution, where resulting particle size 
measurements based on DLS are not reliable (Berne and Pecora, 2000). 
 
Similar to DLS, NTA relies on the measurement of scattered light and Brownian motion 
to determine particle size distributions of a suspension. During NTA analysis, a camera 
captures the scattered laser light and a video file allows separate tracking of each 
particle as they move under the Brownian motion (Carr et al., 2009; Carr and Wright, 
2008; Gardiner and Dragovic, 2014). In addition to single particle sizing, NTA also 
allow for the particle concentration to be determined. Measurement commences with 
selecting the view field using a camera and projections onto a computer for the live 
tracking system. A video file of typically 30-60 seconds is recorded, where the 
localization of the centre of each particle allows tracking on a frame-by-frame basis 
(Figure 3.3). The travelled distances (x and y directions) are used to determine the 
diffusion coefficient using the Stokes-Einstein equation, based on the viscosity of the 
media (µ), the absolute temperature (T) and the Boltzmann constant (k), used to 
determine the hydrodynamic diameter (dH) of the particles (Equation 3.1).  
 
 =	 		
     Equation 3.1 
 
Travelled distances are converted into a particle size distribution, intensity and number 
based distributions are fitted and the concentration of the particles is extrapolated 
based on the known volume of the view field (Carr et al., 2009; Carr and Wright, 2008). 
As opposed to DLS, the hydrodynamic diameter of each particle is tracked rather than 
the sum of particles motion, thereby circumventing intensity-based bias seen with 
larger particles or aggregates present in a sample during a DLS measurement.  
 
Whilst the advantage of the DLS measurement lies in its good accuracy for 
monodisperse samples along with a quick and user-friendly measurement, NTA 
analysis generally requires a higher level of operator training. However NTA generally 
results in a higher resolution (Bell et al., 2012). Nevertheless, the selection of the frame 
is user bias and the equipment requires a higher degree of maintenance, Table 3.1.  
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Figure 3.3: Stepwise procedure during NTA analysis. Adapted from (Kastner and Perrie, 
2015). 
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Table 3.1: Direct comparison of DLS and NTA. 
 
 DLS NTA 
Size Range 1-8 000 nm 10 – 2 000 nm 
 
Concentration Range Max 40% w/v  
(dependent on refractive index 
and particle size)  
 
107 – 109 particles / mL 
 
Sample volume 10 – 500 µL 10-100 µL 
 
Accuracy Good accuracy for 
monodisperse samples, 
inaccurate at higher 
polydispersities 
 
Good accuracy for low and high 
polydispersity samples 
Resolution Low at less than 3 fold 
difference in diameter 
High, higher than 0.5 fold in 
diameter 
 
Reproducibility High Lower (frame selection by user) 
 
Sample preparation  Removal of large contaminants 
by filtration or centrifugation 
 
Removal of large contaminants 
by filtration or centrifugation 
 
Appropriate dilutions required 
Contamination Large particles influence 
measurements (intensity 
measurements) 
Contaminants more easy 
detected, lower influence of 
larger particles 
 
Output Z-Average, intensity, volume 
and number distribution, 
polydispersity 
 
Absolute particle diameter 
Particle concentration 
Visualisation No Yes 
(video recording over 
measurement period) 
 
Device User-friendly, little sample 
preparation, disposable 
cuvettes  
Several adjustments required 
(dilutions, microscope settings), 
cleaning of chamber after each 
measurement, operator 
experience required 
 
Average recording 
time 
 
2-5 min per measurement 5-10 min per measurement 
Application Sizing, size distribution  Sizing, size distribution, particle 
concentration 
 
 
Thus it can be seen that in the development of a new process of liposome production, 
size analysis as well as drug and lipid concentrations are key factors. Therefore, within 
this chapter the two main methods for sizing nanoparticles, both based on light 
scattering techniques, have been investigated. DLS and NTA were used to assess the 
homogeneity of the particle population and for determining particle concentration. To 
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quantify lipid concentration, an ELSD coupled to a HPLC was used. An ELSD detector 
is based on a light scattering detection of solids with a lower volatility than the mobile 
phase, and was chosen to allow for lipid quantification due to lack of UV adsorption of 
most lipids (Brouwers et al., 1998). 
 
3.2 Aim and Objectives 
The aim of this chapter was to investigate the initial development, optimisation, 
evaluation and validation of the core methods based on lipid quantification, particle 
sizing and microfluidic-directed manufacturing of liposomes. To achieve this, 
quantification methods for the lipid, drug and protein molecules used throughout this 
thesis were based on development of HPLC protocols, with quantification based on an 
ELSD. Each developed method underwent extensive validation to align with current 
ICH guidelines (ICH, 2005). Two main methods for particle sizing, DLS and NTA, were 
described and compared. Both methods were assessed for the sizing of liposomes, 
which ultimately defined how each method was used throughout this thesis. Vesicle 
manufacturing methods based on lipid film hydration, sonication, HSM and 
microfluidics were compared and design of experiments for a lipid adjuvant formulation 
which combines the cationic lipid dimethyldioctadecylammonium (Bromide Salt) and 
the immunomodulator trehalose-6,6-dibehenate (DDA-TDB) were adopted to support 
the development of statistical regression models for the prediction and correlation of 
particle size in each method.  
 
3.3 Results and Discussion 
3.3.1 Development and validation of quantification methods based on HPLC 
and ELSD 
The initial focus of this work was to establish quantification methods for a range of 
molecules. Therefore HPLC methods were developed, optimised and validated in 
terms of: linearity, accuracy, precision (intermediate precision and repeatability), limit of 
detection (LOD), limit of quantification (LOQ) and robustness. The separation of all 
compounds was achieved using a C18 reverse-phase column. The composition of the 
mobile phase, the flow rate and gradient flow was optimised for each compound. 
Detection was performed by UV (propofol, CM2) or ELSD (PC, Cholesterol, DOPE, 
DOTAP, DDA, TDB, ovalbumin). As an example, the complete validation protocol for 
cholesterol is shown below; thereafter the same protocols were adapted for all other 
molecules. For quantification of cholesterol, a gradient elution method was optimised, 
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which resulted in the elution of the lipid at 10 minutes and quantified by ELSD (Figure 
3.4). 
 
Figure 3.4: Elution peak for cholesterol detected by ELSD with the elution protocol. The 
flow rate was 1 mL/min throughout. Mobile phase A was 0.1%TFA water, B was methanol. 
 
3.3.1.1 Linearity 
Standard solutions (in chloroform) were prepared (with a minimum of at least five 
different concentrations), ranging from 0.25% to 200% of the target concentration 
(Shabir, 2003, 2005). If overshooting of the elution peak occurred at higher 
concentrations, respective dilution of the standards was adopted. For each 
concentration, three replicates were analysed. A calibration curve was constructed to 
assess the linearity for cholesterol over the concentration of 0.025 to 1 mg/mL. The 
peak area was determined and plotted against the known concentration of cholesterol 
standards. The mean and standard deviation was calculated for each concentration. 
Regression coefficients (R2) was deemed to be sufficient at ≥ 0.99. For example, for 
cholesterol the equation for the resulting calibration curve was y = 63664x +1192.3, 
with a linear regression coefficient of 0.993, passing the pre-set acceptance criteria 
(Figure 3.5).  
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Figure 3.5: Linearity assessment of cholesterol (0.025 to 1 mg/mL) used to determine the 
calibration curve to assess the cholesterol concentration. 
 
 
3.3.1.2 Precision 
Intraday precision (repeatability) and interday precision (intermediate) were determined 
for cholesterol at concentrations from 0.025 to 1 mg/mL. Again for each concentration, 
three replicates were analysed and a calibration curve was constructed. The peak area 
was determined and plotted against the known concentration of cholesterol standards. 
The mean, standard deviation and relative standard deviation (%RSD) were calculated 
for each concentration. A %RSD of ≤ 5% was set as the acceptance criteria. The 
interday precision determined the %RSD over the course of 3 days, intraday precision 
within one day. Examples of this for cholesterol are shown in Figure 3.6, with both 
criteria passing the pre-set acceptance criteria. 
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Figure 3.6: Cholesterol quantification - assessment of A) intraday and B) interday 
variability with linear regression coefficients and %RSD. 
 
3.3.1.3 Accuracy 
To assess the accuracy of the method, spiked samples of a known concentration of 
standard were prepared over the range of 50 to 150% of the target concentration 
(Shabir, 2005). Three prepared replicates were injected three times (n = 9), with for 
example, cholesterol concentrations of 0.05, 0.1 and 0.25 mg/mL. The mean, standard 
deviation and relative standard deviation (%RSD) was calculated for each 
concentration. Table 3.2 outlines the %RSD and recovery for cholesterol based on the 
method developed. The %RSD was found sufficient at ≤ 5% at a recovery ranging from 
90 – 110%, passing the pre-set acceptance criteria (Shabir, 2005).  
 
Table 3.2: Evaluation of %RSD and recovery during the validation of the assay accuracy. 
 
Concentration 
standard (mg/mL) 
Average determined 
concentration (mg/mL) %RSD Recovery (%) 
0.05 0.0512 4.7 104.5 ± 5.1 
0.10 0.1043 5.0 102.3 ± 4.0 
0.25 0.2522 3.1 96.4 ± 6.2 
 
3.3.1.4 Robustness 
Robustness assesses the capacity of the method to remain unaffected by small 
variations, and informs on the reliability of the method during normal usage (Shabir, 
2005). Investigated parameters included the variation in column temperature and flow 
rate. The column temperature was varied by ± 5°C and the flow rate was varied by ± 
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0.2 mL/min. When tested with cholesterol, the increase in temperature accelerated the 
elution, explained by increase in molecule diffusion by temperature increases (results 
not shown). The increase in flow rate also accelerated the elution profile, due to 
increased volumes of elution buffer through the column promoting dissociation of the 
compound from the column (results not shown). Both investigated parameters 
produced acceptable chromatograms, nevertheless effected elution time and area 
under the curve. Thus, the column temperature was fixed at 35°C and controlled 
throughout each measurement. Moreover, the flow rate of the mobile phase remained 
constant and was not altered post method validation. 
 
3.3.1.5 Level of detection and level of quantification 
Limit of detection (LOD) and limit of quantification (LOQ) were calculated by assessing 
the signal to noise ratio in the method and were determined from the standard 
deviation of the response and the slope from the calibration curve established during 
the linearity assessment. Calculations are based on the assumption of a signal to noise 
ratio of LOD 3:1, LOQ 10:1 (ICH, 2005), which may vary with ageing, model, 
manufacturer of detector or column. The slope is determined from the calibration curve 
and Equation 3.1, 3.2 and 3.3 are used to derive the LOD and LOQ. The LOD was 
below the reporting threshold (ICH, 2005) for all lipid protocols established. If the LOQ 
was found above the specification limit, a concentration of the sample was performed 
prior to quantification.  
 
 = 		(	)    Equation 3.2 
  =      Equation 3.3 
  =     Equation 3.4 
With 
  Standard deviation determined in calibration curve 
S  Slope determined in calibration curve 
Y  Intercept  
n  Number of standard solutions on the calibration curve 
 
In the case of cholesterol, a concentration of 0.77 mg/mL was used in a standard 
formulation (Table 2.1) and the LOQ determined was 0.15 mg/mL and within the 
acceptance criteria. The slope is determined from Figure 3.3 and Equation 3.1, 3.2 and 
3.3 were used to derive the LOD and LOQ as follows: 
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 = 	Σ	( −	!)"# − 2 = 	4540011.865 = 952.89		 
 
 =  = 	 ∗ ./. 0.1112 = . 22343 
 
567 = 108 = 10 ∗ 952.8963664 = 	0.150:;:5 
 
 
3.3.1.6 Summary of validation criteria for lipids used 
The overall summary of each validation procedure is shown in Table 3.3. As noted, it is 
important to verify both lipid and drug recovery throughout any work undertaken, first to 
assess the cost-effectiveness and verify concentrations of lipid and drug at ratios 
defined prior to formulation. In contrast to the time and equipment-intensive lipid 
quantification by mass spectrometry (Moore et al., 2007), the here-developed lipid 
quantification method based on HPLC separation and evaporative light scattering 
detection was found to be a simple and robust method, allowing quantification of any 
solids in the elute with a lower volatility than the mobile phase in validated methods. 
 
Table 3.3: Overview over the validation of lipids, drug (propofol) and protein (ovalbumin). 
 
 Linearity LOD LOQ Precision Accuracy 
Compound* R2 mg/mL mg/mL %RSD 
interday 
%RSD 
intraday 
%RSD Recovery 
(%) 
Cholesterol 0.993 0.044 0.150 3.607 3.820 4.277 101.1 ± 4.2 
PC 0.989 0.104 0.349 4.633 4.554 4.333 96.4 ± 3.3 
DOPE 0.996 0.051 0.168 3.543 4.983 2.544 98.6 ± 3.5 
DOTAP 0.995 0.061 0.204 2.987 4.544 4.765 105.3 ± 2.6 
DDA 0.998 0.024 0.079 5.043 4.765 3.433 107.3 ± 2.0 
TDB 0.995 0.102 0.341 5.033 4.654 3.547 103.5 ± 4.6 
Propofol 0.996 0.047 0.159 2.472 2.345 2.433 99.3 ± 5.9 
Ovalbumin  0.991 0.014 0.046 4.554 3.433 2.512 100.9 ± 6,3 
CM2 0.987 0.056 0.187 3.567 3.233 3.159 101.4 ± 3.6 
*PC = Phosphatidylcholine, DOPE = 1,2-dioleoyl-sn-glycero-3-phsphoethanolamine, DOTAP =1,2-dioleoyl-3-
trimethylammonium-propane, DDA = Dimethyldioctadecylammoniumbromide, TDB = Trehalose 6,6′-dibehenate, 
Propofol = 2,6-Bis(isopropyl)phenol, CM2 = 1,1'-(decane-1,10-diyl)bis(9-amino-1,2,3,4- tetrahydroacridinium) diiodide. 
 
3.3.1.7 Bimodal populations measurement by DLS 
Throughout this thesis, a range of particulate systems will be studied, which may be 
mono-, bi- or even multimodal populations. This may not only have an impact on 
therapeutic outcome of the system but may also impact on the measurement results 
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from particle size analysis techniques. To consider the modality of the particle size 
distribution, liposome suspensions (DDA-TDB, 1.25 mg/mL and 0.25 mg/mL 
respectively) containing a mixture of two different liposome size populations were 
prepared and the particle size measured using DLS. Two populations of liposomes 
were manufactured; initially using a rotary evaporation process for generating a larger 
population of ~500 nm vesicles (Table 3.4, Figure 3.7B). Subsequently, vesicles were 
sonicated to generate a smaller sized liposome population (~80 nm; Table 3.4, Figure 
3.7A). Both formulations contained equal lipid concentrations, therefore it follows that 
the 80 nm population comprised a larger number of vesicles. 
 
Table 3.4: Particle size and polydispersities measured from various liposome mixtures to 
assess the impact of bimodal size distributions on the measurement outcome. 
 
80:500 nm  
size ratio 
z-average diameter 
(nm) 
PDI 
1:0 78.1 ± 5.5 0.196 ± 0.005 
0:1 502.2 ± 15.5 0.704 ± 0.086 
1:1 175.6 ± 17.8 0.594 ± 0.008 
1:2 298.0 ± 22.1 0.595 ± 0.052 
1:4 407.0 ± 11.3 0.636 ± 0.046 
2:1 117.9 ± 8.5 0.413 ± 0.085 
4:1 101.1 ± 5.4 0.387 ± 0.057 
 
Subsequently, the two populations were mixed at different ratios in order to prepare 
bimodal populations (Table 3.4). Almost equal-sized intensity plot were obtained once 
mixing the 500 nm and 80 nm populations in a 1:1 lipid weight ratio, 51 % and 47% of 
the distribution at 500 nm and 47% of the distribution and 80 nm respectively (Figure 
3.7C). The representation in a volume % showed a larger proportion of the smaller 
sized vesicles (34% for the 500 nm sized population and 65% for the 80 nm sized 
population; Figure 3.7C). Reporting the z-average here would not reflect the actual size 
as shown in Table 3.4. Once the concentration of the larger-sized vesicle population is 
increased, good peak separation was still given and the changing ratios between 
intensity and volume peaks highlighting on the increase in the larger sized population 
(Figure 3.7C). With the z-average diameter increasing with a higher amount of larger-
sized population added (Table 3.4), highlighting on the inappropriate representation of 
the two populations by simply using the z-average. The 1:4 ratio of 80:500 nm 
liposomes resulted in approximately equal distribution plots (by volume) for both sub-
populations. Following, an approximately 4 times higher concentration of the smaller 
(80 nm) relative to the larger (500 nm) particles could be anticipated (Figure 3.7C). In 
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addition, the resolution between the populations decreased upon increasing the ratio of 
the smaller liposomes (Figure 3.7D). The larger-sized population became difficult to 
accurately detect, represented by peak broadening in intensity and volume based 
distributions, once the ratio was increased to 4:1 for 80:500 nm liposomes (Figure 
3.7D). The determined z-average approached the size of the smaller liposome 
population (80 nm), whereas the high degree of heterogeneity was still represented by 
a higher polydispersity (Table 3.4). The results in Figure 3.7 highlight the importance of 
evaluating both the intensity- and volume-based distribution plots for understanding 
particle size distribution during DLS measurements.  
 
 
Figure 3.7: Resulting intensity and volume based size distribution plots for the A) 80 nm 
sized and B) 500 nm sized population, C) increasing the ratio of the larger 500 nm 
population and D) increasing the ratio of the smaller 80 nm sized population. Adapted 
from (Kastner and Perrie, 2015). 
 
3.3.1.8 Direct comparison DLS and NTA measurement of liposomes 
To consider the two different particle size analysis methods (DLS and NTA) a direct 
comparative study between both techniques for a SUV formulation (PC-Chol, 6.06 
mg/mL and 0.77 mg/mL respectively) was undertaken. DLS analysis revealed a z-
average of 119 nm, with a polydispersity of 0.121 (Figure 3.8A) for the SUV 
formulation. The intensity and volume based distribution plots revealed a monomodal 
size distribution, with 100% intensity at 126 nm and 100% volume at 116 nm (Figure 
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3.8A). The same liposome batch was then analysed via NTA, which yielded a mean 
diameter of 147 nm, a mode of 118 nm and a standard deviation of 60 nm (Figure 
3.8B). In addition to the size distribution, the concentration of the particles was 
determined (8.9*108 particles/mL). A visual image and video were recorded throughout 
the measurement, showing the scattered laser light in the selected frame (Figure 3.8B).  
 
Figure 3.8: Direct comparison of a monomodal liposome size determination as measured 
by A) DLS and B) NTA with particle imaging by light scattering. Adapted from (Kastner 
and Perrie, 2015). 
 
Based on these initial results, the z-average resulting from a DLS measurement was 
found to correspond the most closely to the mode diameter as obtained by NTA for a 
monomodal size distribution. Furthermore, the correct particle size can be assessed as 
mode or mean, whereas the NTA measurement was mainly used as a visual particle 
confirmation in subsequent studies.  
 
Whilst the above described methods based on light scattering techniques are rapid and 
easily adopted, accurate size analysis of multi-modal size populations may be difficult 
and requires detailed analysis of intensity-, volume-based distribution. In order to 
validate measurements additional microscopy remains the most important reference 
method to be implemented for additional validation (Bootz et al., 2004). Therefore, an 
accurate and robust characterisation of suspended particles relies on selecting an 
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accurate measurement principle, accurate sample preparation and analysis. Likewise, 
both particle sizing techniques are based on a number of assumptions, which may not 
match the true attributes of the particles being sized. Throughout this work the size of 
particles was assessed by the z-average for monomodal size distributions, and the 
intensity-weight particle diameter for bi- or multimodal size distributions by DLS. 
Additionally, the comparison between intensity and volume-based distributions was 
used to qualitatively assess any ratios between bimodal size distributions. During NTA 
analysis, the mode diameter was recorded and the imaging tool was used as a visual 
confirmation of particles when required. 
 
3.3.2 Methods for liposome manufacturing: sonication, high shear mixing and 
microfluidics.   
To initially consider different methods of liposome production, a direct comparison of 
the four main methods for manufacturing liposomes (lipid film hydration, sonication, 
high shear mixing, microfluidics) was undertaken using protocols established within the 
laboratory. Liposomes composed of DDA-TDB (1.25 mg/mL and 0.25 mg/mL 
respectively) were prepared using each of the four methods and their size analysed by 
DLS (Figure 3.9). Here, the vesicles prepared by lipid film method (LFM) resulted in a 
population of around 500 nm ± 50 nm, sonication (Sonic.) produced vesicles of 120 nm 
± 25 nm, high shear mixing (HSM) produced vesicles of 230 nm ± 37 nm and vesicle 
produced by microfluidics were around 160 nm ± 25 nm and polydispersities were 
relatively unaffected by the respective methods (Figure 3.9). The sizes obtained and 
displayed in Figure 3.9 represent the averages sizes obtained within the initial method 
development phase, which have been further defined throughout the thesis. This early 
comparison demonstrates the effect of the liposome production method on vesicle size. 
 
Figure 3.9: Overlay plot showing the difference in liposome population in size and PDI 
produced by high shear mixing (HSM), sonication (sonic.) and microfluidics (MF) 
compared to liposomes produced by lipid hydration (LFH) method.  
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The morphology of these vesicles was considered using cryo-transmission electron 
microscopy (cryoTEM) (Figure 3.10). CryoTEM showed that multilamellar vesicles were 
manufactured in the lipid film hydration method (Figure 3.10A), and unilamellar 
liposomes were generated in the microfluidics method (Figure 3.10B), whereas the 
vesicles produced in the HSM method generated vesicles with multiple bilayers (Figure 
3.10C). Vesicles prepared by the sonication method were as unilamellar as would be 
anticipated (Figure 3.10D). However these vesicles do not appear spherical in nature 
as would be expected (Bibi et al., 2011). This may be due to disruptive mechanical 
forces in the process (Wagner and Vorauer-Uhl, 2010). Here, the average size based 
on cryoTEM differed from the size obtained by DLS measurement. Due to differences 
in underlying measurement principles and requirements, average vesicles sizes 
obtained by cryoTEM should not be directly compared to the size averages obtained by 
DLS measurement (Almgren et al., 2000)  and an extensive comparison of particle size 
by cryoTEM and DLS has been done by Egelhaaf (Egelhaaf et al., 1996). 
 
Figure 3.10: CryoTEM pictures obtained of A) MLV produced by lipid hydration B) SUV 
microfluidic mixing C) high shear mixing D) sonication. Bar represents A) 200 nm, B-D) 
100 nm. 
A 
 
 
 
 
 
B 
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The lipid film hydration is a relatively easy, simple, quick and well-established method 
(Bangham, 1961). Nevertheless, despite flushing with N2 after forming the lipid film, 
solvent residues may remain, making the method less applicable based on safety 
concerns. Moreover, the vesicle population is multilamellar and heterogeneous in size 
(ranging up to several microns), often resulting in low encapsulation achieved 
(Bangham, 1961). The vesicle size is influenced by the amount and type of lipids used 
and for a controlled vesicle size consecutive downsizing methods are required. 
Methods such as homogenisation, extrusion or HSM are relatively easy methods that 
allow for a bulk production with the possibility to run in a continuous mode. 
Nevertheless, these processes can require high pressures and/or generate heat, which 
may be damaging to lipids, drugs or proteins. With extrusion methods, filter clogging is 
an often-mentioned disadvantage (MacDonald et al., 1991) and the resulting sizes 
usually depend on the number of recirculation cycles or exposure times to shear or 
pressure (Bally et al., 1991). Sonication, based on a probe tip or a bath sonicator, is a 
quick and easy method, which mainly finds application in a laboratory setting only. 
Common reported problems are linked to contamination with metal residues from the 
probe tip and lipid degradation. The main disadvantage is the lack of scalability, 
making the method less viable for a large scale industrial process setting (Wagner and 
Vorauer-Uhl, 2010).  
 
To address these issues, microfluidics-based liposome production has been explored. 
The advantage of the microfluidics-based nanoprecipitation method lies in the 
controlled environment, leading to a reproducible process setup. Due to mixing in the 
micro-channels, the mixer has been designed to introduce a controlled mixing 
environment in a chaotic advection mixing profile (Stroock et al., 2002). The method is 
flexible and allows for screening over a range of concentration in a high-throughput 
setup, given time for formulation is drastically reduced. Nevertheless, solvent residues 
remain in the process, which require an additional purification process based on 
dialysis or filtration. Here, a spin column process was implemented for purification and 
concentration of the vesicles. The type of chip material dictates the solvent 
compatibility, and the precipitation process is based on a high volume of aqueous flow, 
which results in a dilution of the final formulation based on the settings chosen 
(Belliveau et al., 2012; Zhigaltsev et al., 2012). 
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3.3.2.1 Design of experiments for method investigation and validation 
The results reported in Figure 3.9 were based on protocols within the laboratory. To 
further optimise these, each method was evaluated using a DoE approach. Here, the 
previous described manufacturing methods, sonication, HSM and microfluidics were 
investigated in relation to the ability for controlling the size of the vesicles. The DDA-
TDB liposome formulation was again used for this optimisation process as it is a well-
established cationic adjuvant formulation (Christensen et al., 2007b) and has been 
further investigated in Chapter 8. Models included the variables: 
• Sonication - time (1-2 minutes) and amplitude (1 – 10) in the sonication method. 
• HSM - mixing time (1-10 minutes) and rotational speed (1000 – 25000 rpm). 
• Microfluidics - flow rate ratio (FRR, 1:2 – 1:5) and total flow rate (TFR, 1.2 – 2.5 
mL/min).  
The effect of respective factors to the size of DDA-TDB liposomes was evaluated.  
 
Model evaluation commenced with assessment of the summary plot, which displayed 
R2, Q2, model validity and reproducibility for all three methods: sonication, HSM and 
microfluidics (Figure 3.11A, 3.12A, 3.13A, respectively). Acceptance criterion were pre-
set at: R2 ≥ 0.5, Q2  ≥ R2 -0.3, validity ≥ 0.25 and reproducibility ≥ 0.5 for an excellent 
model. Close situation of R2 and Q2 values indicated that the models were highly 
predictive. Summary plot for the sonication method (Figure 3.11A) showed excellent 
model properties with R2 = 0.91, Q2 = 0.85, validity = 0.97, reproducibility = 0.73.  
Evaluation of the summary plots revealed a high amount of noise in the data set for 
HSM (Q2 of 0.25), with a goodness of fit of 0.81, validity = 0.5, reproducibility = 0.93, 
which was still evaluated and used as a control to the microfluidics method (Figure 
3.12A). The microfluidics method revealed an excellent fit (R2 = 0.92) with an 
acceptable predictability (Q2 = 0.39), indicative of noise in the data set similar to the 
HSM process. Nevertheless, the validity of 0.85 and reproducibility of 0.80 were 
considered good with no lack of fit present in the model and hence additional model 
evaluation was performed (Figure 3.13A). 
 
Given the excellent model fit and acceptable prediction along with good valid and 
reproducible models, further diagnostic tools were performed for outlier detection. The 
observed vs. predicted plots (Figure 3.11B, 3.12B, 3.13B) indicated good models in 
each method, as the points for the observed vs. the fitted values sat close to the 
straight 45° line. One outlier was detected in the microfluidics method (N8) and 
removed for model evaluation. A systematic effect was excluded in each model, as no 
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pattern was seen in the replicate plots (Figure 3.11C, 3.12C, 3.13C). Here, the 
replicate centre points showed a lower variation in each model compared to the 
experimental runs, with the sonication method showing the highest variation compared 
to the HSM and microfluidics model. The response surface plots showed liposome size 
predictions as a function of the factors in each method. Predictions in the sonication 
method showed minimal vesicle sizes of 90 nm and maximum vesicle sizes of 150 nm. 
The sonication amplitude was evaluated as the most important coefficient during the 
sonication process, whereas, the sonication time was found more important at low 
sonication amplitudes only (Figure 3.11D). The model predicting the vesicle size in the 
HSM method revealed the rotational speed as the factor with the biggest impact in the 
process (Figure 3.12D). Here, minimum vesicle sizes predicted were larger than the 
ones obtained in the sonication method, reaching a minimum of 160 nm, with 
maximum vesicle sizes of 320 nm. Overall, the HSM method showed an almost linear 
trend in the response surface with the smallest size achievable for the maximum 
mixing time (10 minutes) and rotational speed (25 000 rpm) and the largest size 
achievable for the minimum mixing time (1 minute) and rotational speed (1000 rpm). In 
the microfluidics method, vesicle sizes ranged between a maximum vesicle size of 200 
nm down to a minimum of 90 nm. Here, both factors, TFR and FRR were found as 
strongly influencing the model predictions, where the effect to size at higher aqueous 
FRR (above 1:3) and at constant TFR showed only limited effect to the size. The TFR 
was found an important factor even at constant FRR, where the smallest liposome size 
was predicted for a FRR of 1:3 to 1:4 at the highest TFR of 2.5 mL/min (Figure 3.13D). 
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Figure 3.11: Design of Experiments predicting the liposome size in the sonication 
process dependent on the factors sonication time (1-2 minutes) and amplitude (1-10). 
Model type was a screening design (full factorial) with 3 centre points. Depicted is A) 
Summary plot (R2=0.91, Q2=0.85, Validity=0.97, Reproducibility=0.73), B) Observed vs. 
predicted, C) Replicates plot and D) Contour Plot. 
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Figure 3.12: Design of Experiments predicting the liposome size in the HSM process 
dependent on the factors mixing time (1-10 minutes), rotational speed (1 000-25 000 rpm). 
Model type was a screening design (full factorial) with 3 centre points. Depicted is A) 
Summary plot (R2=0.81, Q2=0.25, Validity=0.5, Reproducibility=0.93, B) Observed vs. 
predicted, C) Replicates plot and D) Contour Plot. 
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Figure 3.13: Design of Experiments predicting the liposome size in the microfluidics 
process dependent on the factors flow rate ratio (1:2 to 1:5) and total flow rate (1.2 to 2.5 
mL/min). Model type was a response surface model (full factorial, CCC) with 3 centre 
points. Depicted is A) Summary plot (R2=0.92, Q2=0.39, Validity=0.85, 
Reproducibility=0.80, B) Observed vs. predicted, C) Replicates plot and D) Contour Plot.  
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Furthermore to model interpretation (Eriksson, 2008), the ANOVA analysis was linked 
to the replicate experiments; the centre points and all three models (sonication, HSM, 
microfluidics) were determined as statistical significant in the regression model 
(p<0.05) and the LOF test (p>0.05), Table 3.5.   
 
Table 3.5: ANOVA for the response size in the sonication, HSM and microfluidics 
method. The p-statistics were analysed as well as the Lack-of-fit (LOF), together with fit 
power (R2) and predictive power (Q2). 
ANOVA Sonication HSM Microfluidics 
Regression p 0.045 0.034 0.024 
LOF p 0.906 0.130 0.568 
R2 0.910 0.81 0.923 
Q2 0.848 0.25 0.388 
Model Significant? Yes Yes Yes 
 
Other than evaluating the model significance, the actual regression model was 
determined. Here, the response surface model (microfluidics method) was represented 
by a quadratic model, relating the responses (y) and factors (x), Equation 3.5.  
< =	= + =? +	=? +	=? +	=? +	=?? + 	@  Equation 3.5 
 
The screening models (sonication, HSM) were represented by an interaction model, 
Equation 3.6. 
<	A	 =	= + =? +	=? + =?? + 	@    Equation 3.6 
 
Here, y1 represented the response liposome size in the microfluidics method. x1 
represented the factor FRR and x2 the TFR. y2 represented the response liposome size 
in the sonication method. x1 represented the factor sonication amplitude and x2 the 
sonication time. y3 represented the response liposome size in the HSM method. x1 
represented the factor mixing speed and x2 the mixing time. In all models, BC was the 
constant term (representing the intercept), β´s were the effect coefficients, which were 
determined throughout the model evaluation (Eriksson, 2008). ε was the residual 
response variation, which could not be explained by the model. Insignificant model 
terms were removed during model evaluation and the remaining significant coefficients 
generated the regression models for each response (Table 3.6). 
 
Equation 3.5 represents a quadratic model, as not only the model terms are evaluated 
(x1 and x2), but also their quadratic (x12 and x22) and combinatorial effect (x1 * x2) is 
evaluated. The interaction model (Equation 3.6) is a simplified version, only 
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investigating the model terms (x1 and x2) and their combinatorial effect (x1 * x2). Linking 
this to the investigated liposome manufacturing methods, the quadratic effect (x12) of 
the factor FRR had the biggest impact on the resulting liposome size (Table 3.6). For 
the sonication method the factor amplitude (x1) showed a bigger impact to the resulting 
liposome size than the factor sonication time (x2) and the respective combinatorial 
effect (x1 * x2). Similar, for the HSM process, the factor speed (x1) showed the biggest 
impact, with no combinatorial or synergistic effects detected throughout the model 
evaluation (Table 3.6). 
 
 
Table 3.6: Determined significant coefficients and respective regression model in each 
method, predicting the liposome size. Amp = amplitude 
 
Method Significant Coefficients Regression model 
Microfluidics TFR, FRR*FRR, TFR*TFR, 
FRR*TFR 
DE = 	140.968 − 	26.724G" + 	29.34GE" − 		23.29G"" −15.34	GE	G" + 	H  
Sonication amp, time, amp*time D" = 	115.179 − 25.787GE + 	5.637	G" − 	12.767GE	G" + 	H  
HSM speed, time DI = 	238.207 − 55.025GE − 	40.275G" 	+ H	 
 
In addition to the model evaluations and predictions made by the respective response 
surfaces, each model was validated in an additional experimental setup. For each 
method, various points were selected from the model prediction, which were compared 
to the experimentally obtained values. In all methods, three points were chosen and 
experimentally obtained vesicles sizes directly compared to the ones predicted with the 
respective DoE model. The validation revealed that all three models predicted well the 
actual vesicle size obtained, with the error in the experimentally obtained values 
generally exceeding the ones obtained from the model, with increasing error with 
increasing vesicle size (Figure 3.14A, B, C). In the microfluidics as well as the HSM 
method, predicted vesicles sizes were generally underestimated as the experimentally 
obtained sizes exceeded the predicted ones by 15-30 nm (Figure 3.14A, C). 
  Chapter 3: Method Development 
107 
 
 
Figure 3.14: Validation of the DoE models generated by direct comparison of 
experimentally obtained vesicle sizes against predicted vesicle sizes at different set 
points. 
For the well-established sonication method, vesicle sizes predicted ranged from 90 nm 
to 150 nm for the here used high transition temperature lipids (DDA-TDB), coinciding 
with averages sizes reported in literature using probe sonication (Kaur et al., 2012a; 
Milicic et al., 2012; Wagner and Vorauer-Uhl, 2010). Overall, the method was found to 
be quick with reproducible vesicle sizes obtained. However, the removal of metal 
contaminants by centrifugation post manufacturing requires additional time. The model 
evaluated sonication amplitude as the most important factor to be optimised once 
sonication has been chosen as the method of manufacturing. Therefore, for achieving 
small vesicles, it is more beneficial to choose a high amplitude but short duration 
process, which could be considered beneficial for the vesicles themselves being 
exposed to the sonication power only for a minimized period of time. The model 
predicted vesicle sizes in the HSM method ranging from 160 nm to 320 nm depending 
on the HSM time and rotational speed, overall coinciding with literature reporting on 
HSM methods (Bally et al., 1991). Here, the rotational speed was found as the most 
important variable in the process, highlighting on the need to carefully evaluate the 
speed in the process rather than extending the time in the mixing process to achieve 
smaller vesicles, similar to the sonication time a short exposure to the mechanical 
stresses would benefit the vesicles rather than choosing an extended process an 
intermediate or low power input and prolonged exposure time.  
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In the microfluidics method both factors, the TFR and the FRR had a significant impact, 
suggesting that both terms impacted on the resulting liposome size, with the ratio 
between solvent and aqueous stream having a significant impact, emphasized by the 
quadratic term FRR*FRR. The microfluidics method was shown to manufacture small 
vesicles down to 90 nm in size. Previous work on a SHM method for lipid nanoparticle 
manufacturing reported sizes down to 20 - 40 nm as well as emulsions within the range 
of 20 - 50 nm (Belliveau et al., 2012; Zhigaltsev et al., 2012). This highlights the 
importance of the solvent to aqueous flow rate for producing vesicles of a defined size, 
and highlighted on the methods being less disruptive than a sonication method with 
higher reproducibility than the ethanol dilution method (Batzri and Korn, 1973). Noise in 
the microfluidics method, as detected in the DoE, could be explained by the process 
settings. In each formulation, the first sample stream was collected in the waste, 
whether only the core of the sample should be collected to achieve the most accurate 
and reproducible sizes, according to the manufacturer. Noise in the data set here could 
be explained by this waste volume initially not being optimised for the formulation. In all 
following conducted studies, the waste volume was optimised for each formulation, 
allowing for collecting the most reproducible sample core, but reducing the overall 
yield. 
 
Deviation from model predictions and underestimated predicted vesicle sizes may be 
associated with the flexibility of the vesicles and sensitivity to manufacturing 
temperatures. Furthermore, all model predictions strongly depend on the accuracy of 
the method for analysing the particle characteristics, which here was DLS. The HSM as 
well as the microfluidics method were found with a higher level of noise in the data set, 
represented by the lower Q2 values obtained (Figure 3.12A, 3.13A). Nevertheless, 
model evaluation (Table 3.6) and validation (Figure 3.14) confirmed the accuracy of 
each model predictions made, where presumably variation in noise levels was related 
to the choice of lipids. Here, the high transition temperature lipid DDA, with a transition 
temperature of Tm ≈ 47 °C (Christensen et al., 2010) was used. In the microfluidics 
method, a heating block was used to maintain this temperature during the vesicle 
manufacturing process. Nevertheless, given the solubility of the lipids being lower in 
isopropanol might have resulted in solubility difficulties, overall adding a larger variation 
and ultimately resulting in a lower predictive power in the respective model. The 
temperature during the HSM process was maintained by a water bath, where heat 
transfer might have been impeded overall leading to the larger noise level in the HSM 
model. In contrast, the probe sonication has been in direct contact with the vesicle 
  Chapter 3: Method Development 
109 
 
suspension, where the sonication process itself generated heat overall aiding the 
solubility of lipids and the formation of SUV. Above results confirmed the statistical 
validity of the models and allowed to generate regression models and response 
surface plots.  
 
The noise in the models predicting liposome size could furthermore be linked to the 
molecular basis; bilayer fluidity dependency on temperature fluctuations, nucleation 
effect, pH changes, aggregation (Ellens et al., 1984; Sunamoto et al., 1980; Yoshioka, 
1991), all known parameters to influence liposome size and leading to a higher noise 
level than in a completely described and fixed process (Eriksson, 2008). Based on this, 
a certain level of noise can always be expected in a liposome-based DoE study (Ducat 
et al., 2010; Stensrud et al., 2000). 
 
3.3.2.2 Lipid quantification for process recovery  
In addition to evaluating the vesicle sizes, the recovery of the lipids in each method 
was assessed using established HPLC protocols (Section 3.3.1). Here, the DDA and 
TDB lipids were quantified in the DoE optimised lipid film hydration process, HSM, 
sonication and microfluidics method. The quantification of the lipids throughout the 
microfluidics process highlighted the initial dilution of the liposome formulation in the 
aqueous phase, based on the high aqueous flow introduced into the process. Vesicle 
concentration was performed in a spin column process step, which countered the initial 
dilution, p>0.05 (Figure 3.15), with an overall recovery of 82% achieved. The lipid 
quantification revealed a lipid recovery of 80% in the sonication method, remaining 
statistically insignificant on comparison to the lipid amount available prior vesicle 
manufacturing. The high shear mixing method showed a final recovery of 84%, p>0.05, 
(Figure 3.15).  
 
The dialysis protocol was based on a buffer exchange every hour for a total processing 
time of 4 h, with a solvent residue of < 1% (v/v) remaining as quantified by gas 
chromatography (results not shown). The developed purification process based on a 
spin column technique resulted in successful removal of solvent within less than one 
hour. 
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Figure 3.15: Recovery of DDA (%) and TDB (%) within the lipid film hydration (LFH), 
sonication, HSM and microfluidics (MF) process. Lipids were quantified using HPLC and 
expressed as % relative to the initial amount of lipids dissolved in the stock solution.  
 
3.4 Conclusion 
Within this chapter the methods to prepare liposomes and to characterise them were 
evaluated. Size characterisation protocols were established as were lipid recovery 
protocols. DoE models were used to give an initial overview of the size ranges 
obtainable in each method (sonication, HSM and microfluidics) whilst evaluating 
advantages and disadvantages of each method. DoE models were validated, which 
confirmed the accuracy and validity of predictions made overall allowing for a good 
comparison within the different methods. These models were verified by comparing 
predicted values to experimentally obtained results. The HSM process was shown to 
be a relatively quick method for the production of liposomes; however, noise in the data 
set has to be minimized by concise process control. Smaller vesicles are produced 
using the sonication method, but this method is compromised by potential lipid 
degradation or contamination. In the microfluidics method, the optimisation of the 
waste to sample ratio was found important for reducing noise. Also, the time 
associated with dialysis to remove residual solvent was found as the main 
disadvantage in the microfluidics method.  
 
The aim of this work was to identify the most effective way of manufacturing small 
vesicles, and the DoE approach aided the process robustness and validation for the 
methods investigated. Based on the validity of all models generated and the 
advantages of each method being highlighted, the microfluidics method was chosen to 
be taken further into subsequent studies.  
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4 Manufacturing of cationic liposomes by microfluidics 
for in-vitro transfection and assessment of statistical 
tools for process development 
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High-throughput manufacturing of size-tuned liposomes by a new microfluidics method 
using enhanced statistical tools for characterization. International Journal of 
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4.1 Introduction 
The efficient delivery of genetic material to a target site remains challenging. Factors 
like the size, charge and in-vivo degradation by nucleases impede the intracellular 
delivery of ‘naked’ DNA (Al-Dosari and Gao, 2009) and hence vehicles for delivering 
genetic material to a target site are used. Viral vectors promote high transfection 
efficiencies but are limited by their associated toxicity and immunogenic reactions, 
which leads to the preferred application of non-viral delivery systems, amongst which 
liposomes are well explored as non-viral delivery vehicles for genetic material (Bedi et 
al., 2011; Gjetting et al., 2011; Gregoriadis et al., 2002; Perrie et al., 2003). Along with 
enhanced safety profiles, liposomes can be manufactured easily, cost effectively  and 
in a variety of sizes, thus overall fulfilling many requirements of an ideal delivery vector 
(Lui and Huang, 2003). As anionic charges dominate on cell surfaces due to presence 
of negatively charged membrane lipids like phosphatidylserine (PS) and sphingomyelin 
(Ohvo-Rekilä et al., 2002), cationic liposomes have been extensively investigated and 
reported as efficient transfection agents, based on their electrostatic interaction with 
cell surfaces. The term ‘lipoplex’ relates to the fusion product of cationic liposomes with 
negatively charged DNA, which is based on electrostatic interaction and achieves high 
in-vitro transfection rates with low cellular toxicity (McNeil et al., 2010). As such, 
several constraining factors have been investigated for the in-vitro transfection by 
lipoplexes, including the structure of the lipids, net positive charge, structure of the 
complexes formed, lipid/DNA charge ratio, type of lipid, electrolytes used and size of 
the liposomes themselves (Congiu et al., 2004; Moghaddam et al., 2011). 
 
Current methods of liposome manufacturing for lipoplex production comprise top-down 
methods such as sonication or extrusion (Congiu et al., 2004; Moghaddam et al., 
2011), where the control of the resulting liposome size requires time-intensive 
optimisation. This present chapter investigated microfluidics-directed nanoprecipitation 
as a new method for manufacturing cationic liposomes, with reported high in-vitro 
transfection efficiency and ideal immune response (Ciani et al., 2007; Liu and Huang, 
2002; McNeil et al., 2010) and the systems produced via this new production method 
were compared to previous studies.  
 
Here, the on-chip chaotic advection mixer was evaluated and the effect of flow rate and 
flow ratio on liposome physicochemical properties and transfection efficiencies in-vitro 
was investigated. Furthermore two statistical-based tools, design of experiments (DoE) 
and multivariate analysis (MVA) were implemented in order to aid process 
understanding. These optimisation tools were used to build knowledge around the 
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microfluidics-controlled manufacturing of lipoplexes, which ultimately supported the 
development, confidence, understanding, and robustness of the process. 
 
Table 4.1: The chemical structure and key characteristics of lipids used to formulate 
liposomes in this study.  
 
 
Charge 
 
Lipid structure* 
Molecular 
Weight 
Transition 
Temperature 
DOPE Neutral 
 
744.03 -16°C 
DOTAP Cationic 
 
698.54 -12 °C 
Structure obtained from avantilipids.com. 
 
4.2 Aim and Objectives 
The aim of this chapter was to investigate the use of microfluidics to prepare cationic 
liposomal systems that are used as transfection agents. To achieve this, cationic 
liposomes were prepared using two commonly adopted lipids: 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE) and 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP) (Table 4.1). To consider the parameters controlling their manufacture using 
microfluidics the total flow rate through the system and flow rate ratio between the 
solvent and aqueous phase were studied and their effect on particle characteristics and 
in-vitro transfection rate were investigated. To study and develop the manufacturing 
process, design of experiments and multivariate analysis were adopted to support the 
development of statistical regression models for the prediction and correlation of 
particle characteristics and transfection efficiency. 
 
4.3 Results and Discussion  
4.3.1 In-process control of vesicle size using microfluidics-directed 
nanoprecipitation 
Liposomes, consisting of DOTAP and neutral fusogenic helper lipid DOPE were 
formulated using the microfluidics nanoprecipitation method with a SHM design. 
Initially, the two factors total flow rate (TFR) and flow rate ratio (FRR) were related to 
the resulting particle characteristics by varying the TFR from 0.5 mL/min to 2 mL/min 
and varying the FRR of the solvent/aqueous phases from 1:1 to 1:5. The effect of both 
parameters were explored in a one factor at a time (OFAT) method, varying only one 
factor while keeping the other one fixed. 
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The solvent to aqueous ratio substantially affected the size of the resulting liposomes 
(Figure 4.1); a decrease in vesicle size from 200 nm to 80 nm was linked to an 
increase in aqueous FRR from 1:1 to 1:5 (Figure 4.1A). The smallest liposome size 
was detected at a FRR of 1:3 and 1:5 with around 50 - 75 nm whereas the 1:1 
solvent/aqueous formulation resulted in significant larger vesicle sizes of 175 – 200 nm 
(Figure 4.1A). The change in TFR did not significantly affect the resulting liposome size 
when increased from 0.5 mL/min to 2 mL/min at constant FRR of 1:1, 1:3 or 1:5 (Figure 
4.1A). The PDI, a measure of the heterogeneity of the formulation, ranged between 0.2 
and 0.5, with a notable link to the FRR (Figure 4.1B); the lowest PDI of 0.2 was 
observed for a FRR of 1:1, increasing to a maximum value of 0.5 for a FRR of 1:5. In 
contrast, the zeta potential of the liposomes formed by micromixing was independent of 
flow rates and ratios suggesting that surface characteristics of the liposomes were not 
altered by these factors (Figure 4.1C). This would be expected for these cationic 
formulations, a strong cationic zeta potential of around 45 - 60 mV was measured 
(Figure 4.1C), linked to the cationic polar head group of the lipid DOTAP and in 
agreement with previous work on DOPE-DOTAP vesicles prepared by the lipid-
hydration method followed by sonication (McNeil et al., 2010).  
 
Figure 4.1: Liposome characteristics. A) Vesicle size, B) polydispersity and C) zeta 
potential of DOPE-DOTAP formulations manufactured by microfluidic mixing. Results 
denote the mean of triplicate formulations ± SD. 
 
The factor FRR is directly linked to the polarity increase throughout the chamber, which 
is the driving mechanism behind the precipitation reaction (Dong et al., 2012). At high 
aqueous buffer ratios, the mixing rate of the lipid phase with the buffer is enhanced. At 
higher aqueous FRR the fluid velocities between both streams differ dramatically, 
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which decreases the effective diffusion layer thickness of the solvent stream in the 
mixing profile. Additionally, enhancing the ratio of alcohol to buffer reduces the width of 
the solvent stream in the mixing profile, further diminishing the diffusion distances 
(Zook and Vreeland, 2010). Mixing in a chaotic micromixer is primarily dominated by 
enhancing the diffusion due to alterations of the fluid flow profile as here achieved by 
the herringbones in the floor of the mixing chamber (Stroock et al., 2002). The 
enhanced mixing process at FRR with high aqueous content, decreases the solvent 
concentration drastically, leading to the formation of lipid bilayers (Zook and Vreeland, 
2010). With less solvent available for solubilisation of the hydrophobic chains, the 
closure time for the vesicle decreases with smaller vesicles expected at higher FRR 
(Zook and Vreeland, 2010). As seen in Figure 4.1A, the smallest vesicles correspond 
to higher aqueous volumes introduced into the precipitation process. At lower aqueous 
content FRR (here 1:1), more solvent remains present during the mixing process, 
allowing for prolonged stabilisation of the hydrophobic components. The slower 
depletion rate leaves more time for the bilayers to grow before vesicles are formed, 
leading to overall larger vesicles, as seen here for a FRR of 1:1 (Figure 4.1A). 
Furthermore, higher aqueous content FRR reduce the final solvent concentration, thus 
decreasing the synthesis of larger particles due to particle fusion and lipid exchange 
(Ostwald ripening) after complete mixing is achieved. Nanoprecipitation of lipids based 
on microfluidics has been reported based on hydrodynamic flow focusing, where a 
stream of solvent is hydrodynamically focused between two aqueous streams. Similar 
to the chaotic advection micromixer investigated within these studies, the flow focusing 
technique reported a decrease in liposome size with the increase in aqueous ratio 
present in the mixing process (Jahn et al., 2010; Zook and Vreeland, 2010). The larger-
scale precipitation method based on an adapted ethanol-injection method reported the 
significance of the buffer flow rate, where a lower buffer flow rate was linked to a 
broader size distribution and polydispersity (Wagner et al., 2002b). The increase in PDI 
by increasing the FRR (to 1:5), as seen in Figure 4.1C, may be a result of partially 
incomplete mixing due to the higher aqueous volume inputted into the chamber, which 
may be countered by extending the channel length. However, polydispersity remained 
independent of the flow rate applied at constant FRR. The effect of flow velocity to the 
polydispersity was also studied by Balbino et al.; similar to the results reported in 
Figure 4.1, these studies showed that flow velocity remained independent of the 
polydispersity of the formation, which ranged from 0.2 to 0.3 for cationic using egg PC, 
DOPE and DOTAP in a 50/25/25 % molar ratio (Balbino et al., 2013a; Balbino et al., 
2013b). These differences in PDI may be subject to the formulations used; for example 
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it has been reported that the inclusion of PEGylated lipids can reduce PDI (Fang et al., 
2012).  
 
This preliminary screening work reported in Figure 4.1 emphasized that particle size is 
strongly dependent on the ratio of aqueous to solvent rate, thereby offering an ability to 
control the resulting particle characteristics in the microfluidics method. This suggests 
that vesicle size can be in-process controlled. Furthermore, the flow rate was shown as 
an independent variable for cationic DOPE-DOTAP liposomes, indicating on the 
potential of the method to generate a higher production throughput, one of the main 
advantages of using microfluidics controlled liposome manufacture.  
 
In contrast to multi-step “top down” methods like lipid film hydration, sonication, mixing 
or extrusion, the microfluidics-directed nanoprecipitation method is a relatively new and 
quick “bottom-up” method of vesicle manufacturing (Hood et al., 2014b). The 
nanoprecipitation method based on microfluidics has been reported by hydrodynamic 
flow focusing (Hood et al., 2014b; Jahn et al., 2010; Jahn et al., 2007; Jahn et al., 
2004), which was based on the same principle of mixing of aqueous and solvent 
phase. However, flow focusing methods reported significant lower total flow rates, 
ranging from 0.08 to 0.4 mL/min, extrapolated from reported fluid velocities of 100 to 
500 mm/s (Balbino et al., 2013b). Jahn and co-workers presented the hydrodynamic 
flow focusing method for controlled vesicle assembly, using flow rates between 1 to 90 
µL/min (Jahn et al., 2007), magnitudes lower than the reported flow rates in the here 
presented SHM method. Opposed to flow focusing methods, the here evaluated SHM 
mixer allowed for significant higher TFRs, ranging up to 2.5 mL/min, increasing 
throughput up to 30 times. Furthermore, the ratios between solvent to aqueous flow in 
the hydrodynamic flow focusing method ranged from 5 (Balbino et al., 2013b) up to 30 
(Jahn et al., 2007), leading to a significant lower particle concentration post 
manufacturing. This high aqueous ratio has two major impacts; first, solvent residues 
are reduced, which might benefit storage and use of proteins/peptides. Second, the 
effective concentration of the particles is significantly reduced, necessitating an 
additional concentration step, which will increase the total process time. In this here-
presented SHM method, higher solvent concentrations remained after the formulation, 
which ranged between 15 to 25% dependent on the FRR chosen (1:5 to 1:3) and were 
removed by dialysis; however, this increased the processing time. Both the flow 
focusing and SHM methods were previously shown to allow for the control of the 
nanoparticle size, where the SHM method was reported for lipid nanoparticles with an 
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electrodense core for siRNA delivery only (Belliveau et al., 2012; Leung et al., 2012; 
Zhigaltsev et al., 2012).  
 
4.3.2 Evaluating the microfluidics-based manufacturing for process recovery - 
Lipid quantification by ELSD 
Further to the above assessment on the effect of TFR and FRR on particle 
characteristics, their effect on the recovery of the lipids was also assessed. Therefore, 
the lipids DOPE and DOTAP were quantified in the core of each sample. Similar to 
Section 4.3.1, the factor TFR and FRR were investigated separately in an OFAT 
method. Lipid recovery was expressed as the average of DOPE and DOTAP recovery 
and related to the initial amount of lipids present in the ethanol stock (and considering 
the dilution factor based on the FRR). The recovery of the lipids was above 87% for all 
preparation factors considered; this was not significantly different from initial amounts 
in the ethanol stocks and was independent of the TFR and FRR chosen and (Figure 
4.2A). Furthermore the DOPE-DOTAP ratio was maintained in all preparations (Figure 
4.2B). These results suggested that the syringe driven system accurately introduced 
the solvent volumes into the chip even at higher ratios (1:5). Given that the increase in 
FRR increased the polydispersity in the formulation (section 4.3.1), FRR higher than 
1:5 were not considered.  
 
Whilst no significant loss of lipids was noted here, lipid loss due to adsorption onto the 
chip material was important to consider. Polydimethylsiloxane (PDMS) is a transparent, 
elastomeric polymer, with wide application in microfluidics. Chip manufacturing with 
PDMS is relatively cost-effective and the moulding process easy. Nevertheless, it is 
known for its adsorption properties of biologic materials, including proteins, mainly due 
to its porosity and hydrophobicity (Monahan et al., 2002; Toepke and Beebe, 2006). 
Studies have shown that a PDMS matrix adsorbed hydrophobic compounds up to four-
times higher compared to glass or polystyrene (Li et al., 2009). At the time point of this 
study, the PDMS chips and mixer platform were part of a beta-test version. The 
available technology underwent a material change throughout its commercialisation 
process, with chip material changed to cyclic olefin copolymer (CoC), a thermos-plastic 
polymer, with better material properties and manufacturing processes compared to 
PDMS (Jeon et al., 2011). The quantification of lipids was based on the developed 
ELSD technique (Chapter 3), a quick and effective method, circumventing time-
intensive mass spectrometry or assays. Maintaining the lipid content and the lipid ratio 
is important in the overall process yield and the process economy.  
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Figure 4.2: Quantification of total lipid content (DOPE + DOTAP) by HPLC, shown as A) 
recovery (%) and B) ratio of both lipids, DOTAP/DOPE. Results are the mean of triplicate 
formulations ± SD. 
 
4.3.3 In-vitro transfection efficiency and the effect of vesicle size 
Given that above studies indicated the effect to the resulting vesicle characteristics, the 
ability of those vesicles to act as a transfection agent was explored in-vitro with a 
plasmid containing the luciferase gene (gWiz™ Luciferase). Lipofectin™ has been 
reported in various cell lines for in-vitro transfection and acted as a transfection control 
(Fortunati et al., 1996; Malone et al., 1989). Each formulation varied in TFR and FRR 
as described previously, and respective transfection efficiency was assessed as the 
percentage of luciferase activity to the control (Lipofectin™) and reported as luciferase 
activity (%). The highest transfection was determined for a solvent:aqueous ratio of 1:3, 
increasing the transfection outcome to 250% compared to the commercial Lipofectin™ 
(Figure 4.3A). Formulations made at a FRR of 1:1 gave a 150-200% increase in 
transfection whereas the formulations at a FRR of 1:5 gave the lowest transfection, 
matching the transfection rates of the commercial Lipofectin™ product (Figure 4.3A). 
Despite the differences in transfection outcome due to changes in FRR, changes in 
TFR were independent of the transfection activity, which, similar to above, 
demonstrates the microfluidics-method as a highly applicable method for high-
throughput production of liposomes (Figure 4.3A). Furthermore, the potential toxicity of 
these formulations verified that transfection efficacy was independent of cell viability. 
For all experiments and formulations made, the cell viabilities ranged between 60-85% 
with no significant (p>0.05) difference between the formulations (Figure 4.3B). Flow 
rates and ratios were also independent variables of the cell viability (Figure 4.3B). 
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Figure 4.3: A) Comparison of transfection efficiency of cationic nanoparticles. 
Liposomes were complexed with gWiz plasmid DNA expressing firefly luciferase. B) 
Relative cell viability of nanoparticles formulated. Results are the mean of triplicate 
formulations ± SD. 
 
Published transfection efficiencies from our laboratories obtained with the cationic 
DOPE-DOTAP lipoplexes were approximately 250% in comparison to the Lipofectin™ 
(Moghaddam et al., 2011). These transfection efficiencies and cell viabilities (up to 
90%) coincided with the results presented in Figure 4.3, confirming that the method of 
manufacturing was independent of the resulting biological performance. The in-vitro 
transfection efficacy of lipoplexes has been well explored; the size, charge and 
lipid/DNA ratio are all crucial factors for successful transfection (Aljaberi et al., 2007; 
Caracciolo et al., 2007). Here, the lipids/DNA ratio, as well as the cationic zeta 
potential was maintained throughout the formulation, which consequently links the 
resulting transfection efficacies to differences in vesicle sizes (Figure 4.1A). The 
vesicle size has previously been investigated (Esposito et al., 2006; Felgner et al., 
1987; Kawaura et al., 1998; McNeil et al., 2010), with the lowest transfection rate 
correlating to a smaller vesicle size. Additionally, the ideal transfection reagent should 
be simple to manufacture in a reproducible setup (Lui and Huang, 2003).  
 
4.3.4 Statistical impact of the factors flow rate and flow ratio in a design of 
experiments study 
The results from Section 4.3.1 showed that vesicles manufactured by microfluidics 
were size controlled and acted as an efficient delivery system for genetic material. 
However, the variables TFR and FRR were investigated separately in an OFAT 
method, where only one factor was varied while the other one was fixed. Such OFAT 
methods often require a substantial amount of time/resource and may overlook local 
optima along with poor cover of the experimental space. Therefore, a design of 
experiments (DoE) approach investigated the effect of the factors TFR and FRR on 
liposome size, polydispersity and transfection efficiency (luciferase activity), with good 
coverage of the experimental space to determine optima that might have been 
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overlooked in the OFAT method. Thus the next step was to determine the statistical 
effect, along with exploring the significance and interaction between variables while 
generating a regression model. Based on the knowledge developed in the previous 
screening of the factors in the OFAT method, a response surface model (RSM) was 
chosen. This in-depth analysis investigated the factors TFR and FRR, as well as their 
interaction and quadratic terms TFR*TFR, FRR*FRR and TFR*FRR in a quadratic 
regression model (Figure 4.4). In addition to 3 replicates acting as centre points (N11, 
N12, N13), a further replicate set was added to aid the reproducibility of the model (N1, 
N2). The experimental space was chosen to match the exact values of the FRR and 
TFR as investigated earlier, ranging from 1:1, 1:3 to 1:5 and FRR and 0.5, 1, 1.5 and 2 
mL/min for TFR. 
 
 
Figure 4.4: Design space in a two factorial design including 2 Factors (TFR and FRR) with 
a total 15 experimental points, triplicate centre point (N11, 12, 13) and replicate 
experimental point (N1, N2) were added. 
 
Model evaluation commenced with assessment of the summary plot, which displayed 
R2, Q2, model validity and reproducibility and revealed a valid model for all three 
responses: liposome size, PDI and transfection efficiency (Figure 4.5). Acceptance 
criterion were pre-set at R2 ≥ 0.5, Q2  ≥ R2 -0.3, validity ≥ 0.25 and reproducibility ≥ 0.5 
for a good model. Close situation of R2 and Q2 values indicated that the models were 
highly predictive, e.g. the Q2 value of 0.97 in the size model revealed that 97% of the 
model is predictive, which represented an excellent model prediction with only 3% of 
the data not being predictive.  
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R2       0.98  0.84 0.89 
Q2               0.97         0.74         0.68 
Validity                      0.63                0.98                0.88 
Reproducibility                             0.99                       0.59                       0.82 
 
Figure 4.5: Summary plots to evaluate the model fit (R2), prediction (Q2), validity and 
reproducibility for the responses liposome size, polydispersity and transfection 
efficiency. For an excellent model, all values are approaching 1.  
 
Given the excellent model fit and prediction along with valid and reproducible models, 
further diagnostic tools were performed for outlier detection. The model terms 
TFR*TFR and TFR*FRR in the size model were not significant, as confidence intervals 
crossed zero (Figure 4.6A). The most important factor with the highest range was the 
factor FRR in the size model (Figure 4.6A). Here, the terms FRR and FRR*FRR 
showed an inverse profile comparing the size and the PDI model, which gives an initial 
indication of an inverse correlation between size and PDI, e.g. the decrease in size 
may correlate to an increase in PDI. However, this initial model interpretation required 
further confirmed throughout the analysis. Statistical significance terms were 
determined for all responses, where a nonlinear relationship was predicted for all three 
responses, given the significant quadratic interaction term of the FRR, Table 4.2. 
 
The observed vs. predicted plots (Figure 4.6B) indicated a good model for the 
responses size, PDI and transfection efficiency as the points for the observed vs. the 
fitted values sat close to the straight 45° line. Nevertheless, the removal of the outlier 
N5 along with excellent summary plot for size response was indicative of a good 
model. The normal probability plot (Figure 4.6C) displayed the residuals plotted on a 
normal probability scale, which showed the normality of the residuals. Here, N5 was 
R2
Q2
Model validity
Reproducibility
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removed in the size model and N12 removed in the transfection model, both showed 
strong deviation in the normal probability plot, whereas the PDI model showed no 
outliers. Furthermore, no pattern or time dependency was given, with all data points 
randomly distributed in the residuals vs. run number plot (Figure 4.6D), which 
displayed the variation in the responses for the replicated experiments. A systematic 
effect was excluded in the model, as no pattern was seen in the replicate plots. Here, 
experiments 11, 12 and 13 were the replicate centre points; with a lower variation in 
the centre points for all three responses compared to the experimental runs. The PDI 
model had the largest variation, indicated by a lower reproducibility as seen in the 
summary plot (Figure 4.5), which had to be considered in further model evaluation. The 
additional replicates (N1, N2) implied a high reproducibility in the experimental setup 
for all responses. Overall, the size model showed smallest error in the replicates 
(Figure 4.6D), which was an indication of its excellent summary plot (Figure 4.5). The 
outlier detection in the normal probability plot removed one of the triplicate centre 
points in the transfection model, where the addition of the experimental replicates (N1, 
N2) gave further confidence in the replicate error in the model. The evaluation for 
model significance above was followed by the model interpretation. Here, the 
coefficient plot (or regression coefficient plot), displayed the model terms, main effect 
and interaction terms.  
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  Size PDI Transfection Efficiency  
A Coefficient Plot 
 
 
 
Displays regression 
coefficients with 95% 
confidence interval. 
Significant coefficients 
(different from noise) if 
confidence interval does 
not cross zero, 
B Observed vs. 
Predicted 
 
 
 
Displays the observed 
versus predicted values 
of the responses. A good 
model shows the points 
falling on a 45° line 
Figure 4.6: Results from the analysis of the DoE study for the prediction of the liposome size, PDI and transfection efficiency with A) Coefficient Plot B) Observed 
vs. Predicted C) Residuals vs. Normal Probability, D) Replicate plots. 
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C Residuals Normal 
Probability 
 
 
 
Displays the residuals on 
a double log scale. The 
plot is used to detect 
outliers and assess the 
normality of the 
residuals. In a good 
model, residuals are 
random and normally 
distributed, lying on a 
45°C between -4 and +4. 
D Replicate plot 
 
 
     
 
Displays the response 
values against the 
experimental runs. The 
plot is used to assess 
the variation in the 
replicate experiments. 
Replicates are presented 
in blue, experimental 
points in green. 
Figure 4.6: Results from the analysis of the DoE study for the prediction of the liposome size, PDI and transfection efficiency with A) Coefficient 
Plot B) Observed vs. Predicted C) Residuals vs. Normal Probability, D) Replicate plots.  
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Table 4.2: Coefficient list for the responses size, PDI and transfection efficiency. 
Coefficients were determined as statistically significant (p< 0.05). 
 
Response Significant coefficients 
Size (nm) TFR, FRR, FRR*FRR 
PDI FRR, FRR*FRR 
Transfection Efficiency FRR, FRR*FRR 
 
Further to model interpretation (Eriksson, 2008), the ANOVA analysis was linked to the 
replicate experiments; the centre points (N11, 12, 13) and replicate experimental points 
(N1, 2). All three models (size, PDI and transfection efficacy) were determined as 
statistical significant in the regression model (p<0.05) and the LOF test (p>0.05) (Table 
4.3).   
 
Table 4.3: ANOVA for the responses size, PDI and transfection efficiency. The p-statistics 
were analysed as well as the Lack-of-fit (LOF), together with fit power (R2) and predictive 
power (Q2). 
ANOVA Size PDI Transfection Efficiency 
Regression p 0.000 0.001 0.001 
LOF p 0.255 0.973 0.585 
R2 0.989 0.845 0.889 
Q2 0.965 0.749 0.682 
Model Significant? Yes Yes Yes 
 
 
Other than evaluating the model significance, the actual regression model was 
determined. Here, the RSM was represented by a quadratic relationship between 
responses (y) and factors (x), Equation 4.1. 
 
,		 =	
 + 
 +	
 +	

 +	

 +	
 + 	   Equation 4.1 
 
The regression model with two factors (TFR, FRR) and three responses (size, PDI, 
transfection efficiency) was adapted with, y1 represented the response liposome size, 
y2 the response PDI and y3 the response transfection efficiency. x1 represented the 
factor TFR and x2 the FRR,  was the constant term (representing the intercept), β´s 
were the effect coefficients, which were determined throughout the model evaluation 
(Table 4.4). ε was the residual response variation, which could not be explained by the 
model. 
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Table 4.4: Coefficient list with coefficients (scales and centred), standard error, p-values 
and confidence intervals for three responses.  
 Coeff. SC Std Error P Conf. int (+/-) 
Size 
    
Constant 66.5 3.99 1.27 e-008 8.89 
TFR -16.7 3.45 0.00069 7.69 
FRR -56.7 2.88 2.55 e-9 6.43 
FRR*FRR 50.7 5.00 1.41 e-6 11.2 
 
    
PDI 
    
Constant 0.411 0.022 1.44 e-9 0.049 
FRR 0.134 0.018 1.73 e-5 0.040 
FRR*FRR -0.078 0.029 0.022 0.067 
 
    
Trans. Eff. 
    
Constant 202.9 12.6 6.11e-8 28.5 
FRR -33.53 8.00 0.00233 18.1 
FRR*FRR -96.89 13.4 4.989 e-5 30.4 
 
With insignificant model terms removed by help of the coefficient plot (Figure 4.6A), the 
remaining significant coefficients (Table 4.2) generated the regression models for each 
response. 
 
 = 	66.5 − 16.7 − 	56.7 + 		50.7
 + 	 
 = 	0.41 + 	0.13 − 	0.07
 + 	 
 = 	202.95 − 	33.53 	− 96.9
 + 	 
 
Equation 4.1 represents a quadratic model, as not only the model terms are evaluated 
(x1 and x2), but also their quadratic (x12 and x22) and combinatorial effect (x1 * x2) is 
evaluated. Linking this to the investigated microfluidics method, the factor FRR (x1) had 
the biggest impact on the resulting liposome size (Table 4.4), which coincided with 
results obtained in Chapter 3. Same factor FRR (x1) showed a bigger impact to the 
resulting polydispersity than the factor TFR (x2) and no combinatorial effect (x1 * x2) 
was determined. Similar, the quadratic term (x12) of the factor FRR showed the biggest 
impact on the resulting transfection efficiency, elucidating on the importance of the ratio 
between aqueous and solvent stream in the microfluidics directed nanoprecipitation 
method (Table 4.4). 
 
These regression models were used to mathematically determine the liposome size, 
PDI and transfection efficiency as a function of the TFR and FRR in the microfluidics-
based nanoprecipitation process for DOPE-DOTAP lipids. Having determined model 
significance, outliers and significant terms, factor interaction was visualised in a 
response surface plot (Figure 4.7). Given the quadratic interaction RSM, a curved 
response surface was expected underlying the chosen design (Eriksson, 2008). 
  Chapter 4: Transfection 
127 
 
Respective response surface plots showed the predicted response values over the two 
factors, depicting their combinatorial effect in the microfluidics-based vesicle 
manufacturing process with regards to the liposome size, PDI and transfection efficacy. 
Here, minimal vesicle sizes of 60 nm were predicted for high flow rates (2 mL/min) and 
at high flow rate ratios (1:5). Maximum sizes predicted were 200 nm for 0.5 mL/min 
and a low FRR (here 1:1; Figure 4.7A). Evaluating the respective response surface 
plot, minimum PDIs of 0.2 were predicted for low FRRs (1:1) (Figure 4.7 B), with an 
increase in PDI linked to an increase in FRR. Maximum PDIs predicted were around 
0.5, for the highest FRR of 1:5. Furthermore, the response surface plot visualised that 
a change in TFR provided a minimal impact to the resulting PDI, emphasised by the 
insignificance of respective factor, as determined in above model evaluations and the 
coefficient plot (Table 4.3). The link between FRR and PDI was already observed in 
previous OFAT method (Figure 4.1), model prediction confirmed this direct correlation. 
Maximum luciferase activities around 250% were predicted for a FRR of 1:3, 
efficiencies were predicted above 180% for FRR between 1:2 and 1:4, independent of 
the TFR used (Figure 4.7C).  Minimum transfection efficiencies were predicted for the 
highest FRR (1:5) ranging between 80-100%. 
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A 
 
 
B 
 
 
C 
 
 
Figure 4.7: Response surface predictions for A) liposome size, B) polydispersity and C) 
transfection efficiency as a function of TFR (0.5 – 2 mL/min) and FRR (1:1 to 1:3 in the 
microfluidics-directed manufacturing of DOPE-DOTAP liposomes. 
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Predicted values for the liposome size, minimum and maximum of 60 nm and 200 nm 
respectively, coincided with previous determined liposome sizes by a one-factor-
variation method (Figure 4.1), verifying the model predictions. Furthermore, predictions 
reassured the theory of liposome formation by microfluidics-triggered nanoprecipitation 
method, where the increase in aqueous phase (volume) increased the polar phase 
available and thus accelerated the rate of polarity increase, indicated by the significant 
interaction term FRR*FRR (Table 4.2). As a high ratio of aqueous phase present 
triggered a quicker precipitation reaction, smaller vesicles could be expected, as seen 
for the predictions for a FRR of 1:5. The predictions for the transfection efficiency 
coincided with previous observations, where the highest transfection was achieved for 
a FRR of 1:3 (Figure 4.3). Furthermore, these results may allow for targeted selection 
of flow properties (TFR and FRR) depended on desired vesicle characteristics and 
transfection efficiencies anticipated.  Response surface evaluations further elucidate on 
the factor TFR being the primary impact on the overall throughput, with minimum effect 
to vesicle characteristics and transfection outcome. 
 
Additionally, a sweet spot analysis was performed, exemplifying the use of DoE 
predictions. For exemplification, selected criteria comprised a liposome size of 80-150 
nm, a PDI of 0.125 – 0.3 (minimize) and a transfection efficiency of 150-280% 
(maximize). The area shown in green in Figure 4.8 depicts the sweet spot for a FRR 
between 1:1 and 1:2 at a TFR between 1.4 and 2 mL/min. This tool, together with the 
possibility to generate vesicles of different sizes using the microfluidics-directed vesicle 
manufacturing, underlined the usefulness of the DoE method, as the characteristics 
and in-vitro performance of the vesicles can be predicted using the models generated. 
 
Figure 4.8: Sweet spot analysis for the desired criteria 1, size (80-150 nm); criteria 2, PDI 
(0.125-0.3) and criteria 3, transfection efficiency (150-280%). Dark blue = criterion 1 met, 
light blue = criterion 2 met, green = sweet spot. 
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To validate the model, predicted values from the regression model were compared to 
the responses obtained in an additional experimental study. Using the optimiser tool, 
predicted size, PDI and transfection efficiency at targeted TFR and FRR were 
determined, and compared to the values of size, PDI and transfection efficiency 
obtained experimentally post model performance. The comparison of the model 
prediction (minimum to maximum values predicted) to the experimental obtained 
results showed close alignment, with excellent predictions for settings at 2 mL/min, 
FRR 1:3 (Table 4.5). Here, predicted liposome size ranged between 49.8 to 55.0 nm, 
with good correlation with the experimental obtained sizes of 49 ± 11 nm. Additionally 
to the size model, predictions for the PDI and transfection efficiency coincided well with 
results obtained experimentally, with smaller errors in the model predictions.  
 
Table 4.5: Validation of the regression models built during the DoE analysis. Predicted 
values are compared to experimentally obtained results for two process settings; 1 
mL/min, 1:1 and 2 mL/min 1:3 (TFR, FRR). 
  TFR, FRR 
  1 mL/min, 1:1 2 mL/min, 1:3 
Size (nm) Model predictions  
(min – max) 
171.8 – 181.8 49.8 – 55.0 
 Experimental validation 162.1 ± 34.0 49.5 ± 11.3 
PDI Model predictions  
(min – max) 
0.21 – 0.23 0.37 – 0.38 
 Experimental validation 0.18 ± 0.024 0.35 ± 0.13 
Tranf. Eff. (% 
Luciferase activity) 
Model predictions  
(min – max) 
146.6 – 158.69 210.2 – 215.9 
 Experimental validation 142.3 ± 22.5 186.5 ± 80.1 
 
The above results confirmed the statistical validity of the model and supported the 
generation of regression models and response surface plots. Overall, the DoE analysis 
generated three statistical significant regression models that reproducibly predicted the 
size, PDI and transfection efficiency of cationic DOPE-DOTAP liposomes prepared by 
microfluidics. Model evaluations emphasized on the suitability of the microfluidics 
method for particle manufacturing, given that the mixing process was very rapid and 
offers high throughput. This decreases the risk of introducing experimental error over 
time, in contrast to time-intensive manufacturing methods like lipid-film hydration 
(Wagner and Vorauer-Uhl, 2011). The size model showed that both factors, the TFR 
and the FRR had a significant impact. The DoE analysis showed that the term FRR 
had a more significant impact, including a significant interaction term of FRR*FRR, 
suggesting the importance of the solvent/aqueous ratio to the overall liposome size. 
The model developed was additionally used in a sweet-spot analysis to select the FRR 
and TFR to target a specific size and transfection efficiency of the resulting vesicles. 
Overall, the DoE section developed, analysed and validated a set of predictive 
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regression models. In contrast to the OFAT method in Section 4.3.1, this method 
developed a response surface, useful for future predictions and detection of the 
statistical impact of the factors TFR and FRR in the microfluidics-directed liposome 
manufacturing method. 
 
DoE studies were previously investigated for liposomal products in recent trends in the 
pharmaceutical sector involving Quality by Design (QbD) principles. Similar to the 
studies presented in this chapter the aim was the generation of a robust and 
reproducible design space to control liposome quality characteristics. Along with 
evaluating the critical variables in a process, those principles aided the formulation and 
product quality. Using DoE, the effect of lipid chain length, lipid concentration and drug 
concentration was related to the drug encapsulation efficiency, linking to the particle 
characteristics (size, zeta potential). The resulting physicochemical particle 
characteristics were linked to the manufacturing method, ultimately relating to the 
amount of drug encapsulated (Xu et al., 2011). An additional study further increased 
the number of variables, linking the lipid concentration, drug concentration, cholesterol 
concentration, buffer concentration, hydration time, sonication time, freeze–thaw cycles 
and extrusion pressure to the physicochemical vesicle characteristics, along with their 
stability and drug encapsulation. Here, the lipid and drug concentration were found as 
the variables with the highest impact on the drug encapsulation (Xu et al., 2012). Along 
with those examples, the application of DoE for QbD principles was underlined, 
ultimately aiding the optimization of a formulation process. Multivariate tools were 
described in pharmaceutical applications, which overall reported improved processes 
and product quality (Gabrielsson et al., 2002). 
 
4.3.5 Statistical impact of the factors flow rate and flow ratio in a multivariate 
study 
The above DoE study detected the local optima in a design space that predicted the 
liposome size, PDI and transfection efficiency. To strengthen the theory behind the 
microfluidics-based liposome manufacturing method, a multivariate study based on 
PCA and PLS was performed as an additional statistical analysis tool. Here, all 
variables were analysed simultaneously, which identified patterns within those 
variables whilst detecting the relationship amongst input variables (X) and output 
responses (Y). As a predictive tool, the change in one variable was linked to the 
respective effect to the response. This is a method frequently applied in data analysis, 
data mining, classification (e.g. cluster analysis or outlier detection), regression 
analysis and predictive modelling (Eriksson, 2006). Here, two MVA methods were 
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applied; PCA dealt only with X-variables, whereas PLS involved X and Y variables and 
was used for regression modelling. PLS was used for predictions of Y from X, and 
additionally for identifying if and how variables and responses were linked to each 
other. This was achieved by fitting principal components (PC) through the 
multidimensional data set, which generated coordinates for each data point. Those 
coordinates allowed for plotting the data set onto a plane in a so-called loading plot, 
which was be subsequently used for data interpretation.  
 
Here, two PCs were fitted, which together evaluated the effects of the factors TFR and 
FRR to the responses liposome size, PDI and transfection efficacy (Figure 4.9). The 
size model indicated that the data set contained approximately 10% noise, similar to 
the noise level in the PDI model, and both were considered good enough for further 
evaluating the model. The transfection model yielded the lowest fit with a predictive 
power of ca. 50%, which was anticipated sufficient for further evaluation. 
 
 
Figure 4.9: Summary plot with two principal components added, showing the model fit 
(R2) and predictive power (Q2). 
 
The initial performed PCA analysis was represented in a score plot (Figure 4.10), 
which shows a summary of the relationships among the observations. Two PCs were 
fitted to model the systematic variation of the data set to approximate the X-data and 
define the plane of the variable space. All observations were projected onto the space 
of lower dimensions to visualize the data set and by approximation of the two PCs. The 
score plot showed how the observations were situated with respect to each other, 
revealing no outliers as all observation remained in the 95% confidence interval ellipse. 
The structural arrangement of the data points reflected the setup as derived from the 
DoE study, with a total of 15 observations (Figure 4.10). A colour coding was used for 
cluster analysis for visualization help. Groups according to FRR (1:1, 1:3 and 1:5) 
trended from the right to the left with increase in FRR (Figure 4.10A). The same trend 
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was given once coloured according to PDI, with the increase in PDI trending from the 
right to the left, matching the trend seen for the FRR (Figure 4.10B). Once coloured 
according to the TFR, the data points trended from the two lower to the two upper 
quadrants (Figure 4.10C). The colouring according to size depicted a trend from large 
to smaller sizes trending from the right to the left quadrants (Figure 4.10D). Similar 
colour trends (right-to-left) were seen in the plots coloured according to size (Figure 
4.10D), PDI (Figure 4.10B) and FRR (Figure 4.10A); the largest size and lowest PDI 
was depicted in the same quadrant as the lowest FRR of 1:1. Here, the cluster analysis 
revealed a clear link between FRR, PDI and size, a similar trend seen in above DoE 
study, where a decrease in liposome size was predicted for an increase in FRR along 
with the increase in PDI (Figure 4.7A, B). 
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according 
to FRR 
 
 
 
B 
Coloured 
according 
to PDI 
 
 
C 
Coloured 
according 
to TFR 
 
 
D 
Coloured 
according 
to size 
 
 
Figure 4.10: Score scatter plot as identified during the PCA. Colour coding simplifies the 
cluster analysis and trending in the data set with A) coloured according to FRR, B) 
coloured according to PDI, C) coloured according to TFR and D) coloured according to 
liposome size. The numbers represent observations as obtained from the DoE study. 
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The PLS analysis included the Y-variables as an extension to the performed PCA. 
Here, the Y-variables (size, PDI, transfection efficiency) were related to the X-variables 
(TFR and FRR) by a multivariate model (Wold et al., 1984; Wold et al., 2001a; Wold et 
al., 2001b). The PLS model was interpreted by respective coefficients, represented in 
the coefficient plot (Figure 4.11), which showed the importance of the variables TFR 
and FRR linked to the responses (size, PDI and transfection efficiency) for the two PCs 
fitted. The factor TFR was found only significant in the second PC, whereas the factor 
FRR, along with the responses transfection efficacy and size were shown to be highly 
statistical significant in the first principal component (Figure 4.11A). Both PCs were 
found significant for the response PDI. The relationship between the factor TFR and 
the response size was visualized in the loading scatter plot (Figure 4.11B). Here, the 
factor TFR was found in the upper left quadrant, opposite to the response liposome 
size. The coefficient plot for same variable and response indicated their significance in 
different PCs, indicating no correlation between the factor TFR and the response size. 
The factor TFR was found to be independent of the response size and transfection 
efficiency, as indicated by their significance in different PCs in the coefficient plot. 
 
A direct correlation between FRR and PDI was indicated by their significance in the 
first PC (Figure 4.11B). This correlation was observed in above PCA analysis (Figure 
4.10) as well as in the performed DoE model (Table 4.2). The results from the PLS 
analysis correlated an increase in PDI with the increase in FRR. A correlation between 
the size and the transfection efficiency was indicated with their close situation in the 
loading scatter plot and matching significance of the first PC in the coefficient plot 
(Figure 4.11A). This direct correlation predicted the increase in transfection efficiency 
with larger liposomes.  
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B 
 
 
Figure 4.11 Results from the PLS regression analysis coloured according to model term. 
A) Coefficient plot including 95% confidence interval for the two principal components. 
B) The loading scatter plot indicating significance of the factors (X) and responses (Y) to 
each other. 
 
Loading and score plot are complementary and superimposable and can be used to 
interpret the patters seen. A direction or cluster in a score plot corresponds to a 
variable seen in the same direction in the loading plot (Eriksson, 2006). The points for 
larger sized vesicles lie on the right hand side of the score plot (Figure 4.10D), which 
corresponded to the response size and transfection efficiency situated closely together 
in the loading plot. The size response was situated far away from the origin (lower 
right-hand quadrant, Figure 4.11B), overlapping with the same area of the score plot 
for the vesicles with the highest size (Figure 4.10D). The variable FRR was situated on 
the opposite side in the lower left-hand quadrant (Figure 4.11B), indicating an inverse 
relationship to the response size and corresponded to the vesicles with the lowest size 
in and the highest PDI in the score plot (Figure 4.10B, D). The loading plot revealed a 
direct correlation between the PDI and the FRR, with both terms situated in the same 
lower left-hand quadrant. The strong link between particle characteristics (size, PDI) 
and FRR was revealed in both scores and loading plots, as seen in above DoE 
evaluations (Figure 4.10, 4.11B, Table 4.2). 
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As with other models, the validation of the developed MVA models is crucial. Here, 
permutation plots assessed model validation and the risk of a fault in the PLS model 
and eliminated the risk that the model developed just fitted the data set in this study 
without predicting the responses well for new observations. Here, the goodness of fit 
(R2) and prediction (Q2) of the original model were compared to the ones of several 
models based on data where the Y- observations were randomly permuted, while the 
X-matrix was kept constant. The respective permutation plots showed the original R2 
and Q2 values on the vertical axis far to the right, which coincided with the values from 
initial model summary, Figure 4.9. The values for the permuted models were shown on 
the left. A horizontal axis between respective values showed the correlation between 
the permuted and the original Y-vectors for a selected response. The criterion for a 
valid model was pre-set for a Q2 regression line intercept the vertical axis at or below 
zero. For all responses, 40 permutations were added and the original value had a 
correlation of 1 on the horizontal axis. Here, all three permutation plots strongly 
indicated valid models, given that the intercept of the predictive regression line 
intercepted below zero (Figure 4.12A, B). Furthermore, higher original R2 and Q2 in the 
plots for the response size and PDI, were indicated in the summary plot (Figure 4.9). 
Most importantly, the here developed permutation analysis confirmed the validity of 
transfection model, which showed overall lower R2 and Q2 values in the initial summary 
plot (Fig 4.12C, Figure 4.9). 
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Figure 4.12: Permutations plot for A) size, B) PDI and C) transfection efficiency. Model 
validity was assessed for 40 permutations. The correlation between permuted Y-vector to 
the original X-vector is depicted by the horizontal correlation axis. The criterion for 
model validity was selected as the intercept of the Q2 regression line at or below zero. 
 
The MVA results verified the outcome of the DoE study, giving a mathematical proof 
that a better transfection results may be expected for vesicles with a larger size at a 
constant lipid/DNA ratio (Esposito et al., 2006; Felgner et al., 1987; Kawaura et al., 
1998; McNeil et al., 2010). The coefficient plot further revealed the smallest 95% 
confidence interval for the factor FRR, as seen in the DoE study, the factor FRR was 
shown to be highly significant in the size, PDI and transfection efficiency model. 
Together with the results from the DoE study, it can be concluded that the factor FRR 
is the most crucial factor in the microfluidics-based nanoprecipitation process, requiring 
detailed optimisation once the lipid combination is altered. The FRR directly affects 
particle characteristics (size and PDI) but also in the case of the lipid combination used 
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here, the anticipated transfection efficiencies for in-vitro gene delivery and application 
of lipoplexes. 
 
4.4 Conclusion 
In this chapter, the microfluidics-based liposome manufacturing method was explored 
by variation of the process parameters TFR and FRR to produce liposomes of defined 
sizes, which gave reproducible transfection results in standard transfection protocols. 
This SHM method generated homogenous liposomes suspensions in a high-
throughput setup. The advantage of the microfluidics-based method is its high-
throughput and small footprint, allowing for a high number of formulations to be 
screened in a short time period. Here, a series of statistical tools to model the process 
and the effect of vesicle size for an in-vitro transfection were also exploited. The 
implemented statistical-based methods (design of experiments and multivariate data 
analysis) revealed the mathematical relationship and significance of the factors TFR 
and FRR in the microfluidics process to the liposome size, PDI and transfection 
efficacy. The systematic application of statistical based process control determined 
local optima. Furthermore, it revealed how variable interactions and clustering can be 
used for process simulations and predictions. Model predictions coincided with the 
initial performed OFAT experiments, reassuring the suitability of predictive tools in 
pharmaceutical process development. These tools deepen the process understanding, 
assist in development work and possible scale-up (Singh et al., 2005) and further 
enhance the reproducibility of a process for the generation of a design space.  
 
The large-scale counterpart of the here-presented nanoprecipitation method is the 
ethanol injection method described in the 1970s (Batzri and Korn, 1973), which is 
based on the principle of precipitation reaction. Its replicate on a smaller footprint was 
developed (Jahn et al., 2008; Pradhan et al., 2008), however injection into a vortexed 
aqueous solution impeded on controlled mixing conditions and resulted in polydisperse 
liposome formulations (Jahn et al., 2008). The development of the crossflow injection 
techniques as an improvement over the ethanol injection method provided better 
process control and improved reproducibility at flow rates between 500 to 2700 
mL/min; clearly a high-throughput and large footprint operation (Wagner et al., 2002b). 
In contrast, the mixing in microchannels is highly controlled, driven by diffusion and 
chaotic advection in a small-footprint lab-scale technique. Those unique properties 
allow for a precise process control of fluid flow patterns, resulting in a robust mixing 
profile, the key for a controlled vesicle manufacturing on micro-scale.  
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Overall, the FRR in the microfluidic process was verified as the most crucial parameter 
to the formation of size-controlled vesicles, confirmed by predictive modeling tools. The 
successful combination of experimental screening work, multivariate methods and 
experimental design is a powerful tool in any pharmaceutical or biopharmaceutical 
process development, for the development and optimization of new processes and 
finding optima within a defined region of factors and speeding up a developing process. 
Overall, process understanding and confidence is enhanced which gives predictive and 
correlative comparisons between the critical process parameters and their influence on 
desired critical quality attributes, leading to a desired and robust product quality. 
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5.1 Introduction  
Dequalinium, 1,1-decamethylene bis (4-aminoquinaldiniumchloride), is a di-cationic 
compound, which is symmetrical with two charge centres that belongs to the “bola”-
form electrolytes (Figure 5.1). Those bola-amphiphiles comprise two quinaldinium rings 
which are connected by methylene groups, comprising a delocalized charge centre 
(Figure 5.1A). The lipophilic drug dequalinium (DQA) has been used for more than 50 
years as a compound with antimicrobial (Weissig, 2015; Weissig et al., 1998; Weissig 
and Torchilin, 2001), antifungal (Berlin et al., 1998) and anticarcinoma activities 
(Christman et al., 1990). Its antitumour activities have been linked to the preferential 
accumulation in carcinoma cells (Berlin et al., 1998; Rotenberg et al., 1990; Weissig et 
al., 1998). In comparison to cisplatin, a frequently applied chemotherapeutic agent, 
DQA was found to be more efficacious and less toxic for the treatment of ovarian 
cancer (Christman et al., 1990). Furthermore, an associated delay in tumour growth 
has been linked to the drug-induced loss and depletion of mitochondrial DNA (mtDNA) 
along with its associated functions (Berlin et al., 1998). In addition to its anticancer 
activity, antifungal and antimicrobial properties, DQA is currently used in a variety of 
creams and topical applications for treating infections (Babbs et al., 1956; Jones, 1995; 
Schneider-Berlin et al., 2005; Weissenbacher et al., 2012; Weissig et al., 1998). In this 
study, a DQA derivative compound 1,1'-(decane-1,10-diyl)bis(9-amino-1,2,3,4- 
tetrahydroacridinium) diiodide (CM2) (Figure 5.1B) was obtained from Procatra 
Biosystems Ltd. It is structurally related to dequalinium where the positive charges in 
two tetrahydroacridinium rings are connected by an alkyl chain of 12 atoms, with 
similar in-vivo activities to that of DQA (Tischer et al., 2012).   
 
 
 
 
 
Figure 5.1: A) 1,1-Decamethylene bis (4-aminoquinaldiniumchloride) and its derivate B) 
1,1'-(decane-1,10-diyl)bis(9-amino-1,2,3,4- tetrahydroacridinium) diiodide (CM2). Adopted 
from (Weissig, 2015). 
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Given the structure of bola-amphiphiles, either a U-shaped or a stretched confirmation 
can be adopted (De Rosa et al., 1986; Gulik et al., 1988; Luzzati et al., 1987), (Figure 
5.2). Initial experiments demonstrated that upon solubilisation in aqueous vehicles, 
DQA formed colloidal particles between 70-700 nm with freeze fracturing imaging 
showing convex and concave structures suggesting the formation of liposome-like 
vesicles, termed DQAsomes (Weissig et al., 1998). DQAsome/DNA complexes (also 
known as DQAplexes) offer high DNA binding capacity and mediated cellular uptake, 
delivery and release of DNA in mammalian cells (Weissig, 2015). Furthermore, 
DQAsomes are considered as quite a unique delivery system based on their in-vivo 
selectivity of carcinoma cells, their affinity for accumulation in mitochondria, and the 
potential of organelle-targeted drug or DNA delivery (Weissig and Torchilin, 2001). 
 
 
Figure 5.2: Assembly of a liposome-like vesicle comprising U-shaped and stretched- 
confirmation of bola-form amphiphiles. Adapted from (Gregoriadis, 2007). 
 
Nevertheless, the manufacture of DQAsomes is challenging, and the applied lipid-film 
hydration and sonication processes do not provide acceptable reproducibility in 
industrial manufacturing (Wagner et al., 2002a). Traditional manufacturing methods 
rely on vesicle self-assembly after a sonication step; the lack of appropriate and 
reproducible methods is one of the current limitations for a process transfer from a 
laboratory setting into a large-scale process. Lipid-film hydration is associated with 
heterogeneous liposome population, whereas sonication may not be applicable for 
sensitive products and might result in protein and or lipid degradation and limited 
control during self-assembly might lead to a poor reproducibility and process control 
(Wagner and Vorauer-Uhl, 2011). 
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5.2 Aim and Objectives 
The aim of this study was to assess the microfluidics-directed manufacturability of 
vesicles consisting of dequalinium-derivate (CM2), a bola-amphiphile with delocalised 
charge centres. To achieve this, the objectives were: 
• Physicochemically characterise the particles formed using this microfluidics. 
• Assess the stability of vesicles formed. 
• Compare vesicles manufactured by methods relying on sonication and 
microfluidics. 
• Investigate the in-vitro transfection of the systems to assess the ability of the 
microfluidics-manufactured particles to act as a delivery vehicle for genetic 
material. 
 
Throughout this chapter, all work was performed on the dequalinium-derivate (CM2) 
compound, and the dequalinium-derivate (CM2) derived nanoparticles were termed 
“DQAsomes”. 
 
5.3 Results and Discussion 
5.3.1 A feasibility study of DQAsome manufacturing by microfluidics 
Initial work focused on the manufacturability of bola-amphiphile nanoparticles by 
microfluidics-directed nanoprecipitation. Initially, a proof-of-concept study was 
performed where three independent batches were manufactured (and each batch 
assessed in triplicate) at the same flow rate conditions on different days, verifying the 
intra-day and inter-day variability. Flow rate conditions (TFR 2 mL/min, FRR 1:3) were 
extrapolated from previous work (Chapter 4). Results (Figure 5.3) show that vesicles 
with an average vesicle size of 250-300 nm were formed, with a polydispersity (PDI) 
around 0.4 and zeta potential highly cationic around +30 mV. In addition to low inter-
day variability (variability between the trials), the intra-day variability (variability within 
one trial) was low, ranging between 20-50 nm in size, 1-5 mV in zeta potential and 
0.04-0.07 in PDI (Figure 5.3). The cationic zeta potential measured coincided with 
recent published work on dequalinium-based vesicles for drug delivery (Zupančič et al., 
2014), linked to its cationic tetrahydroacridinium rings. In comparison, DQAsomes were 
prepared by the lipid film hydration followed by sonication, as initially described and 
patented by Weissig et al. in the mid-1990s upon discovery of DQA-specific assembly 
into nanoparticles (Weissig et al., 1998). Using this method and sonication for 30 
minutes (amplitude 5) yielded an average size of 300 nm (Figure 5.3) coinciding with 
previously published work on vesicles manufactured by sonication (Weissig et al., 
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1998; Zupančič et al., 2014); these vesicles were overall larger in size with a higher 
PDI than vesicles prepared by microfluidics.  
 
Figure 5.3: Reproducibility (intra-day variability) and inter-day variability of DQAsomes 
manufactured by microfluidics (TFR 2 mL/min, FRR 1:3) and sonication (30 min, 
amplitude 5) showing the particle size, polydispersity and zeta potential. Results denote 
mean ± SD of 3 separate batches. 
 
Investigation of the DLS vesicle size data by comparison of intensity- and volume-
based size distribution plots and correlograms (Figure 5.4) reveal low variability within 
the three trials performed (inter-day variability, %RSD =13.2 for size and 14.5 for PDI). 
The intensity-based size distribution plot (Figure 5.4A) revealed an intensity-based 
average particle diameter ≥ 90% intensity. A subpopulation of particulates in the 
micrometer range was visible for all three trials, with significance in the volume pot 
ranging within 3-9 volume% at a size of 4-6 µm (Figure 5.4B); a shoulder in the decay 
function indicated the sub-population in the respective correlograms (Figure 5.4C). The 
intensity-based size distribution showed higher variability in the sonication method, due 
to subpopulation visible below and above the average particle size (Figure 5.4D), with 
larger significance in the volume-based size distribution plot showing multi-modal 
populations (Figure 5.4E), which ranged within 9-30 volume % with a higher variability 
in the associated correlation plots (Figure 5.4F). The volume-based distribution of the 
sonicated vesicles revealed a sub-population around 20 nm in size, which may be 
indicative of micelle formation by the respective method (Figure 5.4E). Given the sub-
populations in both methods, microfluidics and sonication, the presence of larger 
aggregates or contaminants was found independent of the manufacturing method, 
possibly deriving from contaminants based on compound specific aggregation 
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behaviour. Furthermore, correlation functions of sonicated vesicles were suboptimal, 
with a shallow decay referring to a higher PDI and wider size distribution (Figure 5.4F).  
A 
 
D 
 
B 
 
E 
 
C 
 
F 
 
Figure 5.4: A) Intensity-based, B) volume-based size distribution and C) correlogram of 
particles manufactured via microfluidics-based nanoprecipitation. D) Intensity-based, E) 
volume-based size distribution and F) correlogram of particles manufactured via lipid 
film hydration followed by sonication. Plots show the average out of three batches and 
the inter-day variability for the microfluidics-manufactured vesicles. 
 
5.3.2 The effect of flow rate ratio and total flow rate on vesicle characteristics  
Given that previous investigations demonstrated that both the total flow rate (TFR) and 
flow rate ratio (FRR) in the microfluidics process can impact on vesicle characteristics 
(e.g. as shown in Chapter 3), the effect of these factors on DQAsomes was also 
investigated (Figure 5.5). The adjustment from FRR 1:1 to 1:3 resulted in a significant 
(p<0.001) decrease in DQAsome size, with a minimum size of ~250 nm (Figure 5.5A). 
Vesicle size plateaued at a FRR greater than 1:3 (p>0.05), suggesting that the smallest 
size achievable was ~250 nm. All alterations in flow ratios remained independent of the 
PDI (Figure 5.5A), which ranged within 0.3 to 0.5; given the presence of a sub-
population in above correlograms (Figure 5.4), a PDI higher than 0.2 would be 
expected. The zeta potential remained above +25 mV and was not significantly 
influenced by any of the factor variations tested. The effect of increasing throughput in 
the microfluidics-method was evaluated at a constant FRR (1:3) by increasing the TFR 
from 1 mL/min to 8 mL/min; the results show that TFR did not significantly change 
DQAsome characteristics (Figure 5.5B). 
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Figure 5.5: Effect of increase in A) FRR at constant TFR of 2 mL/min and B) TFR at 
constant FRR of 1:3 to DQAsome characteristics. Change is represented in % relative to 
the start size of 250 nm, PDI 0.3. Where shown, significance between data is against 
results at a FRR 1:1 (**p<0.01, ***p<0.001). Results denote mean ± SD of 3 separate 
batches. 
 
The initial work based on the DQAsome formation, patented by Weissig et al., referred 
to a vesicle size between 70 – 700 nm (Weissig et al., 1998) where size was 
presumably controlled by alterations in sonication parameters. More recent work on 
DQAsomes manufacturing by lipid-film hydration and sonication techniques reported 
sizes between 170 – 200 nm dependent on the ratio of lipophilic drug incorporated into 
the DQA-based vesicles (Zupančič et al., 2014). The here-presented microfluidics-
directed manufacturing method allowed for vesicle sizes between 250 – 400 nm, with 
the major advantage of an in-process control of vesicle size dependent on flow 
conditions selected. Similar to work performed on cationic double-chain lipids (Chapter 
4), the FRR factor was most influential regarding the resulting particle characteristics. 
Results in Chapter 3 highlighted on the importance of both, TFR and FRR for 
influencing the vesicle size; however, this was with high transition temperature lipids 
opposed to lipids used in this chapter and in Chapter 4, where the FRR was found the 
most contributing factor for controlling vesicle size. The microfluidics-directed 
nanoprecipitation method uses the advantages of a controlled ratio of aqueous to 
solvent phase to specifically influence the closing time of vesicles formed (Dong et al., 
2012). A high aqueous content FRR allows for a high aqueous volume to be introduced 
in the mixing process, which ultimately enhances the mixing process. This controlled 
alteration first decreases the diffusion layer thickness between both streams and 
reduces the width of the solvent stream, both reducing diffusion distances in the mixing 
profile. The mixing profile itself is enhanced by the herringbone structures in the floor of 
the channel (Stroock et al., 2002), which overall allows for a lower FRR compared to 
the hydrodynamic flow focusing method, resulting in more concentrated vesicles 
manufactured (Jahn et al., 2007). The reduction in solvent concentration below the 
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solubility limit for the CM2 component leads to reduced closure time for the vesicles 
and subsequently smaller vesicles formed at higher aqueous content FRR (Zook and 
Vreeland, 2010). As seen in Figure 5.5A, smallest vesicles correspond to higher 
aqueous volumes, which plateaued at a FRR higher than 1:3, suggesting the smallest 
size possible in the nanoprecipitation method was 250 nm. Additionally, the remaining 
solvent in the final formulation is reduced with increase in FRR, which influences the 
synthesis of larger particles due to particle fusion and lipid exchange (Ostwald 
ripening) after complete mixing is achieved. At lower aqueous FRR (here 1:1), more 
solvent remains present during the mixing process, allowing for prolonged stabilisation 
of the hydrophobic components of the CM2 component, which leaves more time for the 
bilayers to grow before vesicles are formed, resulting in overall larger vesicles formed, 
here 400 nm (Figure 5.5A). A tailored vesicle size dependent on selection of flow 
properties may be advantageous for a specific application of DQAsomes with size-
specific in-vivo performance. 
 
The advantage of the microfluidics based nanoprecipitation method lies in the 
generation of controlled mixing profiles throughout a chamber. Microfluidic devices 
allow for a tight control of mixing efficiencies, which are based on molecular diffusion 
processes. The increased surface-to-volume ratios create fast mixing times, 
emphasized by reducing dimensions and diffusion lengths (Lee et al., 2011; Mengeaud 
et al., 2002). Such on-chip setups allow for tailored and controlled alterations in 
polarities throughout a mixing chamber. These constant mixing profiles are key for a 
reproducible manufacturing process with minimal inter-day variability, as seen in Figure 
5.3, 5.4. Furthermore, results highlighted an 8-fold increase in throughput by increasing 
the TFR, emphasizing on the suitability of using this method for high-throughput 
manufacturing.  
 
5.3.3 The effect of CM2 concentration in the microfluidics-directed DQAsome 
formation 
In addition to the studies evaluating the particle characteristics, the CM2 concentration 
was assessed as a further variable during the microfluidics-directed manufacturing step 
and was increased, aiming for an overall higher concentration of DQAsomes generated 
within the method.  
 
Quantification of the CM2 compound was performed by the HPLC method as 
described in Chapter 3. Here, the CM2 concentration was increased approximately 8-
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fold from initial 0.6 mg/mL to 5 mg/mL (0.7 mM to 6.1 mM respectively; Figure 5.6). 
This allowed for simply manufacturing vesicles at a higher concentration, which 
showed a linear trend in quantification of the CM2 component (Figure 5.6A). Recovery, 
expressed in % and related to the initial amount of CM2 compound available in the 
stock as well as the FRR applied, remained above 87% for all formulations (p>0.05; 
Figure 5.6B). No difference in particle size was noted with the increase in concentration 
from 0.6 to 3 mg/mL (Figure 5.6C), whereas the highest CM2 concentration (here 5 
mg/mL, 6.1 mM) resulted in a significant larger particle size with an additional 
significant increase in PDI (p<0.05), (Figure 5.6C and D). The zeta potential remained 
unaffected throughout (p>0.05, Figure 5.6E).    
 
Figure 5.6: Effect of increase in CM2 concentration to A) quantification, B) recovery (%), 
C) DQAsome size, D) PDI and E) zeta potential. The heating block was used for 
formulations ≥ 3 mg/mL to maintain solubility. Where shown, significance between data 
is against results at a concentration of 0.6 mg/mL (*p<0.05, **p<0.01). Results denote 
mean ± SD of 3 separate batches. 
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The higher PDI and sizes at a CM2 concentration of 5 mg/mL (Figure 5.6B) might be 
explained by solubility difficulties of CM2. Solubility at room temperature was limited to 
1 mg/mL and a heating block was used to heat the chamber inlets to 60°C for all stock 
solutions exceeding 1 mg/mL. Nevertheless, the ability to form DQAsomes with 
nanometer size was restricted to a CM2 concentration of up to 3 mg/mL (Figure 5.6C). 
Previous work has also shown that an increase in amphiphile concentration can lead to 
the formation of larger vesicles (Henriksen-Lacey et al., 2011a). In this study, the lipid 
film hydration method was used for manufacturing vesicles of a larger size by 
decreasing the amount of rehydration buffer. Ten-fold higher concentrated vesicles 
were manufactured, which resulted in an increase the size of the vesicles from initially 
500 nm to 1.5 µm. Studies also showed that the alteration of the hydration buffer 
furthermore increased the size to 2-3 µm by addition of saline PBS buffer, which 
resulted in vesicle aggregation (Henriksen-Lacey et al., 2011a). Here, the movement of 
the liposomes to the lymph nodes was strongly related to the size of the vesicles, with 
small vesicles down regulating splenocyte proliferation rates and the vesicle size 
overall effecting the cell mediated immune response (Henriksen-Lacey et al., 2011a). 
 
5.3.4 DQAsome stability and integrity upon manufacturing by microfluidics 
Given the novelty of microfluidics-directed nanoprecipitation manufacturing of 
DQAsomes, the stability of the vesicles formed upon this method was verified over 5 
hours and 8 days at two storage conditions (4°C and room temperature (RT)). The 
investigation of the vesicle stability was anticipated crucial for two reasons; the novelty 
of the manufacturing method and previous reported instability of DQAsomes (Weissig, 
2015). DQAsomes were manufactured by microfluidics (FRR 1:3, TFR 2 mL/min) and 
kept under controlled temperature conditions throughout the stability study with no 
post-processing steps (e.g. dialysis) performed. Results (Figure 5.7) show the particle 
characteristics expressed as % compared to the vesicles directly after manufacturing, 
with an initial size of ca. 250 nm and a PDI of 0.35. No major effect to the particle size 
was noted upon storage for 5 hours (Figure 5.7A) and 8 days (Figure 5.7B), 
independent of storage temperatures. A slight increase in PDI at 1h was noted (Figure 
5.7A); however, this remained overall insignificant throughout the 8-day study (Figure 
5.7B). Throughout the study, the zeta potential remained highly cationic, ranging 
between 25 – 35 mV (Figure 5.7C). 
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Figure 5.7: Effect of storage temperature to DQAsome size and PDI over A) 5 hours, B) 8 
days and respective effect to C) zeta potential. D) Effect of storage temperature on 
stability of the CM2 compound over 8 days. RT = room temperature. Results denote 
mean ± SD of 3 separate batches. 
 
In addition to the physical stability of the vesicles, the CM2 component was 
simultaneously quantified. Results indicated a complete recovery of the CM2 
component in the formulations (above 95%), indicating no physical degradation or 
unspecific adsorption of the CM2 compound, independent of the storage conditions 
(4°C and room temperature; Figure 5.7D). 
 
The manufacture of the vesicles by microfluidics resulted in a residual solvent amount 
(here methanol) that may impact on the stability of the vesicles if not removed prior to 
storage. Whereas dialysis was used as a simple post-processing method for removal 
of residual solvent (e.g. in Chapter 4), dialysis attempts resulted in poor retention of the 
vesicles in the dialysis bag based on loss of the CM2 compound into the dialysis buffer 
(results not shown). Stability problems have been reported in literature, where the 
vesicle disintegration over several hours has been linked to the chemical structure of 
the dequalinium molecule (Weissig, 2015). Published stability data confirmed vesicles 
integrity up to 96 hours only (Weissig et al., 1998). The critical vesicle concentration of 
dequalinium ranges between 3-7 mM and especially upon dilution loss of colloidal 
structures has been reported (Weissig, 2015). Concentrations below 3 mM did not 
result in vesicle formation and only chemical modifications of the amhiphiles impacted 
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the stability (Weissig and Torchilin, 2001). Here, concentrations ranged within 0.7 mM 
to 6.1 mM, allowing for vesicle assembly and presumably loss of colloidal structure 
upon dilution in the dialysis method at concentrations below 3 mM. Poor chemical 
stability along with formation of micelles upon dilution might be associated with poor 
retention throughout a dialysis procedure. Nevertheless, data here showed that 
DQAsomes manufactured by microfluidics remain stable over the course of 8 days, no 
significant changes in population characteristics and stability.  
 
5.3.5 DQAsome purification and recovery upon manufacturing by microfluidics 
Following the verified short-term stability in the presence of residual solvent, an 
additional post-processing purification method was considered. Given that dialysis was 
not applicable for DQAsome purification, a method based on spin columns was 
investigated. A spin column process was found applicable for concentration and 
removal of residual solvent for liposomes (data not shown), and the same method was 
explored for the applicability of DQAsome purification. This method relies on 
membrane separation by centrifugal forces, often used in post processing of colloids or 
proteins (Chapman, 2005). Here, the spin column process was related to particle 
characteristics, along with possible purification ability by membrane retention. 
 
The ability of the membrane to retain the DQAsomes was tested and the CM2 
component was quantified before and after the spin column process in the retentate 
(concentrate) and permeate (filtrate) respectively. The spin column process acts as a 
dead end filtration process, a separation process based on a membrane. The 
concentrate was recovered on the retentate side of the membrane, containing 
components too large to penetrate through the membrane. In contrast, the filtrate 
contains the wash-through part, components small enough to penetrate through the 
membrane pores.  
 
Both, concentrate and filtrate were recovered independently after membrane 
separation by aids of centrifugal forces. Unfortunately, the CM2 component permeated 
through the membrane, indicative of a failed retention (30kDa and 2kDa cutoff, 
polyethersulfone membrane) (Figure 5.8A). The anticipated membrane separation 
process was based on the retention of the DQAsomes by the membrane and removal 
of solvent residues into the permeate. Based on detection of the CM2 compound in the 
filtrate, this anticipated purification process failed. Despite the lower cut-off membrane, 
the DQAsomes were not retained and were found present in concentrate as well as 
filtrate side (Figure 5.8A).  
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Figure 5.8: A) Effect of a spin column process on vesicle characteristics. B) Effect of 
membrane cutoff to recovery of the CM2 compound. Results denote mean ± SD of 3 
separate batches and purification cycles. Correlogram of the filtrate C) in comparison to 
the concentrate side of the spin column membrane D).  
 
DQAsomes were recovered on the retentate side of the membrane and particle 
characteristics compared to the vesicle characteristics before centrifugation remained 
around 250 nm, with a PDI around 0.4 (p>0.05), 2kDa cutoff, polyethersulfone 
membrane. The control was vesicles manufactured by the microfluidics method that did 
not undergo a centrifugation process (Figure 5.8B). Despite the centrifugation forces 
applied, the vesicles on the retentate side remained intact. Nevertheless, the 
quantification of CM2 revealed its presence in the concentrate as well as the filtrate 
(Figure 5.8A), with majority of the CM2 recovered in the filtrate, indicating that the 
membrane failed to retain the vesicles despite variation in membrane cutoff. Given that 
the permeate did not show the presence of colloids (as revealed in DLS by poor 
correlation function, Figure 5.8C and D), the centrifugation process was found to 
physically disrupt the vesicles once passed through the membrane. Hence, the CM2 
amount detected in the permeate was not related the actual vesicles permeating the 
membrane, which instead broke down into the initial CM2 component once passed 
through the membrane pores. 
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Depending on the DQA concentration and manufacturing temperatures, computer 
simulations have revealed a variety of possible DQAsomes confirmations, including 
micelles, vesicles, cylinders, disks and planar aggregates, U-shaped and stretched 
confirmation (Gregoriadis, 2007; Grinberg et al., 2008; Weissig and Torchilin, 2001). 
This flexibility of the CM2 compound may have resulted in conformational changes 
throughout the centrifugation process and membrane penetration, resulting in poor 
retention of the vesicles. The filtration membranes (2 kDa and 30 kDa) failed to retain 
DQAsomes and any concentration attempts were unsuccessful. Limited stability in an 
aqueous environment and upon concentration has been previously reported (Weissig, 
2015). This was related to the structural instability of the DQAsomes, which may have 
been challenged here by additional centrifugal forces applied. In response to this data, 
the CM2 component has been chemically altered to tackle the limited stability upon 
concentration and dilution in aqueous medium. This work is on-going. 
 
5.3.6 In-vitro transfection efficiency of DQAsomes  
In addition to evaluating the microfluidics-manufactured vesicles regarding their particle 
characteristics and stability, their biological activity was studied in-vitro. The ability of 
DQAsome-directed gene transfer was described and patented by Weissig in the 1990s 
(Weissig et al., 1998); numerous researchers have since used dequalinium as a 
delivery system due to its selectivity for organelle directed uptake, which is well 
reported in literature (Christman et al., 1990; Steichen et al., 1991; Vercesi et al., 1991; 
Weiss et al., 1987). Therefore to consider the biological activity of microfluidics-
manufactured DQAsomes, the system were tested as a non-viral delivery vehicle of 
genetic material using two pDNA structures; a luciferase plasmid (gWiz-Luc) and a 
GFP plasmid (pEGFP-C3) (Figure 5.9).  
 
  
Figure 5.9: Two plasmids used in the in-vitro study evaluating the transfection potential 
of the microfluidics-manufactured DQAsomes. Structures obtained from 
www.aldevron.com. 
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The in-vitro transfection was tested with DQAsomes manufactured from different CM2 
concentrations, linking to above study that higher concentrated vesicles may be 
manufactured (Figure 5.6). The transfection efficiency achieved by microfluidics-
manufactured DQAsomes yielded ca. 70% of that achieved by cationic liposomes, with 
no difference between the vesicles manufactured at different CM2 stock concentrations 
(p>0.05; Figure 5.10). As the CM2 to DNA ratio and the DQAplex to cell ratio was kept 
constant during the transfection studies, these results emphasize that vesicles can be 
manufactured at a higher concentration, without impeding on their in-vitro activity. 
Given that vesicles manufactured at a stock concentration of 5 mg/mL showed a 
significant increase in size (Figure 5.6), the transfection efficiency here was found to be 
independent of the vesicle characteristics. In contrast to the results in Chapter 4, the 
organelle-targeted transfection was found independent of the vesicle size, anticipated 
as the main reason behind the difference to the nucleus-directed transfection (Weissig 
and Torchilin, 2001). Overall, transfection achieved by the vesicles manufactured by 
microfluidics was higher compared to vesicles formed by sonication (p< 0.05), which 
may be related to suboptimal vesicle characteristics (Figure 5.4). 
 
Figure 5.10: Transfection efficiency (RLU, relative light units) as obtained by 
microfluidics-manufactured DQAsomes (FRR 1:3, TFR 2 mL/min), sonicated DQAsomes 
(30 min, amplitude 5) as compared to cationic liposome transfection efficiecy (DOPE-
DOTAP, FRR 1:5, TFR 1.5 mL/min). Significance between data is against the transfection 
efficiency achieved by vesicles manufactured in the sonication method (*p<0.05). Results 
denote mean ± SD of 3 separate transfections. 
 
In addition to the transfection studies performed with a luciferase-encoding plasmid, a 
GFP-encoding plasmid was used for a visual detection of protein expression. Figure 
5.11 shows the expression of the GFP protein, delivered by microfluidics-manufactured 
DQAsomes post transfection. Images verified the expression of a fluorescent protein 
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in-vitro (Figure 5.11A, B). With the fluorescence signal corresponding to the correct 
conformation and full protein folding, the protein has been found small enough (29kDa) 
for secretion into the medium (Tanudji et al., 2002) as seen in images obtained in this 
study. 
 
Figure 5.11: A, B) Confocal microscopy images showing the in-vitro expression of the 
flourescent protein in transfected COS-7 cells. 
 
The in-vitro transfection was performed with a COS-7 cell line, a cell line often used in 
liposome and DQAsome mediated transfection (Jain et al., 2012), allowing for a 
comparison to previous published work. Here, the CM2 component was the only 
amphiphile used for the formation of DQAsomes. To improve transfection efficacy, Jain 
et al. have shown that the inclusion of a helper lipid like DOPE (as used within the 
liposome formulation) enhanced the in-vitro transfection efficiency >100-fold compared 
to dequalinium alone, using a luciferase-encoding plasmid (Jain et al., 2012). 
Nevertheless, in-vitro transfection by DQAsomes formed by microfluidics was 
promoted with both plasmids tested, indicating the biological activity of the vesicles 
manufactured by microfluidics. 
 
Weissig and co-workers first described the application of DQAsomes as transfection 
vehicles (Weissig et al., 2000; Weissig et al., 1998). DQAsomes were found to bind 
DNA and act as transfection vehicles with selectivity for carcinoma cells and targeted 
accumulation in the mitochondria (Christman et al., 1990; Steichen et al., 1991; Vercesi 
et al., 1991; Weiss et al., 1987). Lipophilic cationic compounds preferentially localise in 
mitochondria due to the electric potential of the mitochondrial membrane, making 
DQAsomes an ideal intramitochondrial gene delivery system (Johnson et al., 1981). 
Enhanced by the fact that carcinoma cancer cells have a higher negative mitochondrial 
surface potential, DQA is preferentially taken up, accumulated and also retained 
intramitochondrially (Berlin et al., 1998; Summerhayes et al., 1982). The similarity 
between a mitochondrial and a bacterial cell wall allows DQAsomes not only to bind 
and deliver DNA, but also treat bacterial infections. Opposed to cationic bola-
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amphiphiles, cationic lipids (Chapter 4) have been well described for the delivery of 
genetic material into the nucleus, where the protein is expressed in the cytoplasm 
allowing only for an indirect mitochondrial targeting. The delivery of genetic material by 
DQAsomes however is a direct method, where the DNA is directly delivered and 
followed by transcription and translation in the organelle itself. This direct delivery takes 
into account that the mitochondrial genetic code differs by four codons from the 
universal code (Barrell et al., 1979). Additionally, the proteins encoded by the 
mitochondrial DNA are highly hydrophobic and hence their transport into the organelle 
is unlikely; in fact, the hydrophobicity of mtDNA encoded proteins has been reported as 
a restricting factor for the transport from the cytoplasm into the organelle (Owen Iv et 
al., 2000). Following, a synthesis at the location of function is highly desired (Scheffler, 
1999). The here presented work showed that such organelle-targeted nanoparticles 
may be manufactured in a reproducible and high-throughput method based on 
nanoprecipitation in a chaotic advection micromixer. Work in this chapter additionally 
verified that DQA-vesicles manufactured by microfluidics deliver genetic material 
intracellular, allowing for protein expression and confirming that the biological activity 
has not been compromised by the method of manufacturing. 
 
5.4 Conclusion 
This work verified the suitability of the microfluidics-directed nanoprecipitation method 
for the manufacturing of DQAsomes, assembled from bola-amphiphiles with 
delocalized charge centres. Overall, vesicles manufactured in the microfluidics method 
showed lower variation and better correlation plots for particle size measurement, 
aligning with ideal intercept range (Chapter 3). Results suggested the presence of a 
larger sub-population between 2-4 µm, which may have resulted due to component 
specific aggregation behaviour and was found independent of the method of 
manufacturing. The FRR was evaluated as a crucial variable to influence the resulting 
size of the vesicles, which were shown to remain stable over 8 days. DQAsomes, as 
manufactured here by microfluidics, act as non-viral vectors, highly applicable in gene 
therapy procedures. Several diseases have been linked to mtDNA deficiencies (Taylor 
and Turnbull, 2005) including alzheimers, dementia, Parkinson's disease, and the 
targeted delivery of genetic constructs may treat those diseases associated with 
mitochondrial gene deficiencies (Weissig, 2015; Weissig and Torchilin, 2000). DQA is 
currently used in tumour growth inhibition, by specific destruction of tumour mtDNA, 
related to loss or delay of mtDNA function (Berlin et al., 1998). The variety of potential 
application necessitates a robust and reproducible manufacturing technique, where 
DQAsome manufacturing by microfluidics has been evaluated in this chapter. The 
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microfluidics method generated size-controlled DQAsome vesicles in a robust process 
setting, vesicles were stable, and had in-vitro activity. Nevertheless, the chemical 
instability was noticed throughout concentration and purification techniques employed; 
an issue currently addressed by Procarta Biosystems Ltd.. Results here further 
emphasize on the usefulness of the microfluidics-directed nanoprecipitation method. 
The high-throughput method allows screening over a range of concentrations and 
settings in a relative short period of time, compared to the time associated with lipid-
film hydration and sonication. Relating this work to the previous chapter, results show 
that the microfluidics-method is not limited to “standard” phospholipids (Chapter 4) but 
further amphiphilic compounds, here bola-amphiphiles with delocalized charge centers, 
can be used to yield nanoprecipitated vesicles, highlighting on the versatility and 
applicability of respective method.  Recent work based on DQAsomes showed that 
other than the amphiphilic compounds itself, lipophilic drugs are often required to be 
associated within the lipophilic compartment of a vesicle (Zupančič et al., 2014). 
Following, the next chapter focused on the encapsulation of lipophilic compounds 
within the nanoprecipitation method. 
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6 Microfluidics-controlled solubilisation of a low-
solubility drug and scale-up considerations 
 
 
* Structure obtained from sigmaaldrich.com 
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6.1 Introduction 
Of all new chemical entities in discovery, currently more than 40% have limited 
aqueous solubility and subsequently related bioavailability issues (Savjani et al., 2012; 
Williams et al., 2012). Given the amphiphilic structure of lipids, liposomes are well 
placed as solubilisation agents for drugs with low aqueous solubility. The encapsulation 
of low solubility drugs into the bilayer of liposomes is well described (Allen, 1998). In 
addition to offering solubilisation in an aqueous media, liposomes can offer a drug 
protection from degradation, control over its pharmacokinetic distribution profile and 
improved therapeutic efficacy. The drug encapsulation in lipid bilayers has been linked 
to a range of factors including the properties of the drug, the composition of the 
liposomes, the lipid choice and concentration (Ali et al., 2010; Ali et al., 2013; 
Mohammed et al., 2004). Besides research focusing on the optimisation of formulation 
parameters on the application of liposomes as solubilising agents, more focus may be 
required into the manufacturing process itself. Microfluidics-based methods have been 
described for the manufacture of liposomes and lipid nanoparticles (van Swaay, 2013) 
and previous work investigated the manufacturing of size-controlled liposomes as 
transfection agents (Chapter 4). 
 
6.2 Aim and Objectives 
The aim of this chapter was to investigate the microfluidics-based nanoprecipitation 
method for simultaneous liposome manufacturing and drug encapsulation. To achieve 
this, the drug encapsulation process was incorporated into the vesicle assembly by 
incorporation of a low-solubility model drug into the solvent phase (Figure 6.1). The 
ability of the method to encapsulate a low solubility model drug was evaluated and 
compared the drug encapsulation achieved by a top-down method based on 
sonication. The effect of flow rates, ratios and drug concentration was related to the 
efficiency of drug encapsulation, which was verified over a stability period of six 
months. In addition, the developed microfluidics-directed vesicle manufacturing method 
underwent a scale-up study, by a process transfer into a design with an increased 
channel diameter. Final scalability studies were undertaken at Precision Nanosystems 
Inc. in Vancouver, CA, where the process of drug encapsulation was evaluated in a 
scale-out system based on planar chip parallelisation. 
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Figure 6.1: Schematic depiction of the proposed drug encapsulation methodology by 
incorporation of a low solubility drug into the solvent stream during the microfluidics-
directed nanoprecipitation reaction of liposome formation.  
 
6.3 Results and Discussion 
6.3.1 Influence of the flow rate ratio of the aqueous and solvent streams on 
particle characteristics 
Similar to investigations in previous chapters (Chapters 4 and 5), the rate of mixing as 
well as the ratio of aqueous to solvent stream was anticipated as crucial factors in the 
formation of here neutrally-charged liposomes. Liposomes were prepared from PC and 
Cholesterol (16:4 molar ratio, 8:1 w/w) (based on previous studies; Ali et al., 2010) at 
different total flow rates (TFR) and flow rate ratios (FRR), ranging from 2 to 6 mL/min 
and 1:1 to 1:5 without loaded drug and the vesicle size, polydispersity (PDI) and zeta 
potential (ZP) were measured.  
 
The largest size of around 450 nm was linked to a low FRR (1:1), where the increase 
of the aqueous content FRR resulted in smaller liposomes (around 40 - 50 nm) at 
constant flow rates of 2 mL/min (Figure 6.2A). Liposome sizes remained between 40-
55 nm (p>0.05) within a FRR 1:2 to 1:5, with no notable influence on resulting ZP 
(Figure 6.2A). Similar to previous studies (Chapters 4 and 5), the PDI was found to 
increase significantly (p<0.05) with increasing aqueous FRR to a maximum of 0.4, 
(Figure 6.2B). In contrast, the sizes obtained by the top-down sonication method were 
significantly (p<0.05) larger, remaining above 150 nm for all sonication times tested, 
with the lowest PDI obtained via sonication coinciding with the largest PDI obtained by 
microfluidics (around 0.4);(Figure 6.2 C, D respectively). ZP remained independent of 
sonication times tested, coinciding with the ones obtained in the microfluidics method 
(Figure 6.2A and C). 
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Figure 6.2: Particle size, polydispersity and zeta potential of empty liposomes. The effect 
of increasing flow rate ratio (FRR) in the microfluidics method on A) particle size and 
zeta potential and B) polydispersity. Where shown, significance between data is against 
results of the FRR 1:1 (*p<0.05). The effect of increase in sonication time on C) particle 
size and zeta potential and D) polydispersity.  Where shown, significance between data is 
against the control (****p<0.0001). ns, not significant; CTR, control. Results denote mean 
± SD of at least 3 separate batches. 
 
The impact of FRR on vesicle size was in agreement with previous work (Chapter 4 
and 5) showing that the increase in FRR reduced the resulting size of the liposomes 
(Jahn et al., 2010; Zook and Vreeland, 2010). The SHM design has been developed to 
primarily enhance the diffusion and advection due to alterations of the fluid flow profile 
by the herringbones in the floor of the mixing chamber (Stroock et al., 2002). The 
mixing process is further enhanced by high aqueous content FRR, which decrease the 
solvent concentration drastically (Zook and Vreeland, 2010). With less solvent 
available for solubilisation of the hydrophobic chains, the closure time for the vesicle 
decreases. Here, the mixing rate of the lipid phase with the buffer was enhanced at 
high solvent to aqueous ratios, where the differences in fluid velocities between both 
streams decreased the effective diffusion layer thickness of the solvent stream in the 
mixing profile. In addition, reduced width of the solvent stream in the mixing profile 
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further diminished the diffusion distances. Decreased closure time for the vesicle leads 
to the formation of smaller vesicles at higher FRR (Zook and Vreeland, 2010). The 
nanoprecipitation-directed vesicle formation reported a correlation between FRR and 
particle size for liposomes composed of 1-palmitoyl, 2-oleoyl phosphatidylcholine 
(POPC), cholesterol and the triglyceride triolein; a higher aqueous content FRR was 
linked to overall smaller particles, ranging from 140 nm to 40 nm and triglyceride 
emulsions between 20 − 50 nm in size with nonpolar cores (Zhigaltsev et al., 2012). 
The authors noted that the higher aqueous content FRR employed decreased the 
particle fusion (Ostwald ripening), which lead to the formation of smaller particles 
(Zhigaltsev et al., 2012). The link between FRR and PDI, as seen in earlier Chapters 
(Chapter 4 and 5), may be a result of increased dilution at higher FRR, which reduces 
the rate of diffusional mixing within the micromixer. Given the correlation between 
diffusion to concentration, the decreased lipid concentration reduced the rate of 
diffusion at higher aqueous content FRR, which lead to partly incomplete nucleation 
and a lower rate of liposome formation inside the micromixer (Balbino et al., 2013b). 
Overall, these findings demonstrated that the liposome size plateaued at a FRR 
greater 1:2, which suggested that the smallest vesicle size achievable was 40-50 nm. 
 
6.3.2 Influence of flow rate on throughput and particle characteristics 
Besides the FRR, the effect of the TFR on particle characteristics was studied and 
linked to the overall method-throughput. Here, the TFR was increased 3-fold from 2 to 
6 mL/min whilst maintaining the ratio between solvent and aqueous stream constant 
(1:3). Liposome size was independent of the applied flow rate, with no significant 
change in vesicle size, PDI and ZP (p>0.05) throughout the TFR alterations (Figure 
6.3).   
 
Figure 6.3: The effect of increasing n total flow rate (TFR) on vesicle size, polydispersity 
and zeta potential. Results were not significant compared to the vesicle characteristics 
obtained at 2 mL/min. Results denote mean ± SD of 3 separate batches. 
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Liposome characteristics were maintained with increasing TFR, which demonstrated 
the suitability of microfluidics manufacturing for a high-throughput bench-top liposome 
manufacturing. Results further confirmed previous finding (Chapter 4) with the FRR as 
the most crucial variable impacting on liposome size, which has been demonstrated 
with other formulations (Balbino et al., 2013a; Balbino et al., 2013b; Jahn et al., 2007; 
Jahn et al., 2004). Nonetheless, the FRR is directly linked to the resulting vesicle 
concentration, where an increase in FRR will inevitably dilute the final formulation 
manufactured. Liposome concentration processes have been proposed, relying on 
either filtration (Pattnaik and Ray, 2009), chromatography (Ruysschaert et al., 2005) or 
centrifugation, with all methods adding processing time. In order to circumvent this 
additional step, the lipid concentration was increased according to the FRR chosen. 
Results showed that liposomes up to a 6-fold higher concentration could be 
manufactured, with no significant influence to their characteristics at FRR of 1:3 and 
1:5 compared to the standard lipid concentration (Figure 6.4A, B). However, the two-
fold increase in lipid concentration did result in a significant (p<0.05) decrease in 
vesicle size at a FRR of 1:1, which may be linked to the low aqueous content FRR, 
where an increase in lipid concentrations may affect the particle fusion, which lead to 
the formation of smaller particles (Zhigaltsev et al., 2012). 
 
Figure 6.4: The effect of increased lipid concentration on A) vesicle size and B) 
polydispersity for the standard lipid concentration and increased lipid concentrations. 
The lipid concentration is shown in the table below the graph, which was tailored to the 
FRR. Where shown, significance between data is against results of standard lipid 
concentration (*p<0.05). Results denote mean ± SD of 3 separate batches. 
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Based on the advantage of diffusional mixing, the final liposome concentration could be 
increased according to the FRR in the method, with minimal effects on vesicle 
characteristics (Figure 6.4). This method allowed for manufacturing vesicles at a higher 
concentration, circumventing time intensive post-processing concentration techniques. 
In comparison to the microfluidics-counterpart, the flow-focusing method, dilution factor 
(due to flow ratios chosen involved in the SHM method) are overall lower, which can 
reach up to 60 in the flow focusing method (Jahn et al., 2010; Jahn et al., 2007; Jahn et 
al., 2004).  
 
6.3.3 Drug loading studies: The effect of drug encapsulation by the liposome 
manufacturing method  
In addition to the particle characteristics studied, the method was evaluated for its 
ability to produce liposomes as solubilising agents by assessing the loading capacity. A 
low-solubility model drug, propofol, was included in the solvent stream while liposomes 
were manufactured at a FRR of 1:3 and a TFR of 2 mL/min, based on previous studies 
(Figure 6.2, 6.3). Initially, the drug loading was examined as a function of propofol 
concentration in the solvent stock, which ranged from 0.5 to 3 mg/mL. The propofol 
concentration in the solvent stream strongly influenced the resulting particle 
characteristics; a particle size of ~50 nm and a low PDI was observed at a propofol 
concentration of 0.5 and 1 mg/mL (Figure 6.5A, B), which matched the characteristics 
seen at same TFR/FRR without the drug incorporated in the process (Figure 6.2A, B).  
The highest propofol concentration of 3 mg/mL in the solvent stream increased particle 
size and PDI notably to ca. 600 nm and 0.8 respectively (Figure 6.5A, B). Drug loading 
was highest at a propofol concentration of 1 mg/mL and reduced when the initial 
propofol concentration increased to 3 mg/mL (Figure 6.5C). This suggests a saturation 
or destabilisation at higher propofol concentrations (drug-to-lipid ratio 1.72 mol/mol). 
Propofol encapsulation (mol%) in liposomes was found independent of the FRR tested, 
ranging from 1:1, 1:3 and 1:5 and remained at approximately 50 mol% (p>0.05), Figure 
6.5D. In comparison to the sonication method, drug loading was overall significantly 
higher (p< 0.0001) in the microfluidics method (Figure 6.5D). The recovery of the drug 
was reduced at a propofol concentration of 3 mg/mL in the solvent stream, with the 
lowest recovery of 67% corresponding to the FRR of 1:5 (significantly lower than at the 
FRR of 1:1; p< 0.01; Figure 6.5E). The recovery of both, lipids and drug in the 
nanoprecipitation method was linked to the cost-effectiveness of the process and the 
importance of maintaining the lipid to drug ratio (here, 1 mg/mL propofol in solvent 
stream). The drug was recovered between 88 - 92% (Figure 6.5F), independent of the 
FRR (p>0.05). The highest lipid recovery was at FRR of 1:1 and 1:3 (97% and 89%; 
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respectively; Figure 6.5F). Reduced lipid recovery of 79% a FRR 1:5 (p<0.05), which 
suggested that higher FRR may impede lipid recovery due to enhanced dilution in the 
chamber (Figure 6.5E). Given that the lowest vesicle size was found at a FRR 1:3, the 
increase in FRR beyond that point would not benefit the formulation (size, PDI and 
drug encapsulation). 
 
Figure 6.5: The effect of incorporating a low solubility model drug (propofol) at 0.5, 1 and 
3 mg/mL in the solvent stream on A) particle size, B) polydispersity, at different FRR and 
C) total loading (mg) in 3 mL formulation and encapsulation (mol%). D) Direct 
comparison of the loading (mol%) at different FRR to the loading in the sonication 
method, achieved with a propofol concentration of 1 mg/mL in the solvent phase for both 
methods. Significance between data is against results of loading achieved in the 
sonication method (****p<0.0001). E) Recovery of propofol in the formulations at different 
FRR and in comparison to the recovery obtained in the sonication method. F) Recovery 
of lipids and propofol at different FRR employed (TFR 2 mL/min, 1 mg/mL propofol in 
solvent stream). Significance between data is against the recovery achieved in at the 
FRR of 1:1 (*p<0.05, **p<0.01). Results denote mean ± SD of 3 separate batches. 
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The larger vesicle sizes and PDI of vesicles manufactured with high drug 
concentrations in the solvent stream highlights the importance of screening for the 
ideal starting drug concentration, which was found to be best at 1 mg/mL and was 
independent of the FRR applied. Based on these results, all subsequent studies 
adopted a propofol concentration at 1 mg/mL in the solvent stream at a FRR of 1:3. 
Here, the control method was a top-down method involving lipid-film hydration and 
sonication. This control method was chosen for comparison to published data on the 
encapsulation of low solubility drugs into liposomes. Here, the encapsulation of ~20 
mol% by the sonication method coincided with literature values (Ali et al., 2013). 
Overall, loading of the drug into the bilayer by the microfluidics method was 
significantly higher compared to the top-down method. The efficient mixing process, 
based on chaotic advection and diffusion in the channel, was anticipated as the key 
mechanism behind drug encapsulation, which was favoured and occurred 
simultaneously with the synthesis of the vesicles themselves. Overall, the propofol 
encapsulation reached ~50 mol%, which represented a total propofol amount of ~300 
mg/mL in the final liposome formulation. In comparison to the published aqueous 
solubility of propofol (150 µg/mL), the chaotic advection nanoprecipitation method 
yielded a 2000-fold increase in solubility (Altomare et al., 2003). Following these 
recovery studies, a FRR of 1:3 was maintained throughout a long-term stability study. 
The here-developed quantification method verified that desired lipid to drug ratios were 
maintained and opposed to time intensive mass spectrometry, allowed for a quick 
quantification of any solids in the eluate with a lower volatility than the mobile phase 
(Moore et al., 2007).  
 
The use of liposomes as solubilising agents for low solubility drugs is well explored (Ali 
et al., 2010; Ali et al., 2013; Mohammed et al., 2004); however this is the first time that 
the manufacturing method itself was linked to the overall increased amount of drug 
solubilised within the bilayer. The log P and molecular weight were often considered to 
impact on bilayer loading, where the molecular weight was shown as an important 
factor (Ali et al., 2013). With regards to the design of liposomes, a range of parameters 
were shown to impact the bilayer loading efficacy; the increasing the bilayer lipophillic 
volume (by adopting longer alkyl chain lipids within the liposomes) was linked to an 
increase in the loading ability of liposomal systems (Mohammed et al., 2004; Ali et al., 
2013). Similarly, the lipid charge within the liposomal system was found important 
based on electrostatic repulsion of drugs with like-charged liposomal bilayers 
(Mohammed et al., 2004). Where the incorporation of cholesterol is known to stabilise 
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the liposomes, it was also shown to inhibit bilayer drug loading (Ali et al., 2010) due to 
the space-filling action of cholesterol in the liposomal bilayer.  
 
Work also highlighted the current deficiencies in the SHM method. Firstly, reduced 
propofol recoveries at higher drug concentration (3 mg/mL) and reduced lipid recovery 
that a FRR of 1:5 (Figure 6.5E, F), which may be linked to the amount of waste volume 
collected prior to collecting the core of the sample. This effect can be countered by 
simply increasing the waste volume, making a process less economical. Also, drug or 
lipid adsorption onto the PDMS matrix might have occurred (Toepke and Beebe, 2006), 
turning significant at an overall lower amount of solvent present, as seen at a FRR of 
1:5. The material affect has been addressed, by changing the chip material from PDMS 
to CoC (reference Precision NanoSystems Inc.).  
 
6.3.4 Microscopy images for vesicle verification  
To investigate the morphological nature of these vesicles, liposomes were studied 
using free fracture microscopy. Images taken by freeze fracturing electron microscopy 
verified the small unilamellar nature of vesicles manufactured by microfluidics, found in 
agreement with average sizes of the vesicle diameters obtained via dynamic light 
scattering (~40 nm), Figure 6.6A-D, with no notable difference in images obtained 
between empty and drug loaded vesicles manufactured by microfluidics (Figure 6.7A-
D). Furthermore, an aqueous fluorescent dye, carboxyfluorescein (CF) was included in 
the aqueous phase in both methods, sonication and microfluidics. Particles were 
visualised by confocal microscopy after removal of any unentrapped drug by dialysis. 
Vesicles manufactured showed bright green fluorescent cores, where particles 
produced by lipid film hydration/sonication (Figure 6.8A, B) acted as a control method 
and images verified the formation of liposomes in the microfluidics method (Figure 
6.9A, B). 
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Figure 6.6: Freeze fracturing electron microscopy images (A-D) obtained of PC-Chol 
liposomes manufactured by microfluidics (TFR 2 mL/min, FRR 1:3). 
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Figure 6.7: Freeze fracturing electron microscopy images (A-D) obtained of PC-Chol 
liposomes loaded with propofol manufactured by microfluidics (TFR 2 mL/min, FRR 1:3, 
1 mg/mL propofol in solvent stream). 
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Figure 6.8: Images obtained by confocal microscopy showing liposomes manufactured 
by (A, B) lipid film hydration/ sonication, encapsulating the aqueous marker 
(carboxyfluorescein). Note that fluorescence spot size does not correspond to actual 
vesicle size as liposomes in this sample were below the optical resolution.  
 
 
 
Figure 6.9: Images obtained by confocal microscopy showing liposomes manufactured 
by (A, B) microfluidics (TFR 2 mL/min, FRR 1:3), encapsulating the aqueous marker 
(carboxyfluorescein). Note that fluorescence spot size does not correspond to actual 
vesicle size as liposomes in this sample were below the optical resolution. 
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6.3.5 The effect of manufacturing method to drug release 
In addition to the drug loading, the in-vitro release profile was monitored at 37°C over 
16 h and compared to vesicles manufactured by the top-down sonication method 
(Figure 6.10). At the start of the release study, vesicles manufactured by microfluidics 
(2 mL/min, 1:3) showed a higher drug encapsulation (~55 mol%) compared to vesicles 
formed by sonication (~20 mol%). Results showed an initial drug release of ca. 40% at 
1 h independent of the manufacturing method followed by a continuous release of 90% 
of the encapsulated drug over 8 h and drug release rates were independent from the 
manufacturing method when plotted as % cumulative release of total amount loaded 
(Figure 6.10A), other than plotting the mol% release (Figure 6.110B). Previously 
published work demonstrated that PC liposomal bilayer-loaded propofol followed a 
zero-order release kinetics (Ali et al., 2013), and the incorporation of cholesterol into 
the liposomal systems shifted the release rates towards a first-order release model (Ali 
et al., 2010). The authors described that bilayers containing cholesterol are more 
condensed and less permeable, where without cholesterol the bilayer can be thought 
of as more ‘porous’ in nature (Ali et al., 2010). This suggests that the release rates are 
dictated by the formulation rather than the method of manufacture. Given the 
independence of the manufacturing method from the release profile, the microfluidics-
directed vesicle manufacturing may prove advantageous in the development of an IV 
formulation due to its high-throughput and robustness. Pharmacokinetic release profile 
of propofol has been studied in a colloidal dispersion between 20-100 nm (Cai et al., 
2012), where data compared the distribution of propofol to the commercial product 
Diprivan®. The authors showed that propofol in a microemulsion required less time to 
be released from the oil phase compared to a commercial product. Besides the rapid 
distribution of propofol, it also penetrated quickly into the tissue (Cai et al., 2012). The 
authors emphasised on the need for new technologies, given current drawbacks of the 
commercial product like instability (Park et al., 2003) and pain upon injection due to 
free propofol (Sim et al., 2009). 
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Figure 6.10: In-vitro drug release profile for propofol-loaded liposomes manufactured by 
microfluidics and sonication. Release profiles show A) the cumulative drug release and 
B) the release of the drug in mol% over 16 hours. Results denote mean ± SD of 3 
separate batches. 
 
6.3.6 The effect of manufacturing methods on liposome stability and drug 
encapsulation over 6 months  
The stability of the vesicles manufactured by microfluidics at different storage 
temperatures was assessed, in addition to a stable and long term drug encapsulation. 
Vesicles were prepared using the microfluidics-nanoprecipitation method as described 
above (FRR 1:3, 1 mg/mL propofol in solvent stream). After removal of the 
encapsulated drug by dialysis, the initial amount of propofol encapsulated was 
quantified and the liposomes were stored at 4°C, 25°C/60%RH and 40°C/75%RH (as 
per ICH guidelines) in pharmaceutical grade stability cabinets for a storage period of 6 
months. Vesicles manufactured by the sonication method acted as the control and 
were stored at 25°C/60%RH.  
 
Vesicle size remained constant throughout the storage over 6 months at 4°C and 25°C 
for liposomes prepared by microfluidics, with a slight increase noted for the vesicles 
stored at 25°C at the end of the study (Figure 6.11A). In contrast, vesicles stored at 
40°C significantly increased (p<0.05) in size from initially 55 nm to 800 nm throughout 
the study, with no notable effect on PDI (Figure 6.11A, B), suggesting that the whole 
liposome population has changed in size rather than a sub-set of the vesicles. Similar 
to above results, vesicles manufactured by the microfluidics-directed method were 
smaller with a lower PDI than those obtained by lipid film hydration / sonication (Figure 
6.11A, B). The liposomes manufactured by sonication (stored at 25°C) showed good 
stability in terms of size retention over the initial 50 days of around 100 ± 20 nm, after 
which a size increase was noted (Figure 6.11A). The formulations at 4°C and 25°C 
showed minor (but not significant) drug loss after the first 7 days of storage, after which 
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the formulations remained stable with final drug encapsulation values of 43 ± 10 mol% 
and 29 ±12 mol% at 4°C and 25°C storage conditions respectively (Figure 6.11C). 
Similarly, liposomes manufactured by the sonication method showed and initial drug 
loss when stored at 25°C/60%RH, which plateaued out approaching complete drug 
loss over the storage period of 6 months (Figure 6.11C). Notable drug loss from the 
microfluidic-based vesicles was seen at elevated storage temperatures (40°C), which 
resulted in almost complete drug loss over the course of the stability study, with only 3 
± 1 mol% drug remaining encapsulated after 6 months, still higher that the final drug 
encapsulated in the sonicated liposomes which were stored at 25°C/60%RH (Figure 
6.11C). In addition to the stability of propofol-loaded vesicles, the drug itself was 
subjected to same storage duration and temperatures, which showed complete 
recovery of the drug independent of the storage condition (Figure 6.11D), which 
verified its physical stability. The drug loss over time could hence be linked to its 
diffusion over the lipid membrane, and not its physical degradation throughout the 
storage period. Given the dependence of solubility on temperature and enhanced 
diffusion at elevated temperature, the aqueous solubility of the drug increased, 
resulting in reduced drug encapsulation at higher storage conditions (here 40°C).  
 
In addition, a microfluidics-manufactured formulation with a higher lipid concentration 
was subjected to the 6 months storage conditions (4°C), Figure 6.11E, linked to 
previous study where the lipid concentration was increased to counter the dilution 
(Figure 6.4). Here, both lipid and propofol concentration was increased four-fold, 
remaining the lipid to drug ratio.  Vesicles showed identical particle characteristics 
(size, PDI) as well as loading (mol%) in comparison to the vesicles manufactured at a 
one-fold concentration (Figure 6.11A, B, C), with particle characteristics remaining 
throughout the stability study, the drug loading was reduced to ca. 30 mol%, overall 
lower compared to the one-fold concentration at similar storage conditions (ca. 43 
mol%). Given the higher concentration gradient during dialysis, enhanced drug 
diffusion may be linked to the higher propofol concentration. 
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Figure 6.11: Results depicting the effect of long term storage conditions to A) vesicle 
size B), polydispersity, C) drug encapsulation, D) drug recovery and E) stability at 4-fold 
lipid and drug concentration. Results denote mean ± SD of 3 separate batches. 
 
No visual precipitation throughout the stability study for vesicles manufactured by 
microfluidics was seen, whereas the sonicated vesicles showed flocculants present 
after 14 days of storage (Figure 6.12), which however dissolved after vortexing the 
solution, not impeding on the respective size measurements (Figure 6.11A). 
Formulation stored at higher temperatures turned slightly yellow during the stability 
study (Figure 6.12), linked to the oxidation of propofol (Baker et al., 2003). A clear 
solution was only maintained at a storage temperature of 4°C (Figure 6.12), which also 
allowed for a stable drug encapsulation throughput the study (Figure 6.11C). 
Quantification of propofol was performed by HPLC, which does not distinguish between 
oxidization states of the drug, not impeding the measurements over the course of the 
stability study (Figure 6.11D).  
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Figure 6.12: Images taken throughout the stability study duration, showing vials of 
microfluidics-manufactured vesicles stored at 4°C, 25°C and 40°C and sonication-
vesicles (25°C), from left to right at respective time points. 
 
The results in Figure 6.11 and 6.12 suggest that vesicles formed by microfluidics-
directed nanoprecipitation and loaded with a low solubility drug remained stable over 
six months at conditions of 4°C. The SHM nanoprecipitation-method was previously 
investigated for the encapsulation of a highly water-soluble drug only, with 
approximately 100% loading efficiencies using doxorubicin as a model drug. The 
authors demonstrated high drug retention of the encapsulated drug in liposomes stored 
at 4°C over the course of eight weeks (Zhigaltsev et al., 2012). Despite widespread use 
of propofol emulsions e.g. Diprivan®, stability concerns are currently a major limitation 
(Baker and Naguib, 2005; Driscoll et al., 2002); were the microfluidics-based 
manufacturing was shown to potentially overcome this issue. 
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6.3.7 The effect of drug, drug loading and manufacturing method to the 
biological toxicity 
In addition to the performed in-vitro drug release study, the biological effect of the 
vesicles manufactured was assessed in a toxicity assay. Initially, the toxicity of the drug 
itself, propofol, was investigated. Given a constant drug to cell ratio, no difference 
(p>0.05) was noted within the different drug concentrations tested (Figure 6.13), which 
linked to the previous study of determining the ideal drug/lipid ratio (Figure 6.5 A, B, C). 
Vesicles manufactured by microfluidics were tested in various combinations with (+) 
and without (-) drug at concentrations ranging from the standard lipid concentration 
(6.08 mg/mL PC, 0.77 mg/mL Chol), to the two-fold (12.16 mg/mL PC, 1.54 mg/mL 
Chol), four-fold (24.32 mg/mL PC, 3.08 mg/mL Chol) and six-fold lipid (36.48 mg/mL 
PC, 4.62 mg/mL Chol) concentration, which all remained insignificant (p>0.05) with a 
biological viability above 72% (Figure 6.13). Vesicles manufactured by lipid film 
hydration / sonication showed a reduced viability between 60 -70 %, significantly 
reduced compared to the control (p<0.05 and <0.001). The incorporation of the drug 
however had no significant impact (p>0.05) on the cellular viability, confirming its 
independence on the cellular toxicity (Figure 6.13).   
 
Figure 6.13: Viability (%) as determined by a MTT study. Significance between data is 
against the viability of the control (untreated cells) (*p<0.05, ***p<0.001). Results denote 
mean ± SD of 3 separate measurements in 3 independent cell passage numbers (n=9). 
 
The biological toxicity was independent of the incorporation of the drug, with the 
vesicles manufactured by microfluidics showing a higher viability compared to the 
vesicles subjected to sonication. Sonication is a method frequently applied for size 
reduction, which is however known for contamination due to direct contact of the probe 
tip and metallic residues (Wagner and Vorauer-Uhl, 2011). Despite centrifugation, 
metallic residues might not have been completely removed, impacting on the cellular 
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toxicity as seen in this study. These results further emphasize on the suitability of the 
microfluidics method for potential industrial application, as the method was shown to 
not only benefit the particle characteristics and drug loading, but also allowed for the 
manufacturing of a less contaminated sample, with beneficial biological impact, which 
may be advantageous for transferring this method in an industrial-scale process. Given 
the limited scalability of a lipid-film hydration method and potential contamination based 
on a sonication process, the microfluidic-based vesicle manufacturing process might 
be a viable option for a robust and controlled particle manufacturing for large-scale 
industry setting. In order to approach that, scalability studies are vital, not only for 
understanding the critical process parameters, but furthermore for a seamless transfer 
into a large-scale version of the respective method.  
 
6.3.8 Assessment of the scalability of the microfluidics-directed 
nanoprecipitation method 
In order to verify the suitability of the microfluidics method for industrial scale 
application, scalability studies were undertaken by firstly increasing the channel 
diameter and secondly parallelising the design in a planar scale-out platform, both 
aiming for an enhanced production throughput. Initially the channel width was 
increased from 200 µm to 300 µm and the height was increased from 78 µm to 130 
µm, both designs with a similar aspect ratio and hydraulic diameter (design obtained 
from Precision NanoSystems Inc.). In order to determine the flow rates for the 300 µm 
design, scale-up calculations were performed. Therefore, dimensionless numbers (Re 
and Pe) were determined for the average flow rates applied in the 200 µm design, 
which ranged between 1-3 mL/min in the current used SHM design (200 µm width and 
78 µm height). The average fluid velocities, Re and Pe numbers were determined as 
exemplified below (Equation 6.1). 
 = 	    Equation 6.1 
With  
u  Fluid velocity (m/s) 
Q  Volumetric flow rate (m3/s) 
A  Cross sectional area of channel (m2) 
 
 = 2	 	
 = 2000	


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
  
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	 ∗ 	78 ∗ 	10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		 
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The dimensionless Re and Pe numbers were determined based on above determined 
fluid velocities (Equation 6.2, 6.3). 
!" = 	 #$%&	'    Equation 6.2 
With  
L0  Characteristic length = channel diameter = 200	μ = 	200 ∗ 	10)	 
u  Fluid velocity (m/s) 
µ  Dynamic viscosity = 10*+	 
ρ  Fluid density = 10 ,-./ 
 
01 = 	 2345	' =
666∗768/	9:	∗66∗	768;	.∗	76/<=9/
768/>?	@ 	≈ 400  
 
A" = 	 $%&	B    Equation 6.3 
With  
L0  Characteristic length= channel diameter = 200 µm = 200 ∗ 	10)	 
u  Fluid velocity = 2000 ∗ 10 	.@	  
D  Diﬀusion coeﬃcient lipid = 3 ∗	107 	.E@  (Almeida et al., 2005)  
 
*1 = 	u	G	D =
2000 ∗ 10 		 ∗ 200 ∗	10)		
3 ∗ 	107 	
≈ 10 ∗ 10I	 
 
Above calculations determined Re and Pe for flow rates from 1 to 3 mL/min in the 200 
µm design, Table 6.1. 
 
Table 6.1: Determined Re and Pe numbers in the chip design with a channel diameter of 
200 µm ranging at TFR between 1 to 3 mL/min. 
 
Total Flow rates  
(mL/min) 
Re Pe 
1 200 6* 107 
 
2 400 10 * 107 
 
2.5 500 17* 108 
 
3 650 20 * 108 
 
Based on a micromixer review, passive micromixers are recommended at either low 
Re (< 1) or high Re (>50), Figure 6.14, (Nguyen and Wu, 2005). Given the Re numbers 
in the 200 µm design (Table 6.1), the mixing based on chaotic advection was 
anticipated feasible even at higher Re, which could be expected in the 300 µm design. 
Given the high Pe numbers, convection is the dominant way of mixing, here the 
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movement of the lipid particles by the fluid motion. If the mixing would be achieved 
solely by diffusion, a long channel length would be required due to high Pe (Squires 
and Quake, 2005). Here, the dominant convective forces allow for a shorter channel 
length (here 19 *103 µm in the 200 µm design and 14 *103 µm in the 300 µm design), 
as mixing is primarily dominated by convection. Given a linear pressure-flow 
relationship in a low-Re Newtonian fluid, the pressure drop in the design was 
anticipated as the scale-up factor to be maintained constant. 
 
Figure 6.14: Overview over micromixers identifying the operating ranges for passive 
micromixers at low (< 1) and high (> 100) Re numbers. Adopted from (Nguyen and Wu, 
2005). 
 
Following the determination of Re numbers, scalability calculations were based on 
Hagen-Poiseuille Law (Equation 6.4). 
 
∆A = 	 KLM	N	%	OP	QR    Equation 6.4 
With  
∆*  Pressure difference (Pa) 
S Viscosity of medium (Pa s) 
L  Length of channel (m) 
Q  Volumetric flow rate (m3 s-1) 
d  Diameter of channel (m) 
Assumptions: Incompressible and Newtonian fluid, laminar flow, constant cross-section, no fluid 
acceleration.  
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For scale-up consideration, the pressure drop (∆*) in the microfluidics system was 
anticipated as the crucial variable to maintain constant, given its key role in determining 
mixing times (Kockmann et al., 2011; Squires and Quake, 2005). Therefore Equation 
6.4 simplifies to Equation 6.5 
 
∆A ≈ 	 	O	QR    Equation 6.5 
 
Given a rectangular channel, equivalent pipe diameter was calculated, which estimated 
the diameter of a circular pipe with the equal pressure loss as obtained in the 
rectangular channel, Figure 6.15, Equation 6.6. 
 
Figure 6.15: Depiction of rectangular cross section and equivalent diameter in a pipe. 
 
Q" = K. TU ∗ ((W∗XYU.ZL[(W\XYU.L[Y  Equation 6.6 
With 
de = Equivalent diameter (m) 
a = Width of channel (m) 
b =  Height of channel (m) 
 
The equivalent diameter for the 200 µm and 300 µm design (de200 and de300 
respectively) was calculated and the pressure drop between both chips anticipated as 
the constant, leading to Equation 6.7. 
∆*66 	≈ 	∆*66 
]E^^ = 1.30 ∗ _(200 ∗ 10
)		 ∗ 78 ∗ 10)		Y6.)`
(200 ∗ 10)		 + 78 ∗ 10)		Y6.`b ≈ 0,00013		 ≈ 	130	μm	 
]/^^ = 1.30 ∗ _(300 ∗ 10
)	 ∗ 130 ∗ 10)	Y6.)`
(300 ∗ 10)	 + 130 ∗ 10)	Y6.`b ≈ 0,00021		 ≈ 210	μm 
 
	OLUU
	QRLUU 	≈ 	 	OTUU	QRTUU    Equation 6.7 
 
Flow rates in the 300 µm design were calculated based on Equation 6.7 and equivalent 
channel diameters and flow rates in the 200 µm design (Table 6.1). 
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66 	≈ 	
e66		e66 ∗ 66	 
66 	≈ 	210
e
	130e ∗ 66 
 
Table 6.2: Corresponding flow rates in the 200 µm and 300 µm design considering a 
constant pressure drop throughout scale up. 
 
Q200 Q300 Re300 Pe300 
0.5 3.4 360 12*107 
 
1 6.8 750 25*107 
 
1.5 10.2 1200 40*107 
 
2 13.6 1650 55*107 
 
2.5 17.0 2000 70*107 
 
3 20.4 2500 85*107 
 
Based on these calculations, the TFR in the 300 µm design ranged from 5 to 20 
mL/min (Table 6.2) and resulting particle characteristics were compared to those 
obtained by the 200 µm design. The Re numbers indicated that flow remains laminar, 
entering the transition range to a turbulent flow at a TFR of 20 mL/min (Re>2300), with 
a full turbulent flow expected at Re>4000 (Kirby, 2010).  
 
The increase in FRR at constant TFR of 10 mL/min showed the same profile as 
obtained in the 200 µm design (Figure 6.2A), where largest vesicles were obtained at a 
FRR of 1:1 and a minimum particle size of 50 nm obtained at higher FRR (Figure 
6.16A). The increase in TFR form 5 to 20 mL/min did not influence resulting particle 
size, PDI and ZP, which remained insignificant (p>0.05) in comparison the ones 
obtained with the 200 µm design (Figure 6.16B). Once incorporating the low solubility 
model drug in the solvent phase, encapsulation capacity was assessed in the 300 µm 
design at TFR of 5 to 20 mL/min, at constant FRR of 1:3. Physicochemical vesicle 
characteristics (size, PDI and ZP) of vesicles manufactured by the 300 µm design 
remained insignificant in comparison to those obtained with the 200 µm design. 
Additionally, and most important, the drug encapsulation was maintained at ca. 50 
mol% throughout the scalability assessment, with no significant (p>0.05) change in 
drug loading compared to the 200 µm design (Figure 6.16C). 
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Figure 6.16: Evaluation of the scale-up design with a channel diameter of 300 µm for 
effect of increase in A) FRR at constant TFR of 10 mL/min and B) TFR at constant FRR of 
1:3 on vesicle size, PDI and zeta potential. Significance between data is against the FRR 
of 1:1 (*p<0.05). C) Effect of increase in TFR at constant FRR (1:3) on drug loading and 
vesicle characteristics. Results denote mean ± SD of 3 separate batches.  
 
To further evaluate the 300 µm scale-up design, the concentration of the lipids was 
increased to allow for a higher concentrated formulation. The TFR was based on 
previous results (Figure 6.16B) and maintained at 10 mL/min, whereas the 
concentration of the lipids was varied according to the FRR, with no significant effect 
(p>0.05) on the physicochemical vesicle characteristics (Figure 6.17A). Given ideal 
particle characteristics at a FRR of 1:3, the previous determined lipid/drug ratio was 
maintained and both, lipid and drug concentration was increased four-fold to 
circumvent the dilution based on respective FRR. Besides maintaining the particle 
characteristics at a four-fold higher lipid and drug concentration, the overall drug 
loading was maintained (Figure 6.17B) with no significant difference (p>0.05) to the 
loading achieved with the 1-fold lipid and drug concentration in the 300 µm and the 200 
µm design. 
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Figure 6.17: Evaluation of the scale-up design with a channel diameter of 300 µm for A) 
increase in lipid concentration to counter dilution of liposomes tailored to the FRR at 
constant TFR of 10 mL/min. B) Particle characteristics and loading achieved with a 
higher concentrated lipid/drug concentration compared to the 200 µm design, at constant 
FRR of 1:3. Results denote mean ± SD of 3 separate batches. 
 
These initial results showed that determined TFR, based on the scale-up consideration 
of a constant pressure drop, maintained the critical particle characteristics as well as 
the drug loading capacity of those vesicles. Furthermore, the 300 µm design allowed 
for manufacturing of vesicles up to a six-fold higher concentration without adversely 
impacting on physicochemical characteristics. In addition, vesicles were not only 
manufactured at a higher throughput and a higher concentration, but also with constant 
drug loading capacities. Overall, the scale up from the 200 µm to the 300 µm design 
resulted in a 10-fold increase in throughput, up to a maximum of 20 mL/min. 
 
In addition to increasing the channel diameter (scale-up), the setup was evaluated in a 
scale-out platform. Here, mixers, all with a channel diameter of 300 µm, were 
parallelised in a planar way (Figure 6.18A, B). Fluid manifolds were used to split the 
flow, solvent and aqueous respectively, in the parallelised chips, which were 
assembled into a 2-fold and 4-fold platform (Figure 6.18C, D), referred to as 2x and 4x 
scale-out platform in subsequent results and discussion section. Scale-out platforms 
were evaluated in syringe driven systems in 2x and 4x setup (Figure 6.18E) as well as 
in continuous flow pump system in a 1x and 4x setup (Figure 6.18F). 
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Figure 6.18: Scale-out platform from A) side and B) top view, fluid manifolds as set for a 
C) 4x and D) 2x flow, E) syringe driven and F) continuous flow pump system. 
 
In comparison to the standard bench-top system, the syringe driven system allowed for 
a higher throughput by volume, with larger syringes connected to the inlet streams, but 
still remaining a batch-type process. Physicochemical characteristics (size, PDI and 
ZP) were maintained in the 2x and 4x syringe-driven scalability platform (Figure 6.19A), 
and the recovery of lipids and drug was found independent of the scale-out setup 
(Figure 6.19B). Vesicles were no significantly different in size once the drug (propofol) 
was incorporated into the manufacturing process (Figure 6.19A), with a comparable 
drug loading compared to the batch system (Figure 6.19B). 
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Figure 6.19: Effect of scale-out by a syringe-driven 2x and 4x setup to A) particle 
characteristics of empty and drug loaded liposomes and B) recovery of lipid and drug as 
well as overall drug encapsulation. All runs were performed at a FRR 1:3 and a TFR of 10 
mL/min per chip. SUV, small unilamellar vesicles. Results denote mean ± SD of 3 
separate batches. 
 
Further to the syringe driven scale-out platform, the platform was connected to 
continuous flow pumps, Figure 6.18F. The formulation was collected in cumulative 
batches in a 1x and 4x continuous flow system, with the initial 5 and 10 mL collected in 
the waste. A total of 50 mL was collected in the 1x continuous flow system, whereas a 
total of 125 mL was collected in the 4x continuous flow system. The collection of the 
waste volume in the 1x and 4x continuous flow system highlighted on the significance 
of collecting the core of a sample once the system reached a steady-state condition. 
Overall, particle characteristics throughout the 1x and 4x continuous flow system were 
maintained (Figure 6.20A, B), highlighting on the robustness of the process once 
operating in a steady-state condition. Similar to above, particle size increased once the 
drug was added into the manufacturing process in the continuous flow process (Figure 
6.20C, D). 
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Figure 6.20: Effect of scale-out by a continuous flow setup to particle characteristics in a 
A) 1x and B) 4x setup as well as on drug loaded liposomes in a C) 1x and D) 4x setup. All 
runs were performed at a FRR 1:3 and a TFR of 10 mL/min per chip, 5 mL were collected 
as waste in the 1x setup, 10 mL in the 4x setup. SUV, small unilamellar vesicles. Results 
denote mean ± SD of 3 separate batches. 
 
In comparison to the batch process, recovery of lipids and drug was impeded (Figure 
6.21). Both, lipids (p<0.01) and drug (p<0.05) recovery were found reduced in the 1x 
and the 4x continuous flow platform in comparison to the recovery in the batch system. 
Additionally, drug encapsulation reduced (p<0.05) for both platforms tested, a reduction 
from ca. 50 mol% to 38 mol%, Figure 6.21. 
 
Figure 6.21: Effect of scale-out by a continuous flow 1x and 4x setup to the recovery of 
lipid and drug as well as overall drug encapsulation. All runs were performed at a FRR 
1:3 and a TFR of 10 mL/min per chip. Significance between data is against the results 
obtained in the batch system (*p<0.05, **p<0.01). Results denote mean ± SD of 3 separate 
batches as the average out of the cumulative batches collected in the continuous flow 
setup. 
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Figure 6.22: Overall comparison between the different scale-up platforms tested on A) 
size, B) PDI, C) ZP, D) encapsulation and E) recovery of lipids and drug. Significance 
between data is against the results obtained in the batch system (*p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001). Results denote mean ± SD of 3 separate batches and the 
average out of the cumulative batches collected in the continuous flow setup. 
 
The reduced performance in the continuous flow system might be explained by the 
underlying principle. The transfer from batch to syringe driven 2x/4x system can be 
considered seamless, as both systems work with syringe pumps. However, the 
continuous flow system used pulsating pumps, which may have disturbed the flow in 
the tubing prior to reaching the SHM, visualised by air bubbles in the outlet stream. 
Additionally, pressures were higher in the continuous flow system, ranging up to 50 psi, 
and lipid solution remained in the tubing for a prolonged period due to a longer flow 
path (Figure 6.18F). Anticipated compression of lipids and drug in the tubing followed 
by sudden relaxation in the chip itself might have led to an alteration in fluid flow 
behaviours in the setup, resulting in larger sized particles with reduced drug 
encapsulation properties, as seen in Figure 6.22A and D. A change in the viscosity of 
the solvent stream due to the addition of the drug was anticipated as the reason for 
change in particle size, based on alterations in fluid flow behaviour under compression 
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(Figure 6.22A). Furthermore, the solvent solution was manually recycled over the pump 
heads prior to the start in the continuous flow system, which was anticipated as the 
main factor behind reduced lipid and drug recovery (Figure 6.22E). An additional study 
quantified respective recovery independently at different pressures and different tubing 
material, with the pressure being linked to the flow rate by Hagen-Poiseuille Law 
(Equation 6.4). 
 
At constant tubing diameter/length a direct link between pressure and flow rate can be 
assumed and Equation 6.4 simplifies to Equation 6.8. Flow rates varied from 1 to 6 
mL/h, which represented pressures of 0.08 to 0.5 psi. 
 
∆A ≈ O     Equation 6.8 
 
Whereas the tubing material itself was shown to be an independent factor of the 
recovery, a higher pressure in the process were indicative of a reduced lipid recovery 
(Figure 6.23), here up to a maximum of 0.5 psi only. Given higher pressures in the 
continuous flow system (max. 50 psi) compared to the batch and syringe driven 
system, results might be indicative of the importance of pressure and lipid adsorption to 
the tubing wall. Given a direct link between tubing diameter and pressure (Equation 
6.4), a suggestion might be to alter the pump heads for operation with lower pressure 
and reduced pulsation or selecting the appropriate tubing diameter in the continuous 
flow system. 
 
Small imperfections in a microchannel may result in variation of the hydraulic 
resistance, which especially in parallelised micro channels may result in flow variations. 
Furthermore bubbles should be avoided, which may block the channels (Vladisavljević 
et al., 2013). Such variations may have resulted in the alteration of the flow profile, 
ultimately leading to variations in physic-chemical particle characteristics and 
encapsulation efficiencies achieved in this study. The concept of microreactor 
parallelisation was found to result in a larger, but still considered acceptable, variation 
of 9% in particle size compared to the size obtained in a single reactor, which was 
found less than 5%. This deviation was linked to the variation in emulsion formation 
within the 10 parallelised reactors (Mbanjwa et al., 2014).  
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Figure 6.23: Effect of tubing material (PEEK vs. FEP) and pressure to the recovery of the 
lipids and drug. Significance between data is against the results obtained in the lowest 
flow rate and pressure (*p<0.05). Results denote mean ± SD of 3 separate batches. 
 
Scalability and increase in throughput together demonstrate the industrial applicability 
comparable with scale-up options available (Wagner and Vorauer-Uhl, 2011), viable for 
any method aiming for industrial application. Considering commercial aspects of 
formulation development, the translation of a product to market at a reasonable price 
remains a key consideration (Holtze, 2013). The use of microfluidic devices is known 
for successful application in research and development for pharmaceutically relevant 
nanoparticles (Dittrich and Manz, 2006; van Swaay, 2013); however, the realisation of 
larger-scale microfluidic process depends on the technology deriving a product that is 
difficult to achieve with any other technology and strongly depends on the market need 
(Holtze, 2013). Considering the significant increase in drug encapsulation by the 
microfluidics technology achieved and presented in this chapter, the transfer of this 
method for a larger scale production might be economically justified.  
 
Parallel-flow microfluidics has been suggested as one of the key methods in 
continuous manufacturing (Martel et al., 2015). The scale-up of microfluidic reactors is 
considered an ongoing challenge (Vladisavljević et al., 2013), where the two main 
approaches applied include parallelisation and internal scale-up. Scale-up based on 
internal scale-up is the less frequently applied approach (Vladisavljević et al., 2013). A 
successful version included a design with a higher available surface area, providing an 
overall 9-times higher power output (Fuerth and Bazylak, 2013). In this chapter, the 
change in diameter yielded an overall 10-fold increase in TFR from 2 to 20 mL/min, 
maintaining particle characteristics and drug loading. The alteration of the channel 
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diameter allowed for a seamless process transfer, which was based on a constant 
pressure drop in the channel.  
 
For parallelisation, identical microchips are set in parallel, where flow-splitters are 
required to split the flow over the chosen number of reactors (Vladisavljević et al., 
2013). This approach has the advantage, that still one pump per phase can supply 
multiple chips, rather than one pump per microchip (Holtze, 2013). This approach has 
been developed for the mass productions of droplets by planar microfabricated units to 
an overall throughput of 320 mL/h (Nisisako and Torii, 2008). The concept of parallel-
flow microfluidics was further exemplified for the production of emulsions and 
microparticles in 10 microfluidic reactors, drastically increasing the throughput 10-fold 
by maintaining a small footprint (Mbanjwa et al., 2014). In this chapter, the syringe 
driven scale-out platform allowed for a four-fold higher throughput in comparison to the 
batch system. In combination with the 10-fold higher throughput by changing the 
channel diameter, an overall 40-fold throughput could be achieved. The TFR per chip 
was maintained at 10 mL/min, which gave an overall throughput of 40 mL/min in the 4x 
system. The collection of 125 mL sample in the continuous flow system required ca. 3 
minutes. This transfer into a continuous flow system highlighted on the importance of 
achieving and maintaining a steady-state process, which resulted in reproducible 
particle characteristics.  
 
Overall, advantages by parallelisation comprise the reduced number of pumps allowing 
to operate multiple chips, a smaller footprint than multiple systems, the ease of 
handling and diminished costs due to scale-up development work (Mbanjwa et al., 
2014). The work on the continuous flow system highlighted on the necessity of a 
pressure control along with further future optimisation with regards to eliminating the 
manual recirculation process and optimising material. Possible non-uniformity of the 
micro- or nanoparticles formed, as found in this chapter, along with possible complexity 
in microchip fabrication, might be associated disadvantages (Mbanjwa et al., 2014). 
 
6.4 Conclusion  
This chapter demonstrated a high-throughput, robust and scalable method of preparing 
liposomes as solubilising agents based on microfluidics-directed nanoprecipitation. 
Resulting particles have well defined, scalable and process controlled demonstrating 
this method is suitable for pre-clinical and clinical application (Biebuyck et al., 1994). 
Furthermore, the method combined liposome manufacturing and drug encapsulation in 
a single process step, circumventing an additional drug loading step downstream, 
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which overall diminishes the time for production of stable drug-loaded vesicles of 
specified physico-chemical characteristics. The results in this chapter showed that the 
microfluidics-directed nanoprecipitation method is well suited for a high-throughput 
batch-type processing, which allows screening over a range of drug and lipid 
concentration with minimum time requirements. Despite success in the scale-up 
format, the continuous flow system still requires optimisation, which is linked to 
optimizing the pressures and flow profiles in the system as well as the process of 
recirculating the solvent through the pumps. Overall, waste volumes were higher in the 
batch and syringe driven system, whereas the ratio of waste to total sample volume 
was significantly reduced once the system is used in a continuous flow mode, making a 
continuous flow system more economical. Most importantly, results here show that the 
method based on chaotic advection is scalable, by changing the channel diameter and 
parallelising the chip design. The scalability of a method is important for its 
consideration for an industrial large-scale process.  
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7.1 Introduction 
Besides the necessity of a robust process characterisation, quality control of the 
liposomal formulation and reasonable production and development costs, there 
remains a need for rapid, robust and reproducible development techniques. Indeed 
robust cost-effective manufacture of liposomes remains a key bottleneck in liposome 
technologies (Wagner et al., 2002a). With an increasing number of liposomal products 
in clinical trials and development (Chang and Yeh, 2012) the demand for rapid process 
development tools continues to rise. To address this several microfluidic-based 
methodologies are currently being exploited in drug development (Dittrich and Manz, 
2006; Hood et al., 2014a; Weigl et al., 2003; Whitesides, 2006). Whilst reducing 
volumes during development processes, costs can be diminished whereas throughput 
is increased (Jensen, 2001; van Swaay, 2013; Weibel and Whitesides, 2006). 
Compared with process optimisation on a larger scale, process development with 
microfluidic devices allows for a better control of mixing efficiencies, which at this scale 
is predominantly based on molecular diffusion. The increased surface-to-volume ratios 
generate fast mixing times by minimising dimensions and diffusion lengths (Lee et al., 
2011; Mengeaud et al., 2002).  
 
Nevertheless for any liposomal-based process, be it industrial-, bench- or micro-scale, 
the separation of non-entrapped contaminant molecules, small molecule drugs or 
proteins, from the final liposome product is required (Wagner et al., 2002a). To date, 
separation is typically achieved by filtration (Pattnaik and Ray, 2009; Wagner et al., 
2002a) or centrifugation. Centrifugation needs sufficient density gradients between 
particles and suspending fluid to be efficient. Therefore this method is more suitable for 
larger particles. For smaller vesicles, centrifugation is either prohibitive or very time 
consuming (Torchilin and Weissig, 2003). Furthermore, with time-intensive size 
exclusion chromatography, problems including reduced product yield by column 
equilibration and dilution of the final liposomal product is often reported (Ruysschaert et 
al., 2005). Dialysis is a simple alternative and is commonly employed following 
microfluidics-based liposome manufacturing (Chapter 4 and 6), removing solvent 
residues prior to an in-vitro or in-vivo applications. Yet dialysis is also relatively time-
intensive, diminishing the time saving gained during particle manufacturing. Filtration of 
liposomes for purification is reported for large-scale manufacturing (Pattnaik and Ray, 
2009; Wagner et al., 2002a).  
 
 
  Chapter 7: Continuous Manufacturing 
195 
 
Work in this chapter describes a microfluidic liposome purification process based on a 
tangential flow filtration (TFF) device (O'Sullivan et al., 2012) and explores on-chip 
process development. The on-chip TFF device relies on separation of liposomes and 
contaminants based on a membrane separation process. Components larger than the 
cut-off value of the membrane are retained on the retentate side of the membrane, 
whereas components small enough to penetrate through the membrane pores are 
found in the permeate. The setup is based on a clamping device, sealing the 
membrane sheet within a PDMS gasket, with an overall hold up volume of 50 uL, 
(Figure 7.1A and B). The resulting set-up reports on a fully microfluidic liposome 
formation and purification process train with exchangeable membrane. 
 
 
Figure 7.1: A) 3D image of the TFF system with two PMMA plates used as in a clamping 
system to hold the membrane in place. B) Dimensions of the assembled TFF device. 
Adopted from (O'Sullivan et al., 2012). 
 
7.2 Aim and Objectives 
The aim of this chapter was to develop a continuous-manufacturing unit based on 
microfluidic systems (Figure 7.2). To achieve this, a purification method based on an 
on-chip tangential flow filtration unit was developed and optimised. To consider the 
parameters controlling the filtration unit, backpressure regulation was studied and its 
effect on particle characteristics was investigated. Furthermore, the filtration unit was 
challenged with a range of cationic, anionic and neutral liposomes and explored for 
purification of a model protein and a small drug molecule from these liposome systems. 
To study and develop a continuous flow microfluidics-based system, the upstream 
mixer for vesicle formation (Chapter 4, 5 and 6) was connected to the downstream 
purification unit supporting the development of microfluidics-tools in continuous 
manufacturing. Off-line monitoring verified the purification in comparison to vesicle 
characteristics and efficacy of drug encapsulation as described in Chapter 4 and 6.  
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Figure 7.2: Overview over the continuous flow microfluidics-based liposome 
manufacturing and purification setup. 
 
7.3 Results and Discussion 
7.3.1 Backpressure regulation 
The aim of this section was to implement a backpressure regulation for the purification 
of liposomes by a TFF membrane. The backpressure was controlled by attaching a 
constricting capillary (inner diameter 50, 63 and 100 µm) to the retentate outlet (Figure 
7.2). The backpressure was regulated by relating the capillary inner diameter (I.D.) and 
the fluid flow to the pressure drop as described in the Hagen-Poiseuille Law (Equation 
7.1), relating the theoretical pressure drop in a fluid flowing through a cylindrical pipe, 
assuming that an incompressible Newtonian fluid is used at a laminar flow with no 
acceleration in the pipe. 
 
∆  	
				

	
   Equation 7.1 
 
With  
∆  Pressure difference (Pa) 
 Viscosity of medium (Pa s) 
L  Length of tubing (m) 
Q  Volumetric flow rate (m3 s-1) 
d  Diameter of tubing (m) 
 
Equation 7.1 was used to determine the required capillary length whilst aiming for a 
backpressure between 5-80 psi. Pressure drop was calculated for the capillary and the 
tubing connecting the TFF unit to the capillary (Figure 7.2) respectively, and overall 
pressure drop included both values as additive values. Results highlighted on the linear 
relationship between backpressure, depended on the flow rates and the length of the 
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capillary (Figure 7.3). Backpressures determined for the tubing (ID 800 µm) were below 
0.02 psi (Figure 7.3A), significantly lower than backpressures achieved by the 
capillaries. For maintaining a backpressure below 100 psi, a short capillary or low flow 
rates are desired (Figure 7.3B) and by increasing the capillary diameter (Figure 7.3C 
and D) a higher flow rate can be achieved by still remaining below 100 psi 
backpressure.  
 
Figure 7.3: Determined theoretical backpressures at different flow rates from 0.01 to 3 
mL/min at various capillary lengths and I.D. of A) 800 µm, B) 50 µm, C) 63 µm, D) 100 µm. 
 
The validation of these theoretical backpressures was performed by connecting the 
TFF to a pressure transducer, which was connected to LabView, where a voltage 
signal was converted to a pressure. Actual pressures inside the TFF were recorded 
until a stable pressure reading was obtained. The direct comparison of theoretical and 
measured backpressure (Table 7.1) showed close match, with the theoretical pressure 
(Equation 7.1) slightly underestimating the pressures in the channel by 1 to 10 psi, with 
the difference getting bigger with higher flow rates applied (Table 7.1). 
 
Table 7.1: Comparison of theoretical and actual backpressures in the TFF setup at 
increasing flow rates from 0.01 to 0.1 mL/min. Deviation in actual backpressure was 
extrapolated from fluctuations in the pressure recordings and expressed as ± compared 
to the average pressure recording (5 cm capillary I.D. 50 µm). 
 
Flow rates (mL/min) Theoretical Backpressure 
(psi)  
Actual Backpressure 
(psi) 
0.01 7 8.4 ± 1 
0.02 15 19.5 ± 1 
0.03 23 27 ± 3 
0.05 39 55 ± 3 
0.1 80 86 ± 5 
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The maximum rated pressure of the selected membrane according to the manufacturer 
was 100 psi. Here, the ideal backpressures in the TFF was set between 5-80 psi (Van 
Reis and Zydney, 2001, 2007), which is a common range for backpressures in filtration 
processes in industry (Cheryan, 1998). The calculated theoretical back-pressures were 
found to correlate well with increasing flow rate and decreased capillary diameter 
(Figure 7.3 A and B), in line with previous backpressure regulation using the TFF 
(O'Sullivan et al., 2012). The overall pressure drop accounted by the tubing was 
negligible, with maximum values of 0.013 psi at the highest flow rate and the longest 
tubing length of 0.55 meters (Figure 7.3A). Here, the backpressures achieved by the 
capillary were found most contributing to the overall pressure drop (Figure 7.3 B, C, D). 
Overall, a shorter capillary was anticipated beneficial given the recovery of the vesicles 
from the retentate side. Furthermore, reduced residence time of the vesicles in the 
capillary might reduce any adverse effects to shear stresses. Generally, the control of 
back pressures with capillaries can be considered more reproducible compared to 
commercially available micrometering valves. Furthermore, controlling backpressure 
with a capillary is considerably cheaper, and any moving parts can be avoided 
(O'Sullivan et al., 2012). 
 
Given the close overlap between theoretical and actual backpressure, the theoretical 
backpressure has been used throughout further development work. Also, the 
calculation based on Equation 7.1 was used to tailor the I.D. and the length of the 
capillary to the desired flow rate. 
 
7.3.2 Membrane fouling 
This section aimed to verify membrane fouling as a function of flow rates in the current 
filtration system. Based on work in section 7.3.1, the flow rate was investigated as a 
function of membrane fouling. Membrane fouling occurs once filtered products 
(liposomes) accumulate on the membrane surface and restrict flow through the 
membrane, determined by a reduced flux through the membrane. The resistance of the 
membrane can be assumed using Darcy´s Law (Equation 7.2), which relates the 
transmembrane pressure (TMP) and the membrane resistance to the flow through the 
membrane (Bolton et al., 2006). 
 
  	
∗	∆
∗
    Equation 7.2 
With 
J  Flux (l m-1 s-1) 
TMP  Transmembrane pressure (psi) = (Pfeed-Pret) /2 –Pperm 
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∆P  Axial pressure drop (Pa) = Pfeed - Pret 
Rm  Membrane resistance (m-1) 
µ  Viscosity of fluid (Pa s) 
 
Fouling was assessed by comparison of the normal water permeability (NWP) 
compared to the filtration performance using liposomes. Membrane fouling tested with 
water and liposomes filtered through the TFF at increasing flow rates of 0.01 mL/min, 
0.02 mL/min and 0.05 mL/min. The slopes for the cumulative permeate volumes of 
water were compared to the one of liposomes filtered, where a deviation from the 
NWP-slope was an initial sign for reduced permeate volume, associated to reduced 
flux and hence membrane fouling. At higher flow rates of 0.05 mL/min and 0.02 
mL/min, slopes of cumulative permeate volume of NWP and liposomes matched 
(Figure 7.4). Membrane fouling was indicated at the lower flow rate of 0.01 mL/min. 
Here, permeate volume levelled after 150 min filtration time, indicating built-up on the 
membrane surface and liposomes fouling the membrane (Figure 7.4, small insert).  
 
 
Figure 7.4: Determination of membrane fouling at flow rates of 0.01 mL/min, 0.02 mL/min 
and 0.05 mL/min for liposomes (SUV) and water (NWP). Smaller picture represents a 
zoom of NWP and SUV cumulative permeate volumes at the lowest flow rate of 
0.01mL/min, with initial indication of membrane fouling. All experiments were performed 
at a particle concentration of 5 x 1010 P/mL. 
 
Given the indication of an inverse relationship between membrane fouling to the flow 
rate; fouling was anticipated reduced by increasing the flow rate through the filter. At 
higher flow rates liposomes may be swiped off the membrane surface, where at lower 
flow rates liposomes might be more prone on accumulating on the membrane surface 
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leading to membrane fouling over time. In order to maximize the recovery of the 
liposomes from the TFF system, low flow rates of 0.01 mL/min were avoided in all 
work. Here, a higher flow rate could be associated to a higher throughput in the TFF 
system, beneficial for a high throughput purification system for liposomes.  
 
7.3.3 Batch -type purification of liposomes – pressure testing 
The aim of this initial test was to assess the impact of purification by TFF on the 
physico-chemical properties including size, PDI, ZP and particle number of liposomes, 
whilst verifying the integrity of the liposomes at increasing flow rates and 
backpressures, maintaining previously determined flow rates to avoid membrane 
fouling (Section 7.3.2). The selection of capillary diameters and lengths allowed 
controlling the backpressure in the system and permeability through the membrane as 
a function of the flow rate (Equation 7.1) with the aim of achieving a high throughput in 
the TFF system as described in section 7.3.1.  
 
Initial measurements assessed liposomes retention on the retentate side of the 
membrane, a vital criteria for a successful separation of liposomes from un-entrapped 
drug or protein. Liposome physico-chemical characteristics were found independent of 
increasing backpressures during filtration at backpressures ranging from 5 to 80 psi, 
with no significant alteration in size and PDI (p>0.05; Figure 7.5A). The integrity of 
liposomes was evaluated at increasing backpressures between 5 – 80 psi, with a range 
of capillaries of different lengths and inner diameter tested (Figure 7.5B). At 
backpressure higher than 75 psi, particles were detected in the permeate (Figure 
7.5C), with a significant (p<0.05) increase in particle size from initial 115 nm to ~140 
nm and a significant (p<0.05) increase in PDI from 0.15 to 0.3 when compared with the 
initial formulation before filtration.  
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Figure 7.5: Particle size and polydispersity as a function of increasing backpressures in 
the TFF system. A) Samples collected and analysed on the retentate side including 
images obtained from NTA analysis and particle characteristics obtained via DLS. B) 
Backpressures were controlled with differently sizes capillaries, varying in inner 
diameter (I.D.) and length allowing different flow rates to be used in the system. C) 
Samples collected and analysed on the permeate side including images obtained from 
NTA analysis and particle characteristics obtained via DLS. n/a = not applicable. All runs 
are presented as average of three independent runs ± SD. 
 
The presence of particles within in the permeate side above a backpressure of 75 psi 
was confirmed by qualitative image-based NTA analysis (Figure 7.5C). Furthermore, 
  Chapter 7: Continuous Manufacturing 
202 
 
DLS measurement of collected retentate and permeate verified vesicles present based 
on an intensity-based (Figure 7.6A) and volume-based (Figure 7.6B) size distribution.  
A 
 
 
 
 
 
 
 
B 
Figure 7.6: DLS measurement of A) intensity and B) volume based size distribution 
profiles comparing the retentate (red) and permeate (green) at 80 psi backpressure, 
confirming presence of particulates in the permeate. 
 
Backpressures >75 psi resulted in extrusion of the vesicles through the membrane, 
altering physico-chemical particle characteristics as seen in the increase in size and 
PDI. Particle reformation on the permeate side may be associated to well-known 
liposome extrusion processes, which are reported to operate at pressures as high as 
100-700 psi; where polycarbonate filters are reported for pressures less than 100 psi 
for lower lipid concentrations (Cullis et al., 1991; Olsen et al., 2001). Operating the TFF 
at 1-2 mL/min allowed faster operations with higher throughput and the flow rates 
matched the ones applied for liposome manufacturing (Chapter 4, 5 and 6). Results 
suggest the selection of backpressures in the TFF unit between 5-80 psi (Van Reis and 
Zydney, 2001, 2007) a common range for backpressures in filtration processes in 
industry (Cheryan, 1998). 
 
Whereas commonly used separation techniques necessitate the formulation of larger 
vesicles to achieve separation (Torchilin and Weissig, 2003), vesicles at or below 300 
nm have been shown to be difficult for separation by centrifugation and are hence often 
subjected to lengthy dialysis for removal of non-entrapped drug and solvent residues 
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(Belliveau et al., 2012; Zhigaltsev et al., 2012). In contrast purification of large 
multilamellar liposomes often use centrifugation to remove un-entrapped drug (Ali et 
al., 2013), where liposome range in the micrometer-size. The presented setup 
demonstrates that a range of capillaries with varying inner diameter and length can be 
easily applied for controlling the backpressures, with the ability to tailor resulting flow 
rates to desired throughput. Furthermore, the clamping mechanism of the filtration 
device allowed for simple membrane exchange, thereby supporting the use of different 
commercially available membrane sheets as required. Overall, the setup allows for 
continuous filtration of the liposomes, while collecting in the same vial. The increase in 
backpressure allowed screening over the ideal operational backpressure under which 
the desired liposome characteristics were maintained and maximum recovery yields 
obtained. 
 
7.3.4 Membrane integrity testing 
In order to verify the membrane integrity at a backpressure of 80 psi, the system was 
challenged with ovalbumin at two different concentrations (1 mg/mL and 0.5 mg/mL). 
Protein was filtered through the membrane at backpressures of 15 and 80 psi and the 
presence of protein in retentate and permeate was qualitatively verified by SDS-PAGE. 
Ovalbumin was detected in the retentate stream at 15 and 80 psi for both 
concentrations of ovalbumin (Figure 7.7, lane 4, 6, 9 and 11), with no protein detected 
in the permeate streams respectively (Figure 7.7, lane 3, 5, 8 and 10). Following, the 
membrane integrity remains at 80 psi with no rupture and subsequent leakage of the 
membrane. Furthermore, the retention of the protein in the retentate stream was found 
to be independent of the protein concentration in the inlet stream. 
 
These results verify that liposome detection in the permeate stream at backpressures 
of 80 psi (Figure 7.5, 7.6) were associated solely to extrusion of the lipids through the 
filter at higher backpressures and reassembly of the liposomes in the permeate stream. 
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Figure 7.7: SDS-PAGE of ovalbumin filtered in the TFF system at 1 mg/mL (red) and 0.5 
mg/mL (green) at backpressures of 15 and 80 psi. 
 
A control of filtration backpressures by a capillary on the retentate side was required for 
purification of the liposomes and retention of the liposomes. Furthermore, 
backpressures of 80 psi were found to force extrusion of the liposomes through the 
membrane with vesicle resemblance on the permeate side of the TFF system, leading 
to increased polydispersities and vesicle sizes (Figure 7.5C). Furthermore it was 
shown that the membrane is capable of withstanding high backpressures of 80 psi 
without loss of its integrity (Figure 7.7).  
  
7.3.5 The effect of filtration on particle characteristics for cationic and anionic 
liposomes  
Based on the established backpressures during liposome purification (< 75 psi), the 
purification capabilities of the TFF device were explored with a variety of small 
liposomes, differing in size and charge (DDA-TDB vesicles, 250 nm, +50 mV; PC-Chol 
vesicles, <100nm, -5 mV; DPPC-Chol-DPPG vesicles, <150 nm, -50 mV;:  DOPE-
DOTAP vesicles, <100 nm, 60-80 mV). The objective was to study the capabilities of 
the on-chip filtration unit to purify broad range of liposomal products. The filtration 
process of a cationic liposomal adjuvant (DDA-TDB) in three diafiltration runs gave 
91% particle recovered throughout three cycles of diafiltration (Figure 7.8) with no 
significant change in size or zeta potential for the cationic formulations, but with a small 
  Chapter 7: Continuous Manufacturing 
205 
 
increase in PDI, still remaining within the polydispersities obtained with DDA-TDB 
systems (Henriksen-Lacey et al., 2011a).   
 
 
Figure 7.8: Vesicle size, polydispersity, zeta potential (zp) and particle concentration 
(P/mL) for cationic (DDA-TDB) and anionic (DPPC-Chol-DPPG) liposomes before and 
after the TFF purification.  Images from NTA show vesicles present on the retentate side 
only.  
 
 
Similarly, when anionic liposomes (DPPC-Chol-DPPG) were tested the vesicle size, 
PDI, ZP and particle concentration remained unaffected with vesicles being around 120 
nm, with a PDI of 0.14 and a zeta potential of -55 mV. The concentration of the 
particles after filtration was 4.4*1010 P/mL, representing an overall particle recovery of 
95% (Figure 7.8). Furthermore, NTA analysis in each diafiltration cycle verified that no 
liposomes were present in the permeate stream (Figure 7.8). 
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7.3.6 Purification of non-incorporated moieties from liposome formulations 
With the system initially investigated for the filtration of liposomes only, the efficiency 
for removal of drug or protein not incorporated within the liposomes was investigated in 
three diafiltration cycles. At each cycle, liposome characteristics were assessed and 
the removal of contaminants (drug or protein and solvent residues) was quantified.  
 
To consider the removal of non-entrapped protein from liposome formulations, 
liposomes (DPPC-Chol-DPPG) were also mixed with ovalbumin (OVA; 100 μg/mL); 
with repulsive forces prominent no electrostatic interaction between liposome and 
protein are expected and therefore all non-entrapped protein should be removed. The 
size and PDI of the liposomes remained unchanged through the course of three 
diafiltration cycles and 93% of the liposome particles were recovered (Figure 7.9A). 
The addition of OVA to the liposome formulation caused an initial reduction in the 
overall anionic ZP from -55 mV to -32 mV; however, upon removal of the free protein 
via filtration, the ZP reverted back to an more anionic nature (-43 mV; Figure 7.9A), 
with no qualitative indication of surface-adsorbed protein. Protein (OVA) and residual 
solvent was removed into the permeate stream throughout the filtration cycle, with a 
final removal of 70% of free protein and 95% solvent (Figure 7.9B). A residue of 10% 
free ovalbumin was found in the final retentate after three diafiltration cycles with no 
liposomes present (Figure 7.9C) which allows estimating a protein remain of 20% using 
the negatively charged liposomes. Electrostatic repulsion forces may have contributed 
to remaining free protein levels, which is anticipated to further decrease with additional 
filtration cycles. 
 
The drug concentration was related to previous work on the encapsulation of a low 
solubility drug (propofol) in the liposomal bilayer by microfluidic mixing (Chapter 6). 
Drug was added post-liposome production at a concentration of 1 mg/mL in a liposome 
formulation containing negatively charged liposomes (DPPC-Chol-DPPG). Overall, 
99% of free drug was removed in three diafiltration cycles (Figure 7.9D). The majority 
(90%) removed in the first diafiltration cycle, with further reductions (by 80%) in the 
second diafiltration run (effective remaining propofol ca 2.5%) (Figure 7.9D). The third 
diafiltration cycle further reduced the available free drug by 60%, with 1% of free drug 
remaining after three filtration cycles (Figure 7.9D). The TFF system was also validated 
by effectively removing residual solvent from the formulation. An initial starting 
concentration of 20% (v/v) ethanol was present in the sample; representing the 
average amount of solvent after a microfluidics-based liposome manufacturing at a 
FRR of 1:3 (Chapter 6). The amount of ethanol was reduced by ca. 50% in the first 
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diafiltration cycle, with a remaining effective ethanol concentration of 3% (v/v), (Figure 
7.9D) after three filtration cycles. Liposome characteristics (size, PDI and ZP) remained 
throughout three diafiltration cycles (Figure 7.8). 
 
 
Figure 7.9: A) Vesicle size, polydispersity, zeta potential (zp) and particle concentration 
(P/mL) for anionic liposomes (DPPG-DPPC-Chol) prior and post ova-addition (ovalbumin, 
100 µg/mL), and particle characteristics after the TFF purification. B) Protein (ovalbumin) 
and ethanol removal in three diafiltration cycles for anionic liposomes (DPPG-DPPC-
Chol), expressed as % to the initial amount of contaminants present. C) Ovalbumin and 
ethanol removal in three diafiltration cycles with no liposomes present D) Propofol and 
ethanol removal in three diafiltration cycles for anionic liposomes (DPPG-DPPC-Chol), 
expressed as % to the initial amount of contaminants present. All runs are presented as 
average of three independent runs ± SD. 
 
The desired application of the liposomes will determine the required final purification 
level, which cannot be generalized, and results here suggest that the on-chip filtration 
unit copes with different levels of purification required. Overall, the on-chip purification 
system showed efficient removal of solvent, non-entrapped protein and drug from the 
liposome product, which fully retained in the TFF setup. 
 
7.3.7 Purification of cationic liposomes with spiked model protein 
The efficient protein delivery through cationic liposomes is well known, with 
electrostatic attractive force dominating and often leading to a surface-adsorption 
reaching close to 100% (Kaur et al., 2013). To challenge the on-chip TFF system, a 
high concentration of protein (100 µg/mL) was added, beyond levels that can be 
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effectively adsorbed onto the cationic liposome formulation (DDA-TDB) to demonstrate 
the ability of the filtration system to separate non-adsorbed protein from liposomes with 
surface-adsorbed protein. 
 
The liposomes without protein had an average size of 230 nm and were highly cationic 
in nature (Figure 7.10A). As expected, the addition of excess protein (which adsorbs to 
the surface of the cationic liposomes) resulted in a decrease in zeta potential and an 
increase in measured vesicle size and PDI due to cross-linking and/or aggregation of 
liposomes, as seen in previous work with DDA-TDB liposomes where a drop in ZP by 
ca. 20 mV was linked to a 100% adsorption of protein onto the liposomes surface at a 
final concentration of 10 µg/mL (Henriksen-Lacey et al., 2010a). When these 
liposomal-protein systems were subjected to TFF and removal of non-associated 
protein, there was no significant difference in the size, PDI and zeta potential of the 
system (Figure 7.10A). The polydispersity was shown to remain stable throughout the 
diafiltration process of cationic liposomes (Figure 7.10A), which following allows 
associating the increase in PDI to the addition of the protein rather than the filtration 
parameters (flow rate, backpressure). Particle recovery showed that 87% of the particle 
concentration (P/mL) (post protein loading) was recovered in the final retentate after 
three filtration cycles (Figure 7.10A).  
 
Using TFF, ethanol residues were reduced to 4% (v/v) and 75% of free protein was 
removed in the filtration setup (Figure 7.10B). Given that the vesicle size and zeta 
potential were maintained throughout the filtration process, this suggests that protein 
adsorbed to these liposomes was effectively retained during the process, and the 
liposome-protein complexes were not compromised. These liposome-protein 
aggregates as analysed via NTA are shown in Figure 7.10C. A higher PDI post protein 
addition is known to impede effective particle size measurement by light scattering 
processes given the bias of a DLS measurement towards larger particles (Chapter 3). 
The reduction in particle concentration after the addition of protein may be associated 
to the increase in particle size by aggregation rather than the loss of lipids in the 
system, leading to a misleading poorer result for particle recovery. 
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Figure 7.10: A) Vesicle size, polydispersity and zeta potential (zp) for cationic (DDA-TDB) 
liposomes prior and post ova-addition (ovalbumin, 100 µg/mL) and particle 
characteristics after the TFF purification. B) Protein (ovalbumin) and ethanol removal in 
three diafiltration cycles for cationic liposomes (DDA-TDB), expressed as % to the initial 
amount of contaminants present. C) NTA analysis for liposomes before (left) and after 
(right) loading with model protein (ovalbumin, 100 µg/mL).  All runs are presented as 
average of three independent runs ± SD. 
 
Aggregation upon exposure of DDA-TDB liposomes to protein has been reported, 
where a drop in ZP by ca. 20 mV was linked to a 100% adsorption of protein unto the 
liposomes surface at a final concentration of 10 µg/mL (Henriksen-Lacey et al., 2011a). 
The system was challenged by a protein addition of 100 µg/mL, representing a 10-fold 
increase in protein concentration usually encountered in in-vivo dosages (Henriksen-
Lacey et al., 2010a). These results verify that an on-chip TFF system is capable of 
removing non-associated protein without influencing the liposome characteristics, 
providing an effective post-production purification step, with the option to recycle 
purified protein in further application. 
 
Proof-of-principle studies performed in this study verify that liposomes maintain their 
particle characteristics with no significant alterations to particle size and PDI (p > 0.05) 
and overall recoveries from the filtration system are high (87-97%). A diafiltration setup 
(buffer exchange) was shown to successfully remove residual solvent as well as un-
entrapped drug into the permeate side, elucidating the base of purification of liposomes 
based on on-chip TFF whilst providing guidance for backpressure control in a batch-
type process.  
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7.3.8 Continuous setup  
Next, the on-chip purification system was combined with the upstream on-chip 
liposome manufacturing method, as described in earlier chapters (Chapter 4, 5, 6), 
aiming for moving from conventional batch type processing to an on-chip continuous 
manufacturing setup for liposome synthesis and purification. A SHM micromixer was 
employed to directly supply the TFF system with liposomes (Figure 7.11A) in a 
continuous setup.  
 
Figure 7.11: A) Schematic overview of the continuous on-chip liposome manufacturing. 
Liposomes were manufactured with a SHM mixer upstream and lead through the TFF 
system for consecutive on-chip purification. B) Schematic overview of the formation of 
liposomes loaded with a low-solubility model drug. Vesicle assembly and drug loading 
are performed with a SHM, non-entrapped (free) drug to be removed by consecutive TFF. 
C) Schematic overview of the formation of liposomes loaded with a protein model. 
Vesicle assembly is performed with a SHM, with protein addition post assembly, non-
entrapped (free) protein to be removed by consecutive TFF. 
 
However, to decouple the throughput from the two devices and to control 
independently the flow rates an intermediate collection vial was used. The setup allows 
for purification of the liposomes in a diafiltration mode, with complete recovery of lipid 
(Figure 7.12A). Furthermore, once the desired purification level was reached, the 
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formulation was concentrated, by stopping the manual top-up of permeate volume, 
here the filtration of four volumes without replenishing of fresh buffer allowed to double 
the lipid concentration (Figure 7.12B). The setup allows for continuous filtration of the 
liposomes, while collecting in the same vial. The process described here is continuous, 
as only one pump works at a time, allowing independent control over the flow rates in 
the SHM and TFF devices and the addition of the permeate volume was done 
manually. Moreover, multiple diafiltration cycles can run in the TFF until desired purity 
is reached. Adding manually fresh solution to the intermediate collection vial 
compensated for liquid passing into the permeate. The overall process described, 
enables independent control over the flow rates in the SHM and TFF devices both as 
separate or coupled units of operation. This system was then tested with two 
formulations: 1) neutral liposomes (PC-Chol, 4:1 molar ratio) incorporating propofol 
(Figure 7.11A) and 2) cationic liposomes (DOPE-DOTAP, 1:1 molar ratio) loaded with 
surface-complexed protein (Figure 7.11B). 
 
Figure 7.12: Lipid recovery in the continuous process setup for A) lipid recovery after 
four diafiltration cycles. B) Lipid concentration in four concentration cycles, related to 
the initial amount of lipids present prior to the concentration cycles. All runs are 
presented as average of three independent runs ± SD. 
 
7.3.8.1 Continuous manufacture and purification of liposomal solubilisation 
agents  
The encapsulation and solubilisation of low aqueous drug in the bilayer of liposomes in 
a microfluidics based setup has been investigated previously (Chapter 6). The setup 
(Figure 7.11B) was applied here to compare drug encapsulation with previous studies 
in Chapter 6. In this work, the amount of free drug (unentrapped) was removed by 
means of the previously-described on-chip filtration, replacing the earlier reported 
dialysis method (Chapter 6). The resulting particle size of 50 nm with a low PDI of 0.4 
is in line with previously reported liposome sizes at given FRR and TFR (Figure 6.2, 
Chapter 6). The continuous filtration setup maintained particle sizes and PDI (Table 
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7.2) with no significant alteration. The continuous filtration setup was able to remove 
un-entrapped drug at a remaining solvent concentration of 3% (v/v) after three 
diafiltration cycles (Table 7.2). Encapsulation of the drug yielded 50 mol%, according to 
previous reported encapsulation values using the same SHM setup (Figure 6.5D, 
Chapter 6). The assembly presented here allows for complete removal of the free drug, 
which was previously achieved by dialysis, with the remaining amount of drug 
encapsulated in the liposome bilayer. Most importantly, the remaining drug 
encapsulation shows that the pressures applied in the system has no adverse effect on 
liposome integrity, successfully replacing time-consuming dialysis with a microfluidics-
based filtration process.  
 
Table 7.2: Continuous purification of PC-Chol liposomes loaded with propofol. Here, 
propofol and lipids were included in the solvent stream and liposome formation and drug 
encapsulation was performed in a SHM, run at 2 mL/min and a 1:3 solvent:aqueous ratio. 
na= not applicable. 
 
  Liposome with drug after SHM Liposome with drug after TFF 
Size (nm) 49.8 ± 0.5 62.3 ±  11.6 
 
Polydispersity 0.42 ± 0.003 0.35 ± 0.07 
 
Loading (mol%) na 49.3 ± 5.8 
   
Effec. ethanol (% v/v) 16.1 ± 3.9 3.1 ± 1.5 
 
 
7.3.8.2 Continuous manufacture and purification of cationic liposomes with 
adsorbed protein  
The continuous setup for the production of cationic liposomes (Figure 7.11C) verified 
the removal of free protein in the given TFF setup. Here, vesicle size and PDI 
remained unchanged throughout the filtration process. Liposome sizes (before protein 
addition) of 60 nm are in line with sizes reported in a SHM design for production of 
DOPE-DOTAP liposomes (Figure 4.1A, Chapter 4). The continuous system allowed for 
a removal of 75% of free protein (Table 7.3), with the remaining protein adsorbed on 
the liposome surface, evidenced by reduced ZP (Table 7.3). Protein and solvent was 
removed to a final level of 24% and 4% (v/v) respectively (Table 7.3). 
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Table 7.3: Continuous purification of DOPE-DOTAP liposomes loaded with protein 
(ovalbumin). Here, lipids were included in the ethanol stream and liposome formation 
was performed in a SHM, run at 2 mL/min and a 1:3 solvent:aqueous ratio. Protein was 
added post-liposome synthesis. OVA = ovalbumin, na= not applicable. 
 
 Liposome w/o 
OVA after SHM 
Liposome with OVA in 
collection vial 
Liposome with OVA 
after TFF 
Size (nm) 62.8 ± 1.9 88.5 ± 5.7 89.3 ± 10.9 
 
Polydispersity 0.44 ± 0.02 0.45 ± 0.008 0.42 ± 0.02 
 
Zeta potential (mV) 83.9 ± 3.5 43.6 ± 1.6  69.2 ± 6.1 
 
Loading (%) na 100.1 ± 2.5 23.9 ± 0.8 
 
Effec. ethanol (% v/v) na 15.0 ± 6.9 4.1 ± 1.5 
 
7.4 Conclusion 
Overall, work demonstrated feasibility for on-chip purification of liposomal batches 
below 5 mL for developmental purposes. Liposome manufacture, drug loading and 
removal of contaminants (like un-entrapped drug or protein as well as of solvent 
residues) were performed in a continuous on-chip design, allowing for manufacturing, 
purification and concentration of liposomal drug products. The system was challenged 
with a range of liposomes, varying in lipid composition, surface potential, size and 
concentration, demonstrating on the ability of the on-chip filtration unit to be tailored to 
a broad diversity of lipid-based nanoparticles. The setup allows for an efficient and 
quick screening of several lipid or drug candidates, and that is able to cope with high 
throughput requirements of early stage development processes. The continuous setup 
may permit early determination of liposomal characteristics (e.g. size, surface potential, 
particle number) and encapsulation efficiencies of a wide variety of drug molecules, 
allowing for future integration of process analytical technologies to further aid 
reproducibility. Furthermore, the setup is of considerable interest for screening of cost-
intensive drugs or protein, which require a quick and efficient development process. 
The system copes with a wide variety of protein products in development, together with 
its flexibility for incorporating different membrane types, aligned with recent trends in 
biopharmaceutical industry (Walsh, 2010). Nevertheless, scalability by parallelisation of 
mixer chips has been suggested, as highlighted in Chapter 6 and scalability of TFF 
membranes is reported which offers future application and scale-up for larger-scale 
production and purification of liposomal products in a continuous flow setup.  Whereas 
large-scale continuous-based methods for liposome extrusion have been reported 
(Schneider et al., 1994), the here presented method shows applicability for a high-
throughput and small-footprint early-stage development techniques for liposomal 
products.  
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8 A multivariate analysis study to correlate liposomal 
adjuvant characteristics 
 
 
 
 
*Lipid structure obtained from avantilipids.com 
 
 
Papers relating to this chapter: 
Kastner E., Hussain M. J., Bramwell V. W., Christensen D. and Perrie Y. (2015). 
Correlating liposomal adjuvant characteristics to in‐vivo cell‐mediated immunity using a 
novel Mycobacterium tuberculosis fusion protein: a multivariate analysis study. Journal 
of Pharmacy and Pharmacology, 67(3), 450-463. 
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8.1 Introduction 
The new generation of vaccines, based on recombinant DNA or highly purified 
proteins, provide a safer but less immunogenic vaccination strategy (O'Hagan et al., 
2001b). Subunit vaccines contain selected highly purified antigens, which can offer 
reduce side effects and specific immune responses are raised with an overall safer and 
more immunologically defined form of vaccination (Black et al., 2010; Mohammed et 
al., 2010). However, the administration of purified recombinant proteins induces only a 
low immunogenicity, necessitating the co-administration with a suitable 
immunostimulatory adjuvant to produce a more potent vaccine (Holten-Andersen et al., 
2004; O’Hagan and De Gregorio, 2009). Amongst the particulate delivery systems, 
liposomes act as competent immune response stimulators and as immunological 
adjuvants already approved for human administration (Bramwell and Perrie, 2005). The 
key factors for interaction with the immune system and influencing the efficacy of 
liposomal adjuvant activity are vesicle charge, size, bilayer fluidity and liposomal 
composition (Henriksen-Lacey et al., 2011b). Their intracellular presence is important 
for effective vaccine delivery and has been linked to a cationic surface charge 
(Christensen et al., 2007b), which enhances antigen adsorption and retention due to 
electrostatic interaction (Perrie et al., 2008; Smith Korsholm et al., 2007). The 
combination of the cationic dimethyldioctadecylammonium bromide (DDA) with an 
optimised incorporation of the glycolipid trehalose 6,6-dibehenate (TDB) is used in an 
adjuvant system (CAF01), which is capable of stimulating powerful cell-mediated 
immunity against mycobacterium tuberculosis (MTB), upon delivery of the recombinant 
TB subunit protein Ag85B–ESAT-6 (H1 vaccine) (Davidsen et al., 2005). 
 
However in the analysis of vaccines, a range of biological outputs are generated which 
may be interlinked in enhancing immune responses. Multivariate analysis (MVA) is a 
method that allows for analysing several variables at a time and represents a flexible 
and multipurpose tool for data mining and analysis. Other than linear regression tools, 
MVA deals with several variables and observation at a time, handles dimensionality 
problems and provides overview whilst classifying and comparing different groups of 
data, using regression modelling between variables (X) and responses (Y). Despite 
noise in a data set, MVA extrapolates even in limited data sets (Eriksson, 2006). 
Principal components (PC) are computed through the multidimensional space, which 
approximate the best data fit. Generally, at least two orthogonal PCs are required to 
approximate the data and model the systematic variation sufficiently. Principal 
component analysis (PCA) allows for a simple overview of the data allowing to group 
large data sets and identify trends and outliers (Jackson, 2005; Wold et al., 1984). The 
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addition of the Y-variables (responses or measurements) in a partial least square 
(PLS) analysis aims to predict Y from X. This identifies the influence of the variables to 
a response, correlations within the responses and factors responsible for achieving a 
desired response (Wold et al., 1984; Wold et al., 2001a; Wold et al., 2001b). 
 
8.2 Aim and Objectives 
The aim of this chapter was to investigate multivariate modelling for prediction of in-
vivo liposomal vaccine efficiency from in-vitro measured physicochemical vesicle 
characteristics. To achieve this, a model was generated, which comprised the 
experimentally obtained data for predicting liposomal adjuvant in-vivo performance. 
Cationic liposomal adjuvants of well described activities were manufactured containing 
the lipids DDA and TDB (Christensen et al., 2009; Christensen et al., 2007b), and 
increasing levels of the saturated phosphatidylcholine, 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) was incorporated into the DDA-TDB formulation at a locked 
DDA-TDB molar ratio (Table 8.1). 
 
Table 8.1: Incorporation of DSPC into DDA-TDB formulations at 25, 50 and 75 mol%. 
Values of weight or µmoles in the various liposome formulations where DDA-TDB was 
locked at a 5:1 wt ratio/8:1 molar ratio and increasingly replaced with DSPC in a 50 µL 
dose. 
 Weight µg per dose 
Formulation  (mol%) DDA TDB DSPC 
DDA-TDB 250  50  0 
+ 25% DSPC 188  36  88  
+ 50% DSPC 125  25  175  
+ 75% DSPC 63  14  264  
 
This variation in lipid composition was studied in-vivo, relating physical adjuvant 
properties to adjuvant activity using a tuberculosis antigen vaccine candidate, a 
combination of the early secreted antigens of Ag85B–ESAT-6 with the latently 
expressed Rv2660c antigen (H56), known and proved for its protective immunity 
before and after exposure (Aagaard et al., 2011). PCA was performed to cluster the in-
vivo derived immunological vaccine responses upon delivery of a subunit protein by the 
various formulations made, which were linked to the vesicle characteristics, size, zeta 
potential and DDA concentration by PLS regression analysis.  
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8.3 Results and Discussion 
8.3.1 Summary of in-vivo responses 
The molar ratio of DDA-TDB remained locked at 8:1, given this ratio was shown the 
most beneficial in immunological performance (Davidsen et al., 2005). DSPC was 
incorporated in substitution for DDA-TDB at various molar % ratios, which influenced 
vesicle characteristics (Table 8.2). Vesicle characteristics prior to protein addition 
coincided well with previous results, ~500 nm, PDI of 0.3 and ZP of ~50 mV, 
(Christensen et al., 2007a; Davidsen et al., 2005; Henriksen-Lacey et al., 2010b). 
Substitution of DDA-TDB with 25, 50 or 75 mol% DSPC increased vesicle size (p < 
0.05), yet remained in a sub micrometer size range with reduced ZP with increasing 
DSPC content (Table 8.2). The addition of the H56 antigen increased the particle size 
of all formulations (p < 0.05) to 850 -1300 nm depending on the formulation, whilst ZP 
was reduced (Table 8.2). Due to the high content of cationic lipid and anionic antigen, 
antigen loading was > 85 % (results not shown), even with the 75 % DSPC formulation 
(p>0.05). 
 
All four of the liposome formulations induced higher (p<0.05) IgG immune responses 
once compared to mice immunised with antigen alone, remaining insignificant within 
the formulations, p>0.05 (Table 8.2). Results suggested that the incorporation of up to 
50 % DSPC within the liposome formulation did not compromise the immunogenic 
effect of the DDA-TDB adjuvant, which has been shown to induce a protective cellular 
immunity against TB upon co-delivery of a model vaccine antigen (Agger et al., 2008). 
Results suggests that the IgG and IgG1 responses were independent over a range of 
DDA and TDB concentrations and independent of resulting liposome characteristics, 
whilst the decrease DDA content decrease the IgG2b response. 
 
Mice were vaccinated with the liposomal adjuvant and were re-stimulated with the H56 
vaccine at increased concentrations from 0-25 µg/mL, after which the antigen specific 
splenocyte proliferation rates were measured. A strong link between cell proliferation 
and DDA-TDB adjuvant was seen (Table 8.2), with the highest counts obtained for the 
formulations without DSPC incorporated. 
 
Elevated DSPC content lead to a decrease in IFN-γ, IL-2 and IL-6 levels (Table 8.2). 
The mice, which received antigen alone showed similar, if not higher, IL-5 levels in 
comparison to those animals immunized with the liposomal adjuvants, which had a 
similar and low IL-5 production over the different formulations tested. In contrast, the 
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incorporation of DSPC in the liposomal adjuvant increased the IL-10 responses (Table 
8.2).  
 
The replacement with DSPC was linked to a decrease in ZP, which was related to 
skewing the immune response towards a Th2 type response, despite the small 
decreases in ZP noted in these formulations (Table 8.2). The liposomal surface charge 
has been found linked to the quality of immunity stimulated with Ag85B-EAST-6 
antigen (Henriksen-Lacey et al., 2010b),  where especially the levels of IFN-γ were 
linked to a positive surface charge of the liposomal adjuvants, as seen here in the 
study (Table 8.2). In contrast, a weak cellular immune response was seen with the 
formulations that included a high content of DSPC, 75 mol%. The subsequent Th2 type 
immune response was found linked to the increased levels of DSPC, which was overall 
linked to the resulting ZP of the formulations made (Henriksen-Lacey et al., 2010b). 
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Table 8.2: DDA-TDB and its substitution with 25-75 mol% DSPC with effect to particle 
characteristics prior to and post H56 antigen adsorption. Results denote mean ± SD for 
three independent experiments. Mean serum H56 specific antibody isotype titres 
stimulated by DDA-TDB and DSPC substitution (n=5, +/- standard error). Values display 
the positive reciprocal end point dilution (log10). Spleen cell proliferation stimulated by 
H56 vaccine antigen and spleen cell cytokine production in response to re-stimulation 
with H56 antigen. Results represent mean average of five spleens per vaccination group 
± standard error. Experiment performed by M. Jubair Hussain.  
Formulation  Antigen H56 DDA/TDB 25% DSPC 50% DSPC 75% DSPC 
Vesicle size (nm)  517 ± 29 640 ± 24 856 ± 114 734 ± 67 
+ H56 981 ± 198 1266 ± 151 1036 ± 92 852 ± 52 
Polydispersity  0.32 ± 0.01 0.34 ± 0.01 0.32 ± 0.01 0.33 ± 0.02 
+ H56 0.42 ± 0.02 0.46 ± 0.06 0.54 ± 0.14 0.42 ± 0.1 
ZP (mV)  45.7 ± 0.7 42.7 ± 1.9 35.4 ± 3.6 33.2 ± 0.5 
+H56 47.4 ± 6.1 41.4 ± 3.7 31.7 ± 6.4 28.7 ± 5.3 
Specific titer       
IgG 
(log 10) 
Day 9 1.54±0.26 1.46±0.38 1.88±0.67 1.7±0.47 1.08±0.4 
Day 24 3.52±0.11 4.12±0.06 3.94±0.2 4.08±0.11 3.7±0.19 
Day 37 3.34±0.10 4.54±0.13 4.48±0.11 4.53±0.11 4.24±0.15 
Day 49 3.94±0.05 4.3±0.08 4.3±0.08 4.38±0.06 4.18±0.11 
       
IgG1 
(log 10) 
Day 9 1.72±0.18 1.44±0.54 1.28±0.38 2.08±0.18 1.26±0.47 
Day 24 3.76±0.10 4.48±0.14 4.66±0.18 4.45±0.12 4.12±0.14 
Day 37 3.94±0.10 4.66±0.10 4.78±0.13 4.83±0.15 4.42±0.13 
Day 49 4.06±0.05 4.72±0.10 4.66±0.05 4.6±0.10 4.48±0.06 
       
IgG2b 
(log 10) 
Day 9 1.22±0.3 1.32±0.5 2.02±0.16 1.67±0.15 0.58±0.32 
Day 24 2.74±0.13 4.66±0.10 4.3±0.22 4.45±0.15 3.04±0.26 
Day 37 3.28±0.34 4.9±0.21 4.9±0.64 4.75±0.30 3.28±0.54 
Day 49 3.52±0.13 4.78±0.08 4.6±0.25 4.82±0.12 3.64±0.22 
Re-stimulation H56 antigen (µg/mL)     
Spleen 
Prolif. 
(CPM) 
0 366.3±60.6 537.7±190.9 294.1±58.9 366.1±95.3 522.9±127.8 
0.05 745.1±208 20394±1759 13770±2956 8482.4±3614 3290.4±1187 
0.5 1335.5±567 32873±2320 22731±3923 16610±5710 6649±2340 
5 2227±837 36524±1914 27097±4421 20325±6005 8216±2660 
25 3530±1550 42750±2985 32285±4894 28861±6541 11540±4081 
       
INF-γ 
(pg/mL) 
0 178.13±17.1 157.38±11.6 100.20±1.8 105.14±2.6 108.74±2.9 
0.5 207.41±30.6 3754.37±250 2015.21±218.9 316.96±47.3 110.26±6.7 
5 220.46±19.2 3938.64±58.4 3237.68±319 674.58±52.1 112.93±5.7 
       
IL-2 
(pg/mL) 
0 70.82±14.5 66.6±18.7 43.7±17.7 21.9±6.8 29.3±2.2 
0.5 173.7±61.7 2607.7±185 2646.2±303 1383.7±345 39.1±11.3 
5 341.9±93.5 3493.2±307.2 3170.6±230 1753.3±391 38.9±6.7 
      
IL-5 
(pg/mL) 
0 265.45±13.1 214.56±19.4 81.8±22.9 71.9±13.9 98.7±6.1 
0.5 268.4±44.6 249.3±13.5 85.1±22.3 139.1±12.6 147.3±13.4 
5 282.4±5.8 235.9±14.8 207.3±32.5 224.2±9.3 317.4±30.3 
      
IL-6 
(pg/mL) 
0 20.1±4.1 20.4±1.9 62.9±3.4 58. ±1.7 60.6±3.9 
0.5 26.4±5.7 325.1±26.2 109.6±16.9 68.2±6.5 52.7±9.3 
5 10.1±4.6 394.4±16.6 172.2±27.6 86.1±8.9 68.3±4.1 
      
IL-10 
(pg/mL) 
0 51.2±4.4 44.8±1.6 81.8±7.0 69.6±6.2 69.6±8.3 
0.5 65.3±11.6 83.9±4.1 199.2±10.4 102.6±11.9 100.6±7.8 
5 85.8±7.8 73.4±11.3 155.4±12.7 116.2±7.1 140.1±13.5 
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8.3.2 Multivariate analysis for clustering Th1 and Th2 type immune responses 
to adjuvant characteristics 
8.3.2.1 Principal component analysis and partial least square regression 
The aim of this work was to link the multifactorial changes in composition of the lipids 
to the biological attributes of an adjuvant formulation. Therefore, the data set obtained 
from above in-vivo study was used in a multivariate analysis (MVA) and the liposome 
characteristics post-addition of the antigen were used (Table 8.2). Initially, two principal 
components (PC1 and PC2) were fitted, which determined the overall model fit by 
weights and loadings. The data set was subdivided into two different patterns, initially 
selecting the liposomes size and DDA concentration as X-variables, leaving 10 Y-
variables in the PLS analysis at a total of 12 observations. This data set assessed 
whether the most influential factor was the size of the vesicles or the DDA 
concentration for the measured output of the immune response. This model yielded a 
fraction of the X-variation modelled in PC1 of 62 % (eigenvalue 1.24) and 100 % in 
PC2 (eigenvalue 0.764). The Y-variation was modelled 46 % and 13 % with the first PC 
and second PC respectively, with a cumulative goodness of fit of 0.59 and the 
cumulative goodness of prediction of 0.37. 
 
Secondly, the liposome size, ZP and DDA concentration were selected as X-variables, 
leaving 9 Y-variables for the total of 12 observations. The reason for this second set of 
analysis was to verify how the ZP as a variable influenced the immune response of the 
vaccine in-vivo. The model yielded a cumulative goodness of fit of 0.97 and the 
goodness of prediction of 0.52, by fitting two PC (PC1 with 64% of the fraction in the X-
variation modelled (eigenvalue 1.92), 97% respectively in the PC2 (eigenvalue of 0.98); 
Y-variation modelled in first PC was 44%, 53% in PC2). The TDB concentration once 
included as a variable resulted in a statistical not valid model, with respective variable 
found not influencing the immune response. Both model setups comprised satisfactory 
information using both PCs fitted, and cumulated R2 and Q2 values for each Y-variable 
was analysed (Figure 8.1). 
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Figure 8.1: X/Y overview plot indicating the cumulated R2 and Q2 values for each 
response for A) DDA and size and B) DDA, size and zeta potential. Well modelled 
responses show a R2 and Q2 value above 0.5 poor model fit was indicated by negative Q2 
(statistical insignificance).   
 
A threshold value for R2> 0.5 indicated a valid model; values below 0.5 indicated noise. 
Both designs chosen had insignificant models for the responses IgG and IgG1 (Figure 
8.1A and B), as indicated by negative Q2. The responses spleen proliferation, INF-γ, IL-
2, and IL-6 had a good model fit above 0.5, with respective good prediction power 
based on a relatively low level of noise in the data set (Figure 8.1A and B). The 
responses IgG2b, IL-5 and IL-10 had a R2 at or below 0.5, indicating a higher amount 
of noise present for these responses, which was further evaluated throughout the 
model validation. Based on poor model fit, the antibody subtypes IgG and IgG1 were 
removed from further analysis. The response IgG2b remained, and despite low 
confidence level, aiming for further confirmation of its validity throughout the MVA 
analysis. 
 
Modelling of the data revealed no strong or moderate outliers present, as evaluated in 
the PCA analysis (Figure 8.2). The colour coding in the PCA analysis was used for 
identification of trends and clusters within the observations made. The colour coding 
according to ZP (Figure 8.2A) and DDA concentration (Figure 8.2B) and coincided with 
a colour trend shifting from right to left, suggesting a link between DDA concentration 
and ZP; opposed to the colour coding according to size (Figure 8.2C), which a colour 
pattern not coinciding with any of the other responses in the model. Uncorrelated 
response, here exemplified by IgG (Figure 8.2D) did not show an overlapping colour 
profile with any of the variables or responses, suggesting no correlation or cluster for 
this response. The responses INF- γ, IL-2, spleen proliferation and IL-6 (Figure 8.2 E, 
F, G, H) showed a similar colour pattern, shifting from right to left with the decrease in 
measurement output; an early indication of a cluster. 
 
  Chapter 8: Multivariate Analysis 
222 
 
 
 
Figure 8.2: PCA cluster analysis with colour coding according to A) ZP, B) DDA 
concentration, C) vesicle size D) IgG, E) INF-γ, F) IL-2, G) spleen proliferation and H) IL-6. 
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Figure 8.3: PLS analysis results with coefficient overview, displaying the coefficients for 
all responses to interpret how the X-variables affect the Y-variables for A) DDA and size 
and B) DDA, size and zeta potential. Loading scatter plot, where the relation between X 
and Y- variables are displayed for C) DDA and size and D) DDA, size and zeta potential. 
 
The X-Y relation was depicted by specific regression coefficients (Figure 8.3A and B) in 
the PLS model; streamlining the model overview and coincided with the loading plot. 
The coefficient plot was used to detect correlated responses due to similar coefficient 
profiles, whereas uncorrelated responses are revealed due to a different profile in their 
X-Y relationship. The coefficient plot revealed a strong correlation between the 
variables DDA (Figure 8.3A) and ZP (Figure 8.3B) to the splenocyte proliferation, 
indicative of the promotion of splenocyte proliferation upon re-stimulation with the H56 
antigen. The variable liposome size did not correlate to any of those responses, as 
seen by the respective confidence interval crossing zero. The most influential variable 
for the response spleen proliferation was the variable DDA concentration, due to its 
high coefficient value approaching 1 with relative small confidence interval. The 
response splenocyte proliferation was found closely correlating to the variable DDA 
(Figure 8.4C) and ZP (Figure 8.4D), due to close situation in the loading scatter plot in 
the upper right hand quadrant. Results indicate that the biggest effect to spleen 
proliferation rates is the increase in DDA content in a formulation, with the DDA content 
strongly influencing the ZP of a formulation, the ZP was found correlative as variable 
and response in both models. The peak of proliferation correlated with the formulation 
with the highest ZP, here DDA-TDB alone.  
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The cytokine responses (INF-γ, IL-2, IL-6 and IL-10) were found statistically linked to 
the variables DDA (Figure 8.3C), and ZP (Figure 8.3D). Both variables showed a 
positive correlation to cytokine responses INF-γ, IL-2 and IL-6. The opposite situation 
of the response IL-10 in the loading scatter plot revealed an inverse correlation to the 
variables DDA concentration and ZP. The coefficient plot showed this inverse 
relationship due to negative predictions by the DDA concentration as well as the ZP 
(Figure 8.3A and B). The increase in DDA in a vaccine adjuvant formulation did not 
influence the size of the liposomes formed significantly, but resulted in a higher surface 
charge. This link, as seen in Table 8.2, was identified by the PLS analysis, which 
predicted an increase the specific INF-γ, IL-2 and IL-6 production in-vivo. The highest 
INF-γ production in the in-vivo study was detected for the formulation with the strongest 
cationic ZP, here DDA-TDB (Table 8.2). Literature reported the effect of cationic 
surface charge to cytokine response in-vivo, with enhanced responses of INF- γ as well 
as IL-6 (Hussain et al., 2014). PLS model predictions were able to detect this 
relationship in line with reported effect of cationic surface charge (but with constant 
TDB concentrations across the formulations).  Additionally, the model revealed 
independence of the DDA content on IL-5, and an inverse correlation between the 
response IL-5 and the liposome size (Figure 8.3C and D), predicting an increase in IL-5 
production by smaller vesicles, as seen in the in-vivo data given that the highest IL-5 
production was measured for the DDA-TDB formulation, which also had the smallest 
size (Table 8.2). The responses INF-γ, IL-2 and IL-6 showed coincided coefficient 
profiles for the variables DDA and ZP, which suggested a grouping and relation 
between those cell mediated responses, as clustered collectively as Th1-specific 
immune responses. Both loading scatter plots (Figure 8.3C and D) revealed this 
cluster, showing that the ZP, independent of its use as variable or response, clustering 
the Th1 specific immune responses INF-γ, IL-2, IL-6 and IgG2b. 
 
Generally, the DDA concentration was overall strongly linked to the ZP of a 
formulation, as seen once the ZP was selected as a Y-response (Figure 8.3A) as well 
as a X-variable (Figure 8.3B). The ZP as linked to the DDA concentration, both 
important variables for initiating a Th1 mediated immune response in-vivo. Model 
generated were found statistically valid for the variables, DDA and ZP (spleen 
proliferation, IFN-g, IL-2, IL-6, IL-10, IgG2b). The liposome size was found important 
only to a limited extent, here in the case of IL-5. The variable influence on projection 
plot (VIP) (Figure 8.4), revealed all components and Y-variables (Kubinyi, 1993), 
indicated the importance of the variable DDA content (Figure 8.4A) and ZP (Figure 
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8.4A, B), both shown as the variables with the highest impact in the PLS models, 
whereas the size variable was found of only limited importance.  
 
Figure 8.4: VIP plot (variable importance for projection) summarizing the importance of 
the variables liposome size and zeta potential. The VIP plot is sorted from high to low 
and indicates the value of the variable DDA and zeta potential as the most important X-
variables in the PLS model for A) DDA and size and B) DDA, size and zeta potential. 
 
Results indicate the usefulness of PLS analysis, where a higher dimensional dataset 
can easily be projected onto a plane, allowing for a simple depiction of several Y-
variables, rather than analysing each response at a time in a separate model. Overall it 
is beneficial to analyse strongly correlated Y-variables together and group them, mainly 
due to the stabilisation of a model due to variable-correlation (Eriksson, 2006), mainly 
for dependent responses, which are based on similar measurements. Results 
confirmed the importance of the DDA concentration in a vaccine formulation as a 
crucial variable influencing the immunological response to a bigger extend than the 
size of the vesicles (across the size range considered here).  
 
Results here emphasize on MVA as a novel tool allowing for in-vitro to in-vivo 
predictions, cluster analysis for Th1 specific immune responses. In this study, a range 
of factors were varied, here DDA, TDB and DSPC content which affected vesicle size 
and ZP. A cluster analysis (PCA) identified trends, outliers and initial links. Developed 
models clustered and predicted Th1 immune response, which was found dependent on 
key liposomal adjuvant characteristics, DDA concentration and ZP. DDA-TDB was 
substituted with DSPC, which reduced the cationic surface charge with limited effect to 
vesicle size. Some data sets were indicative of a higher level of noise, e.g. for the 
variables IgG2b, IL-5 and IL-10, which might be associated with the assay accuracy 
leading to moderate interpretation power. Furthermore, despite this initial analysis, it 
might be required to expand the analysis on a wider formulation in more complex 
vaccine adjuvant studies. Obtaining vaccine efficiency data is so far limited to in-vivo 
results, sacrificing animals. The MVA analysis might be a novel and cost effective way, 
to speed up the drug and process development process, by predictions of an in-vivo 
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immune response based on the characteristics of the adjuvant or delivery system. This 
might be a powerful tool for vaccine adjuvant characterisation by clustering of in-vivo 
specific immune responses and help to generate future predictions of vaccine 
efficiency, which may overall accelerate the development process of a vaccine 
candidate. MVA can be used for summarizing and visualizing data sets, for 
classification and identification of quantitative relationships between variables 
(Eriksson, 2006). Its application is flexible and not limited to a number of variables or 
observations, which determine relationships between several system or process based 
analytical measurements (Lopes et al., 2004). The effect of one property to another 
one can be measured and links the dependent and independent variable together in 
one model by regression analysis. Furthermore, many variables can be analysed 
simultaneously, achieved by a reduction in the dimensionality of a data set by 
projection onto a plane of lower dimension interpretations (Kourti et al., 1996). The 
visualisation and simplification of complex sets of data is highly applicable in any 
process or product development particularly in pharmaceutical research (Rajalahti and 
Kvalheim, 2011) as well as in diagnostics tools, often used in industrial processes for 
product quality control (Kourti et al., 1996).  
 
8.3.2.2 Model validation 
In addition to the performed PCA and PLS analysis, the models generated were 
validated by respective permutations plots for each specific Y-response (Figure 8.5), 
which is a crucial diagnostic tool in the analysis of a multivariate model. The 
permutation plots assessed the validity of the PLS model by evaluating the risk of 
invalidity. Additional, the permutation plots verified that the model fit is not only valid for 
the current data set, but can also be applied for new observations and predictions of Y. 
For the permutation, the X-data was left unchanged while permuting the Y-data and 
arranging it in a different order. Consequently, a new PLS model is fitted using the 
permuted data set. R2 and Q2 verified the derived models by cross-validation. The Y-
data was randomly shuffled, and the permuted values were compared with the real R2 
and Q2 values of the model. The repetitive permutation generated parallel models 
according to the number of permutations, mostly between 25 and 100, (here, 40). 
Based on random data, reference distributions could be made which assessed the 
validity of the initial PLS model (van der Voet, 1994). The comparison of the goodness 
of fit and prediction (R2 and Q2) of the current model to the ones of the randomly 
permuted Y-observations was performed at constant X-variables. R2 and Q2 of the 
original model were shown on the far right and the permuted values, 40 for each Y-
response, were depicted on the left side of the graphs, with a respective correlation line 
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between permuted Y-vector to the original X-vector. Model validity was pre-set as the 
intercept of the Q2 regression line at or below zero.  
 
The evaluation of the permutation analysis revealed excellent model validity for the ZP 
as a response (Figure 8.5A), confirming above PLS model. The previously highlighted 
invalidity of the responses IgG, IgG1, IgG2b, IL-5 and IL10 resulted in poor permutation 
plots as seen earlier, Figure 8.1 A and B and exemplified here by the permutation plot 
of IgG, where scattered permutations above the original Q2 and R2 were strongly 
indicative of a poor model validity, Figure 8.5B. Additionally, model validity for the 
responses spleen proliferation, INF-γ, IL-2 and IL-6 was confirmed (Figure 8.5 C, D, E, 
F). 
 
Figure 8.5: Permutations plot for A) zeta potential, B) IgG, C) spleen proliferation, D) 
IFNg, E) IL-2, F) IL-6. Model validity was assessed for 40 permutations. The correlation 
between permuted Y-vector to the original X-vector is depicted by the horizontal 
correlation axis. The criteria for model validity have been selected as the intercept of the 
Q2 regression line at or below zero. 
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8.4 Conclusion  
The accumulation of a large quantity of data is further enhanced by modern and high 
throughput analytical equipment, leading to the challenge of extraction of valuable data 
in a reasonable timeframe. The incorporation of computer-based methodologies 
simplifies the analysis of large data sets, extracting key features within a reasonable 
timeframe. Tools like DoE and MVA accommodate this need, combining regression 
models with experimentally obtained data or offline analysis. The aim is to provide 
extra information and confidence in a given research application based on critical 
quality parameters (like here the selection of immune responses) of a given system, 
here liposomes varying in lipid composition, size and ZP. The MVA clustered and 
predicted key liposome characteristics dependent on specific in-vivo immune 
responses. The validity of derived PLS models was found key for a confidence 
prediction of in-vivo specific immune responses from offline analytical measurements 
and key characteristics could be correlated to critical quality attributes of a vaccine 
formulation. The tool presented may accommodate the need for screening many 
variables at a time, often required in early stage development processes. 
 
Despite potentially curative pharmacotherapies available, tuberculosis (TB) remains 
the primary cause of preventable deaths worldwide (Sosnik et al., 2010). A host’s 
stimulation of cellular Th1 type immunity is required to inhibit Mycobacterium 
tuberculosis (MTB) infection. The H56 subunit vaccine, delivered by a liposomal 
adjuvant consisting of DDA with the glycolipid TDB is capable of stimulating powerful 
cell-mediated immunity against MTB (Davidsen et al., 2005). Nevertheless, time 
intensive optimisation required screening over a range of lipid concentration, resulting 
in different vesicle sizes and surface potential, which quickly accumulates the numbers 
of formulations tested. The formulation consisting of DDA-TDB with well described 
adjuvant activity (Christensen et al., 2009; Christensen et al., 2007b) was correlated 
within this study as the formulation which generated the highest levels of INF-g, IL-2,IL-
6 responses, as required for a strong Th1 type immunity. Therefore, this formulation 
was further investigated and translated into the on-chip manufacture of adjuvants. 
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9.1 Introduction 
Liposomes are well-described delivery systems for vaccines (O’Hagan and De 
Gregorio, 2009), based on their flexibility, particulate nature and ability to incorporate a 
range of immunogenic molecules such as proteins, peptides or genetic constructs. A 
successful vaccine adjuvant should be able to carry and deliver its antigen to the target 
cells thus raising the desired immune response. Based on Chapter 8 the formulation 
DDA-TDB was found a potentially effective adjuvant providing a strong Th1 immune 
response upon delivery of an antigen triggering the formation of a liposome-antigen 
depot at the site of injection for subcutaneous and intramuscular administration 
(Henriksen-Lacey et al., 2010a). Previous work investigated the correlation between 
the adjuvant´s in-vivo to in-vitro activity with formulations containing various amounts of 
cholesterol using human macrophage-like cells to investigate the interaction of cells 
and adjuvant formulation (Kaur et al., 2013). However, in addition to liposomes 
systems nanoparticles prepared with poly(D,L-lactide-co-glycolide) (PLGA) or poly(D,L-
lactide) (PLA) have also been shown as effective for in-vivo delivery of protein, 
peptides and DNA antigens (Ataman-Önal et al., 2006), and as controlled release drug 
delivery systems with proven safety profile (Okada and Toguchi, 1995; Xiao et al., 
2012). Here, microfluidics-based nanoprecipitation was exploited for nanoparticle-
based adjuvant manufacturing. These nanoparticles were assessed for potential 
protein loading capabilities based on surface adsorption. 
 
9.2 Aim and Objectives 
The aim of this chapter was to investigate the microfluidics-based nanoprecipitation 
method for manufacturing of vaccine adjuvants. Two formulations were considered: 
 
1. Cationic liposomal vaccine adjuvants: vaccine adjuvants consisting of DDA-
TDB (Chapter 8) were prepared by varying the flow rate and ratio in the 
microfluidics-directed nanoprecipitation method and a model protein was added 
into the process for assessing qualitatively protein association with adjuvant 
assembly. 
 
2. Polymer-based nanoparticles: different polymers were used for manufacturing 
nanoparticles by the microfluidics-based nanoprecipitation method. 
 
Both systems were characterised and compared to system prepared using standard 
laboratory protocols. The in-vitro activity of the microfluidics-manufactured liposomal 
vesicles was assessed in an assay based on association and migration of APCs.   
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9.3 Results and Discussion 
9.3.1 Manufacturing of lipid-based vaccine adjuvants by microfluidics 
The first objective was to manufacture, using microfluidics, DDA-TDB adjuvants with 
physicochemical attributes matching the key parameters identified in Chapter 8 and 
manufacturing models in Chapter 3. Initially the impact of the FRR and TFR during the 
nanoprecipitation-based manufacturing of DDA-TDB liposomes using the 200 µm chip 
design was considered. Results in Figure 9.1 show that the combined alteration of the 
TFR and the FRR triggered the assembly of the smallest vesicle size possible at 2.5 
mL/min and a FRR of 1:4. The alteration in FRR and TFR correlated well with liposome 
sizes; smaller vesicles were obtained with enhanced polarity in the assembly process 
Figure 9.1A, leading to minimum size of about 100 ± 10 nm, coinciding with model 
predictions at respective TFR and FRR (Chapter 3). Maximum vesicle sizes (350 ± 100 
nm) were achieved at a TFR of 1 mL/min combined with a FRR 1:1 further coincided 
well with model predictions obtained in Chapter 3. ZP remained between 40-50 mV as 
would be expected given the total cationic lipid content was not varied. The PDI 
remained between 0.2-0.4 without a notable link to TFR and FRR (Figure 9.1).  
 
Figure 9.1: The effect of alterations in A) TFR and FRR at a constant solvent flow rate of 
0.5 mL/min and B) FRR at constant TFR of 1 mL/min to the physicochemical vesicle 
characteristics in the 200 µm chip design. Results denote mean ± SD of 3 separate 
batches.  
 
Here, only the simultaneous alteration of both factors, TFR and FRR was found 
influencing the vesicle size significantly, whereas solely enhancing the aqueous 
content did not result in a reduced vesicle size (Figure 9.1B). This is in contrast to 
previous chapters, where the FRR was the only important variable influencing the 
resulting vesicle size (Chapter 4, 5, 6). Here, the heating block maintained the 
temperature of 60°C as required for the high transition temperature lipids and the 
solvent flow rate was kept constant at 0.5 mL/min throughout manufacturing of DDA-
TDB liposomes. The setup of maintaining a constant solvent flow rate was based on 
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initial work by Zhigaltsev et al., where all alterations retained a constant solvent flow 
rate at 0.5 mL/min (Zhigaltsev et al., 2012). This setup allowed for constant introduction 
of the lipid stream, which, together with increasing the TFR and FRR, was found 
important for generating the smallest vesicle size possible for high transition 
temperature lipids formed by microfluidics-directed nanoprecipitation method. Here, the 
heating block was used for maintaining the lipids above the transition temperature by 
solely heating the syringe inlet and not the chip compartment itself. Heat transfer 
limitations by the syringes, together with a rapid cooling within the chip itself might lead 
to larger vesicles at lower flow rates and ratios, as seen in Figure 9.1A. Only the 
combined alteration of TFR and FRR might allow for a process where the 
nanoprecipitation process is faster than the rate of heat transfer and the cooling down 
of the streams within the chip. 
 
In addition to physicochemical particle characteristics, images by freeze fracturing 
electron microscopy were obtained and evaluated regarding average liposome size, 
bilayer configuration and general appearance of the vesicles as manufactured by the 
nanoprecipitation method. Images showed a unilamellar bilayer confirmation, and 
verifying the average sizes obtained by DLS, ranging between 100 – 400 nm, 
depending on the setup used (Figure 9.2 A-D). 
  
  
Figure 9.2: Freeze-fractured liposome samples manufactured with the microfluidics-
method. Bar represents A) 1 µm, B) 200 nm, C) 100 nm and D) 200 nm.  
A      B 
C      D 
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The rippled liposome surface visible in Figure 9.2 may be linked to a cluster formation 
of TDB and DDA, as noted earlier by Meyer and Richter in 2001. Here, the effect was 
associated with a disorder in the transition of the fatty acid chains in the lipids. Lipids 
might have varying direction and conformation changes which may alter with the lipid 
packing. Furthermore, variation in incubation temperature between pre-transition and 
actual transition temperature might have resulted in ripples (Hope et al., 1989; Meyer 
and Richter, 2001). 
 
Following the work on manufacturing DDA-TDB liposomes, the applicability of the 
method to incorporate an antigen was investigated. The simplicity of the method for 
continuous manufacturing was explored, by incorporating the antigen in the 
manufacturing process, as schematically depicted in Figure 9.3. Whilst three options 
can be considered, the options in Figure 9.3A and B avoid exposure of the protein to 
elevated temperatures. Incorporating protein into the vesicle assembly process itself 
(Figure 9.3C) would be feasible for low transition temperature lipids only, to avoid 
protein denaturation and therefore was not considered in these studies.  
 
 
Figure 9.3: Schematic depiction over the setups for antigen incorporation for A) 
consecutive liposome mixing, B) consecutive mixing of liposomes and antigen and C) 
direct mixing of lipids and antigen.  
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First, vesicles were run through the microchip to assess the physicochemical vesicle 
characteristics and stability (Figure 9.3A). Here, vesicles were manufactured by the 
nanoprecipitation method and led through the mixing chamber at varying TFR and 
FRR, assessing the effect of fluid flow, mixing with buffer and shear stresses on the 
vesicle characteristics.  Both an increase in TFR at constant FRR (Figure 9.4 A) as well 
as increase in FRR at constant TFR did not influence vesicle characteristics (Figure 
9.4B). At flow rates of 3 mL/min, a significant (p<0.05) decrease in liposome size was 
observed, whereas ZP and PDI remained independent (p>0.05) of TFR and FRR 
(Figure 9.4A, B).  
 
Additionally, a model protein (ovalbumin) was included in the process of forming 
antigen-loaded vaccine adjuvant particles. Model protein was integrated in the vesicle 
manufacturing process subsequent to vesicle manufacturing (Figure 9.3B). An increase 
in vesicle size upon protein addition was noted, the vesicle sizes increase from initially 
200 nm to 600 nm, indicative of vesicle aggregation (Figure 9.4C). In addition to the 
increase in size, the PDI increased upon addition of the protein to 0.8, indicative of a 
heterogeneous particle population upon protein addition. The significant drop in ZP 
from initial 55 mV to 15 mV was a qualitative indication of surface adsorbed protein. 
The process of protein addition was performed at varying TFR, remaining below 3 
mL/min as previously determined, and a mixing at 0.5 to 2 mL/min had no effect to 
vesicle characteristics (p>0.05, Figure 9.4C).  
 
In comparison to the protein addition post vesicle manufacturing without the use of the 
micromixer, larger vesicles were obtained (p<0.05) compared to the average sizes 
achieved by mixing the protein within the micromixer. However, similar PDIs indicate 
no physico-chemical advantage of the resulting formulation. The decrease in zeta 
potential was in line with results as obtained from protein addition within the micromixer 
(Figure 9.4C). Therefore, the main advantage of the in-process addition of protein 
could be considered the potential of implementing continuous manufacturing in a 
microfluidic system. 
  Chapter 9: Adjuvant and Polymer Manufacturing 
235 
 
 
Figure 9.4: The effect of increasing A) total flow rate and B) flow rate ratio (TRIS buffer 
only) to liposome vesicle characteristics. C) The effect of increase in flow rate to 
liposome vesicle characteristics at consecutive protein addition in the microfluidic 
mixing process and addition of the protein to vesicles without microfluidic mixing. Start 
formulation was manufactured at 2 mL/min, 1:3. Where shown, significance between data 
is against the start formulation characteristics (* p<0.05). Results denote mean ± SD of 3 
separate batches. 
 
Overall, rerunning vesicles though the mixing chamber was found independent of 
vesicle characteristics once run at a TFR below 3 mL/min. The significant decrease in 
liposome size at high TFR could be linked to a rearrangement into smaller vesicles due 
to shear stresses occurring within the chamber. The efficient protein delivery through 
cationic liposomes is based on electrostatic attractive force dominating and often 
leading to a surface-adsorption reaching close to 100% (Kaur et al., 2013). The 
addition of protein adsorbs to the surface of the cationic liposomes and as expected 
resulted in a decrease in zeta potential and an increase in measured vesicle size and 
PDI based on cross-linking and/or aggregation of liposomes. Previous work comprised 
DDA-TDB liposomes, which were loaded with protein by addition to the formed 
vesicles, where a drop in zeta potential by ca. 20 mV was linked to a 100% adsorption 
of protein onto the liposomes surface at a final concentration of 10 µg/mL  (Henriksen-
Lacey et al., 2011a). The exposure of DDA-TDB liposomes to protein at a 
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concentration of 10 µg/mL maintained the vesicle size, with 96% antigen association, 
which has been reported for small (Henriksen-Lacey et al., 2011a) and large 
(Henriksen-Lacey et al., 2010b) liposomal systems upon antigen loading of 10 µg/mL. 
Here, a loading of 100 µg/mL was used to trigger an effect to particle characteristics, 
assessing the capability of the microfluidics method to load the protein to the adjuvant 
formulation in comparison to a loading without the micromixer method. These results 
show that the protein loading process was independent of the TFR, suggesting an ideal 
high flow rate to accommodate the need of a high-throughput loading process.   
 
9.3.2 In-vitro activity of adjuvants manufactured via microfluidics 
Antigens or other immunstimulatory compounds may be located in the interior, the 
bilayer, or the particle surface of liposomes, which act as delivery systems of these 
components, ultimately delivering cargo to antigen presenting cells (APCs). Such 
immunstimulatory compounds might be specific to natural ligands from specific 
pathogens (Hafner et al., 2013). For a vaccine adjuvant to be effective it needs to 
promote involvement of APC and may mediate this through the attraction and 
activation of APC. In this study, the in-vitro behaviour of APCs was evaluated in the 
presence of liposomes manufactured via the microfluidics method and the standard 
lipid film hydration method. 
 
Here, DDA-TDB vesicles were manufactured by the lipid film hydration method as 
previously reported (Henriksen-Lacey et al., 2011a) and via microfluidics (Chapter 3). A 
comparison of resulting particle characteristics is shown in Table 9.1. As expected, the 
size of the resulting vesicles was the main difference between the two manufacturing 
methods, whereas both methods resulted in a cationic ZP round 40-50 mV. Solvent 
residues in the microfluidics method were removed via dialysis to a remaining solvent 
concentration <1% v/v (data not shown), whereas in the lipid film hydration method, 
flushing with N2 removed residual solvent.  
 
Table 9.1: Vesicle characteristics of DDA-TDB adjuvants manufactured. 
 
Method of manufacturing Size (nm) Zeta potential (mV) 
Lipid film hydration 600 ± 90 48  ± 8 
Microfluidics (TFR 2 mL/min, FRR 1:3) 150 ± 25 41 ± 7 
 
To consider if the microfluidics manufactured liposomes were as effective as the 
standard DDA-TDB formulation previously demonstrated to be a strong adjuvant 
(Christensen et al., 2009), both systems were compared using a series of in-vitro 
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assays. First, the migration of APCs (macrophages or immature dendritic cells (iDC)) to 
the liposomes was assessed via a migration assay. Both, macrophages and DCs are 
phagocytes, which engulf and digest the liposomes and would later present the antigen 
from the same to the T-cells in the lymph nodes, which will generate the respective 
immune response against the antigen. Despite liposomes in this study not carrying an 
actual antigen, the migration of the cells towards the liposomes is an indication of their 
in-vitro activity. Data showed an enhanced migration for DCs (Figure 9.5A) and 
macrophages (Figure 9.5B) for DDA-TDB vesicles compared to the control, which was 
found higher for the microfluidics-directed vesicles (p<0.05, time point 12 hours). Given 
the low migration for cells without any liposome addition (control), the migration is 
associated to the formulation (DDA-TDB), with respective in-vitro attraction of APCs. 
Furthermore, the microfluidics-directed formulation was not compromised by the 
method of manufacturing, with a strong in-vitro cell migration triggered as seen for the 
optimised DDA-TDB formulation manufactured via a lipid film hydration process. 
 
Previous work has demonstrated the ability of this in vitro study to test the potency of 
liposomal vaccine adjuvants; Kaur et al. (2013) showed that increased cholesterol 
content within the formulation decreased the liposomal uptake by phagocytes from 
75% of the cells associated with the liposomes without any cholesterol to 40% of the 
cells associated with the liposomes with cholesterol incorporated. This reduction in 
liposomal uptake correlated with a reduced in-vivo efficiency based on a reduced Th1 
immune response (Kaur et al., 2013). Given the previously investigated impact on lipid 
composition to the in-vitro cell association, Figure 9.5 suggests that the cell migration 
was independent of the method of manufacture and that these cationic liposomal 
adjuvants can be prepared by microfluidics thus allowing their translation into high-
throughput manufacture.  
 
Figure 9.5: Time dependent migration assay for A) immature dendritic cells (iDC) and B) 
macrophages (MO) over 12h. 
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To further compare these two liposomal adjuvants, their uptake by phagocytes was 
measured using fluorescently labelled liposomes. The association of the fluorescently-
labelled liposomes with the APCs (iDCs and macrophages) was quantified by an flow 
cytometric association assay and expressed as mean fluorescence intensity (MFI, 
mean amount of fluorescence per cell) and %positive cells (%+ve, % of macrophages 
or DC that are positive for liposomes). Figure 9.6 shows the time dependent uptake of 
fluorescently labelled DDA-TDB liposomes manufactured via lipid film hydration and 
microfluidics after application to derived macrophages and DCs.  
 
The liposomes-associated DCs were found with a MFI of 45, remaining overall 
insignificant (p>0.05) if comparing the MFI after 120 min incubation time for the 
liposomes manufactures via both manufacturing methods (Figure 9.6A). Furthermore, 
around 75 – 80 % of the DCs were found associated with the fluorescently labelled 
liposomes (Figure 9.6B), which was found in line with previous studies (Kaur et al., 
2013). The liposomes-associated macrophages were found with a MFI of 76-87, 
remaining overall insignificant (p>0.05) if compared after 120 min incubation time for 
both manufacturing methods (Figure 9.6C). Furthermore, around 94-96 % of the 
macrophages were found associated with the fluorescently labelled liposomes (Figure 
9.6D), significantly higher than the association measured with the DCs. Macrophages 
are considered as professional phagocytes, with a higher efficient phagocytosis than 
DCs (Savina and Amigorena, 2007). Despite the lower uptake of fluorescently labelled 
liposomes by DCs as seen in this study, DCs are efficient in antigen presentation to T-
cells, aiding in antibody production (Apostolopoulos et al., 2013). Data suggests that 
the macrophages and DC association with liposomes was independent of the method 
of manufacturing and both cell types, were found associated with the fluorescently 
labelled liposomes.  
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Figure 9.6: Association assay for dendritic cells (DC) expressed as A) MFI, B) %+ve cells 
over 2h and for macrophages expressed as C) MFI, D) %+ve cells over 2h. 
 
Data here compared the in-vitro efficiency of vesicles manufactured with the novel 
microfluidics method to the vesicles manufactured with the well-established lipid film 
hydration method using migration and association assays. Overall, liposomes 
manufactured via both methods were shown to trigger substantially higher APC 
migration, indicative of the biological activity of DDA-TDB vesicles as seen previously 
(Kaur et al., 2013). Given the constant liposome to cell ratio, the smaller microfluidics-
directed vesicle population comprised a higher number of vesicles. This resulting 
difference in liposome number to cell ratio was anticipated linked to the higher 
migration of the microfluidics-manufactured vesicles for both macrophages and DCs. 
Furthermore, the association of the fluorescently labelled liposomes with the APCs was 
found independent of the manufacturing method and vesicle size (thereby correlating 
with the MVA studies in Chapter 8).  
 
Overall, using this in-vitro method the microfluidics directed manufacturing of the DDA-
TDB adjuvants was shown to be as effective as the previously small scale batch 
method for liposome production.  
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9.3.3 Manufacturing of polymer-based nanoparticles 
In addition to liposomes, polymeric nanoparticles have been considered as vaccine 
adjuvants. Therefore, preliminary work to consider if nanoparticles could be formulated 
using microfluidics was undertaken. Considerations here evolved from previous work, 
where the ratios were varied between 1:1 and 1:5 (solvent:aqueous phase) at a fixed 
flow rate of 4 mL/min. The FRR was found to significantly (p<0.05) effect the size of the 
polymer nanoparticles (Figure 9.7). The lowest ratio of 1:1 showed the largest particle 
size, around 2 µm with a relatively large standard deviation, remaining statistically 
significant (p<0.05) to every other ratio used. The optimal region for smallest particle 
sizes was achieved at a FRR between 1:2 and 1:4, with the smallest sizes of 120 ± 10 
nm. A further increase in FRR to 1:5 further increased the size (ca. 300 nm). The ratios 
between 1:2 to 1:3 had the lowest standard deviation of size, with low average PDI 
value and highly negative ZP (Figure 9.7A). Overall, polydispersities of 0.2 to 0.3 were 
in line with previously reported polydispersities of polymer based NP (Ataman-Önal et 
al., 2006). ZP (Figure 9.7A) was shown to be relatively unaffected by the choice of flow 
ratio, with strong negative surface potentials recorded overall. Furthermore, solvent 
removal by dialysis made no impact on vesicle characteristics (Figure 9.7B). 
 
The common trend within the systems evaluated was the ratio between the solvent and 
the aqueous stream, which was found important in controlling the size of the 
nanoparticles, whilst remaining the zeta potential. The enhanced aqueous volume 
present at higher flow ratios resulted in the formation of smaller nanoparticles based on 
reduced closure time for the vesicles (Zook and Vreeland, 2010), as seen in previous 
chapters with lipid molecules. Lipid and polymer based systems showed the same 
trend as the enhancement of the aqueous content FRR was found to increase the 
heterogeneity within the systems evaluated, as seen in earlier chapters (Chapter 4, 5, 
6). This increase in PDI may be a result of increased dilution at higher FRR, which 
reduces the rate of diffusional mixing within the micromixer.  
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Figure 9.7: A) Effect of alteration in flow rate ratio to particle characteristics. The total 
flow rate has been maintained constant at 4 mL/min. B) Effect of dialysis for solvent 
removal to particle characteristics. C) Effect of method of polymer nanoparticle 
manufacturing to particle characteristics. Nanoparticles were prepared by solvent 
evaporation (Rescignano et al., 2013) and microfluidics (TFR 4 mL/min, FRR 1:4). The 
setting in the microfluidics have been maintained at FRR 1:4, TFR 4 mL/min. Results 
denote mean ± SD of 3 separate batches. Solvent = Acetonitrile, 200 µm chip design. 
 
The solvent evaporation method (Rescignano et al., 2013) resulted in particles around 
800 nm, significantly larger (p<0.05) than the smallest size achieved by microfluidics 
(100 nm), which also showed a lower PDI (Figure 9.7C). The fundamental differences 
between nanoprecipitation and the solvent evaporation method, along with the tight 
control of fluid flow properties in the nanoprecipitation method were anticipated to 
result in the enhanced particle characteristics. Furthermore, particles manufactured 
with the microfluidics-based method had a significantly higher negative surface 
potential than the ones manufactured by the solvent evaporation method (Figure 9.1C), 
which was anticipated as beneficial for the later performed surface adsorption of a 
positively charged protein by electrostatic interaction.  
 
The applicability of the nanoprecipitation method was evaluated by applying the 
optimised settings for PLA particle formation to the manufacturing of PLGA particles, 
which showed a slightly larger average size (ca. 130 nm) compared with the PLA 
nanoparticles (ca. 120 nm), remaining statistically insignificant, with similar PDI values, 
p>0.05 (Figure 9.8A). A significant difference in the ZP of the two types of nanoparticle 
was noted; with the PLGA nanoparticles having a significantly larger ZP average 
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(Figure 9.8A), based on structural differences between the PLGA and PLA polymers. 
PLGA nanoparticles were shown to remain their critical physicochemical characteristics 
over a storage duration of 7 days (4°C) (Figure 9.8B). Most importantly, results 
highlight on the ease of method transfer between different polymers, which can be 
anticipated to save a considerable amount of time and money in future development 
and optimisation processes. 
 
Figure 9.8: A) Effect of polymer choice to particle characteristics. The setting in the 
microfluidics have been maintained at FRR 1:4, TFR 4 mL/min. B) Stability of PLGA 
nanoparticles manufactured by microfluidics over a storage period of 7 days at 4°C. 
Results denote mean ± SD of 3 separate batches in each method. 
 
Based on above method development, the polymer particles formed were assessed for 
surface adsorption of two model proteins (lysozyme, IEP 9.3 and ovalbumin, IEP 4.5), 
based on electrostatic interaction. The addition of 0.05 mg/mL of lysozyme significantly 
(p<0.0001) increased the size of the nanoparticles, demonstrating that this 
concentration would not be suitable for loading, as aggregation dominates and the 
resulting size countered the nanoprecipitation-based manufacturing (Figure 9.9A). The 
addition of lysozyme affected the PDI of the nanoparticles formed (Figure 9.9C), with 
significantly increased with the increase in protein concentration. Qualitative protein 
loading was assessed by relative change in ZP, where the highest concentration of 
lysozyme caused the biggest effect to the particles surface potential, indicative of 
surface adsorbed protein (Figure 9.9B). The addition of OVA had no significant impact 
on the particle size, independent of its concentration.  
 
Based on the lower isoelectric point of OVA, it acted as a control, with expected low 
protein association to the negatively charged nanoparticles as reflected by its 
independence to resulting PDI. Furthermore, the increase in ZP was noted upon 
protein addition, suggesting that a small amount of electrostatic bonding does occur 
between the nanoparticles and OVA, although significantly lower than that 
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demonstrated by the change in size and PDI related to the concentration of lysozyme 
addition. Previous work on assessing antigen association with DDA-TDB vesicles 
showed high protein loading (>90%) using a tuberculosis subunit protein (Ag85B-
ESAT6) at a concentration of 10 µg/mL. Loading with lysozyme (10 µg/mL) showed 
only limited adsorption of ca. 30% onto the surface of DDA-TDB vesicles and the 
injection resulted in rapid draining of the antigen from the  injection site, with only about 
7% of the antigen recovered after one day at the injection site (Henriksen-Lacey et al., 
2010b). Generally, the adsorption of the antigen on the surface of vesicles was linked 
to a depot effect at the site of injection (Henriksen-Lacey et al., 2010b).  
 
Figure 9.9: Effect of protein loading to A) size, B) zeta potential and C) polydispersity. 
The setting in the microfluidics have been maintained at FRR 1:4, TFR 4 mL/min, protein 
has been added post particle manufacturing and particle characteristics were assessed 
after 45 min incubation time at room temperature. Results denote mean ± SD of 3 
separate batches. 
 
Whilst the loading studies here were qualitative, based on a relative change in particle 
characteristics and ZP it supports the initial screening of nanoparticles over a range of 
protein concentrations and demonstrates the effect on physicochemical characteristics 
by protein adsorption. A known issue during polymer nanoparticle manufacturing is the 
instability and protein degradation linked to the harsh conditions during traditional 
manufacturing methods as sonication, exposure to harsh solvents (class 3) (e.g. 
chloroform), high shear stress conditions and high temperatures (Tamber et al., 2005). 
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On the contrary, shear stresses in the SHM are low with reported applicability for shear 
sensitive products like siRNA (Belliveau et al., 2012). Furthermore, solvents used are 
less harsh (class 2), acetonitrile compared to chloroform in the solvent evaporation 
method, overall advantageous for using a SHM for nanoparticle manufacturing and 
protein association. Antigen adsorption onto PLA microparticles was described 
(Almeida et al., 1993) and surface adsorption was enhanced by modification and 
inclusion of either cationic or anionic surfactants (Kazzaz et al., 2000). Upon delivery of 
DNA, immune responses were enhanced in mouse and macaque models (O'Hagan et 
al., 2001a). The manufacturing of charged polymer particles was promising for vaccine 
antigen delivery, yet challenged by necessary incorporation of stabilisers like PVA and 
SDS required during the solvent evaporation method, which are necessary for colloid 
stabilisation (Ataman-Önal et al., 2006). The addition of those stabilisers will require 
extensive toxicological and safety studies (Ataman-Önal et al., 2006), whereas the 
microfluidics-based nanoprecipitation allowed for the manufacturing of stable 
nanoparticles, without the necessity of including stabilisers into the process and the 
formulation.  
 
The competitive system on a microfluidic basis is the flow focusing method. However 
this requires mixing ratios up to 60 (Jahn et al., 2007; Jahn et al., 2004), which are 
unfavourable regarding material dilutions in comparison to ratios applied in the SHM 
method, which were found ideal between 1:3 to 1:4. Furthermore, the SHM method 
allows for a higher throughput, here with flow rates up to 2.5 mL/min. The flow focusing 
method in contrast required flow rates ranging between 15 to 90 µL/min for the buffer 
stream and 1 to 6 µL/min for the solvent stream, even the maximum resulting TFR of 
96 µL/min still being magnitudes lower than the throughput achieved in the SHM 
method. Furthermore, the option of parallelisation of the mixer chips, as highlighted in 
Chapter 6, allows for a clinical based application. 
 
The method of nanoprecipitation for polymer nanoparticle manufacturing has been well 
described, and generally comprises the precipitation process of a material (here 
polymers) dissolved in a water miscible solvent (here acetonitrile) after mixing with an 
aqueous phase (here buffer) resulting in the formation of nanoscale particles. The 
solvent evaporation method in contrast relies on the use of only partially water miscible 
solvent (e.g. chloroform, dichlormethaene). Interest in these methods was evidenced 
by patent numbers peaking between the 1950s-1960s (Schubert et al., 2011). The 
application of the nanoprecipitation method for polymeric nanoparticle manufacturing of 
colloids was firstly patented by Fessi et al. (Fessi et al., 1992; Fessi et al., 1989) and is 
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since commonly applied for polymeric systems. Amphiphilic copolymers have since 
been used and described for delivery of a range of hydrophobic drugs like doxorubicin, 
clomazepam, as well as for encapsulation of antigens and proteins (Chiellini et al., 
2001; Jeong et al., 1998; Oh et al., 1999; Yang et al., 2009). The traditional methods of 
nanoprecipitation included either a dialysis membrane or the dropping technique under 
stirring (injection method) (Schubert et al., 2011). However, it has early been noted that 
the control of the mixing profiles during the nanoprecipitation method is necessary for 
regulation of the physicochemical particle properties to a sufficient accuracy. Resulting 
nanoparticles are influenced by the rate of mixing and addition of the solvent into the 
aqueous phase, together with operator variability those variables were found difficult to 
control (Basto et al., 2008; Sitnikova et al., 2005; Wang et al., 2005). Furthermore, 
advances in material science require the implementation of a robust and high-
throughput manufacturing method, able to accommodate the need of screening over a 
range of molecules and concentrations (Schubert et al., 2011), where microfluidic tools 
were shown to accommodate this need. Hydrodynamic flow focusing device for PLGA-
PEG copolymers (Karnik et al., 2008) discovered that the flow rates, polymer 
composition and concentration were significant factors to influence the size, 
polydispersity, drug loading and release of the resulting nanoparticles. Flow rates 
reported range from 0.5 and 10 µL/min for the acetonitrile and aqueous phase 
respectively (Karnik 2008). The difference to the here-presented microfluidics method 
lies in the mixer design, incorporated dilution factor, resulting particle concentration and 
throughput. Flow focusing devices were found optimised at a FRR (ratio solvent to 
aqueous phase) of 1:20, at TFR of 0.6 mL/h (Keohane et al., 2014). The here 
presented method based on a SHM device was found optimised at a FRR between 1:2 
to 1:4, at TFR ranging up 4 mL/min, a significant higher throughput compared to the 
reported flow focusing method. Furthermore, due to lower FRR, the resulting particle 
concentration is higher, whereas the flow focusing method resulted in an approximately 
20 fold dilution of the nanoparticles formed.  
 
9.4 Conclusion 
The here presented method based on nanoprecipitation of lipid and polymer molecules 
was found an effective, reproducible and high-throughput manufacturing technique. 
The flexibility of the method allows for consecutive processing of vesicles, coated with 
an antigen allowing for the manufacturing of surface adsorbed vaccine adjuvants. The 
flexibility of the method allows for tailoring the ratios and concentrations to the desired 
amount of antigen to be associated with the vesicles. The method of generating loaded 
nanoparticles based on a SHM design was firstly described by Belliveau et al., where 
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shear sensitive siRNA was successfully encapsulated into lipid nanoparticles (Belliveau 
et al., 2012; Zhigaltsev et al., 2012). Here, the size of the resulting particles was 
controlled by alteration in the PEG content, with siRNA encapsulation efficiencies of 
95% (Belliveau et al., 2012).  
 
The flexibility of this nanoprecipitation method is anticipated to accommodate the need 
for an easy screening method, allowing a range of different surfactants being 
introduced in the manufacturing process to achieve particles with a desired surface 
potential and physicochemical properties. Furthermore, the method can be considered 
less harsh than conventional solvent evaporation or lipid film hydration method, making 
the nanoprecipitation method a viable method to be considered for manufacturing 
antigen-associated polymer and lipid based particles. The presented SHM design can 
be considered as a high-throughput microfluidics method, achieving a significant higher 
throughput compared to reported microfluidic nanoprecipitation methods, comprising 
the two main needs for a successful nanoprecipitation method, namely reproducibility 
and high-throughout. Additionally, based on the scale-up platform developed (Chapter 
6), this method would allow for a successful transition into larger clinical based 
application.  
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10.1 Development of microfluidics-directed nanoparticle manufacturing 
Within the initial studies, the microfluidics-directed vesicle manufacturing method was 
investigated and compared to the sonication and the high shear mixing (HSM) method 
for manufacturing of SUV. The effect of solvent to aqueous ratio was found directly 
linked to the polarity increase throughout the chamber, which was found as the driving 
mechanism behind the precipitation reaction (Dong et al., 2012). A high volume of 
aqueous buffer enhances the mixing rate of the lipid phase, given that the fluid 
velocities in both streams differ dramatically, overall decreasing the diffusion layer 
thickness of the solvent stream. With decreased diffusion distances and less solvent 
available for lipid solubilisation, closure time for vesicles decreases, leading to smaller 
vesicles at a higher aqueous flow (Zook and Vreeland, 2010). At higher solvent 
volume, hydrophobic components are stabilised for a prolonged time, leading to overall 
larger vesicles. 
 
The microfluidics method was found less disruptive than the sonication method with 
reported higher reproducibility than the ethanol dilution method (Batzri and Korn, 
1973). Even though the sonication method generated smaller vesicles, respective 
method might introduce contaminants due to direct contact with the probe tip (Wagner 
and Vorauer-Uhl, 2011). This makes a translation of the method less applicable for a 
large scale industrial setting, and adds time associated with vesicle manufacturing. The 
HSM method was not able to reduce the vesicle size to the same extend as the 
sonication or microfluidics method, with minimal vesicle sizes of 160 nm achieved. 
Other than the reported hydrodynamic flow focusing method for vesicle manufacturing 
in a microfluidic-based precipitation process (Hood et al., 2014b; Jahn et al., 2010; 
Jahn et al., 2007; Jahn et al., 2004), the here presented SHM chaotic advection 
method resulted in a 30 times higher throughput, with flow rates ranging up to 2.5 
mL/min. Furthermore, particle concentrations due to chosen FRR were significantly 
higher in the SHM method, given that FRR ranged from 5 (Balbino et al., 2013b) up to 
30 (Jahn et al., 2007), leading to a significant lower particle concentration post 
manufacturing in the flow focusing method. 
 
For high transition temperature lipids, the factor FRR and TFR were found to 
significantly affect the vesicle size, whereas for low transition temperature lipids, the 
factor FRR was found most important in affecting the vesicle size. Over the range of 
amphiphilic molecules investigated, the same trend was visible, with a reduced particle 
size with the increase in aqueous content FRR. For all compounds tested other than 
the high transition temperature lipids, the TFR was the prominent factor influencing the 
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method throughput with minimal or negligible effect to the vesicle characteristics. As 
such, the method of microfluidics-directed nanoprecipitation was found not only 
restricted to phospholipids, but furthermore applicable for a range of amphiphilic 
compounds, with lipids differing in charge and chain length, as well as polymeric-based 
nanoparticles. 
 
10.2 The role of quantification and recovery studies 
Within this thesis, a range of drug and protein delivery systems were manufactured by 
various methods, which brings along the need for a rapid and accurate quantification 
methods for the loading as well as the amphiphilic compounds. Here, quantification 
based on an RP-HPLC was performed, with quantification based on an UV detection or 
an ELSD. Separation and quantification based on column chromatography is the most 
applied method, linked to its selectivity, sensitivity and reproducibility compared to 
assay based quantification methods (Umrethia et al., 2010). These quantification 
protocols confirmed that the lipid ratios were maintained throughout microfluidics-
directed vesicle manufacturing. Furthermore, recovery studies were important to 
assess that no lipid is lost due to adsorption onto the PDMS matrix, which is known for 
its adsorption properties of biologic materials, including proteins, mainly due to its 
porosity and hydrophobicity (Monahan et al., 2002; Toepke and Beebe, 2006). Studies 
have shown that recoveries were high, with a loss of lipids occurring at high aqueous 
content FRR (1:5).  
 
10.3 Biological activity of vesicles manufactured by mircrofluidics-
directed nanoprecipitation 
Initially, the biological activity of vesicles formed in the microfluidics-directed 
nanoprecipitation method was investigated with cationic liposomal systems that were 
used as transfection agents. Cationic liposomes were prepared using lipids, 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP), commonly used in transfection protocols for in 
vitro mediated gene transfer (Ciani et al., 2007; McNeil et al., 2010). The microfluidics-
based liposome manufacturing method was explored by variation of the process 
parameters TFR and FRR. Results highlighted on the ability to produce liposomes of 
defined sizes, which gave reproducible transfection results in standard transfection 
protocols. The factor TFR was found mainly affecting the method throughput, whilst the 
FRR was found impacting the size and PDI of the resulting vesicles, which overall 
showed good transfection outcome in a standard transfection protocol.  
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Similar transfection protocol was verified for the microfluidics-directed manufacturing of 
DQAsomes, vesicles consisting of cationic bola-amphiphiles with delocalised charge 
centres (Weissig and Torchilin, 2001). Similarly, the factor FRR was found significantly 
affecting the vesicle size, with minimal sizes of 250 nm achieved, where the TFR was 
the prominent factor only influencing the method throughput. Overall, the microfluidics 
method was found to generate vesicles of better physico-chemical characteristics 
compared to the ones achieved by lipid film hydration and sonication. Despite chemical 
instability, the vesicles showed biological activity by achieving a transfection with two 
different plasmids, highlighting on the feasibility of organelle directed gene delivery.  
 
Cationic liposomal adjuvants were also effectively prepared by microfluidics and shown 
to be as immunogenic as previously investigated lipid-hydration systems, thereby 
demonstrating that these systems can be effectively translated from a small-scale 
laboratory production methods to a high-throughput manufacturing system. 
 
10.4 Drug loading with nanoprecipitation 
Having established the importance of the solvent to aqueous ratio for controlling the 
vesicle size, the method was furthermore explored for simultaneous encapsulation of a 
low solubility model drug (propofol). The use of liposomes as solubilising agents for low 
solubility drugs is well explored (Ali et al., 2010; Ali et al., 2013; Mohammed et al., 
2004); and linked to a significant amount of new chemical entities in discovery, 
currently more than 40%, with limited aqueous solubility and subsequently related 
bioavailability issues (Savjani et al., 2012; Williams et al., 2012). Within this work, the 
low solubility drug was included in the solvent stream within the microfluidics method. 
 
The microfluidics method was able to manufacture significantly smaller vesicles 
compared to a top-down sonication method, to a minimum of 50 nm. Furthermore, the 
concentration of the drug in the solvent stream significantly affected the 
physicochemical particle characteristics, where a concentration of 1 mg/mL was linked 
to ideal particle characteristics. The loading of the low solubility drug in the vesicle 
bilayer was significantly higher as achieved with the sonication method, which was 
found independent of the FRR tested, ranging from 1:1, 1:3 and 1:5 and remained at 
approximately 50 mol%. The encapsulation achieved with the sonication method was 
~20 mol%, coinciding with literature values (Ali et al., 2013). Overall the efficient mixing 
process, based on chaotic advection and diffusion in the channel, was anticipated as 
the key mechanism behind drug encapsulation. The process of encapsulation was 
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favoured and occurred simultaneously with the synthesis of the vesicles themselves, a 
major advantage in microfluidics-directed manufacturing and loading. The release of 
the drug was dictated by the formulation rather than the method of manufacture. Where 
PC liposomal bilayer-loaded propofol followed a zero-order release kinetics (Ali et al., 
2013), the incorporation of cholesterol into the liposomal systems shifted the release 
rates towards a first-order release model (Ali et al., 2010). The loading of a hydrophilic 
drug with the nanoprecipitation method showed almost 100% loading efficiency, and 
formulation remained stable stored at 4°C over the course of eight weeks (Zhigaltsev et 
al., 2012). A modified solvent-injection method for the production of solid lipid 
nanoparticles included the encapsulation of a lipophilic drug, which after lyophilisation 
reached 100% (Wang et al., 2010). Loading of a lipophilic drug into PLA nanoparticles 
was achieved in a simple nanoprecipitation, method, where the solvent phase was 
added to the aqueous phase under stirring. The size of resulting PLA nanoparticles 
was found affected by the PLA amount and the ratio of solvent to aqueous phase, with 
higher encapsulation values achieved reaching almost 100%. Volumes however were 
60 mL per batch, and significantly higher than the here presented chaotic advection 
method (Chorny et al., 2002). 
 
10.5 The role of continuous manufacturing 
In this work, loading was achieved by chaotic advection micromixing with a continuous 
purification system integrated on a microfluidics based filtration device. This highlights 
the use of microfluidic tools for convert a multi-step large scale process into a 
continuous flow microfluidic-scale process, significantly reducing the required 
processing time. As such, on-chip liposome loading and purification technique was 
achieved by remote loading, where a chemical medication of the drug after diffusion 
into the liposomes prevented membrane re-permeation (Hood et al., 2014a). The 
formation of vesicles was achieved by hydrodynamic flow focusing, and an integrated 
counter-flow membrane dialysis was used for a pH shift and buffer exchange. The 
continuous on-chip manufacturing process required less than 3 minutes to produce 
drug loaded liposomes, with enhanced drug encapsulation properties compared to 
conventional bulk scale processes (Hood et al., 2014a). Flow ratio of solvent to 
aqueous stream was 20, at total flow rates of 112 µL/min (Hood et al., 2014a). Dev et 
al. developed a continuous flow microfluidic system for the preparation of polymer 
coated nanoparticles in a scalable microfluidic system (Dev et al., 2011). The 
nucleation process was controlled by a rotating tube promoting high surface to volume 
ratios of the organic and aqueous streams, where the rotating speed was found highly 
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influencing the resulting particle size (Dev et al., 2011). Other than exploring 
continuous microfluidic tools in drug delivery technologies, a continuous version of 
microfluidic devices set in sequence was developed for automated nucleic acid 
purification. Therefore cell isolation, cell lysis, and chromatographic purification of 
nucleic acids was performed in sequential operation on a single chip, which was found 
to allow for sample processing in parallelised chips (Hong et al., 2004). With the 
reduced number of unit operations, development in hot melt extrusion (HME) 
processes demonstrated the interest in continuous manufacturing technologies 
(Andrews et al., 2009). Such HME processes have been used as an alternative method 
for tablet coating, in a process described as rapid and continuous (Andrews et al., 
2008). Furthermore, fluidised hot melt granulation processes have been reported for a 
continuous granulation process where excipients and active pharmaceutical 
ingredients were mixed and agglomerated into uniform particle blends (Andrews et al., 
2007).  
 
Work presented explored the nanoprecipitation technology, which has previously been 
translated into continuous flow processes in large scale. Other than work shown in this 
thesis, large scale static mixers have been used for the manufacturing of solid lipid 
nanoparticles. Flow rates ranged up to 100 mL/min. The nanoprecipitation method was 
described for its potential for scale-up, with minimal batch-to-batch variations based on 
the implementation of a continuous flow system (Dong et al., 2012). 
 
10.6 The importance of scale up and scalability  
The lack of scale-up technologies for drug-loaded nanoparticle manufacturing is one 
factor constraining market introduction (Galindo-Rodríguez et al., 2005). The phase of 
process scale-up is crucial, not only because it allows for realisation of a larger scale 
process but furthermore limitations negligible in smaller scale might become prominent 
factors in a larger scale process.  
 
Within work in this thesis, scale-up has been achieved by the increase in channel 
diameter and mixer parallelisation. Where the increase in channel diameter allowed for 
a seamless process transfer, particle characteristics and loading efficiencies were 
influenced in the continuous flow system. The reduced loading and changed particle 
characteristics may be associated with changes in pressure in the system, affecting the 
hydrodynamic conditions in the scale-up platform as seen with other work on scalability 
assessment of the nanoprecipitation method (Galindo-Rodríguez et al., 2005). The lack 
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of information regarding scale up technologies has been described to hinder the 
transfer of polymeric nanoparticle manufacturing (Galindo-Rodríguez et al., 2005). A 
scale-up version of the nanoprecipitation process has been described for 
manufacturing a 20-fold bigger volume of polymeric nanoparticles (Galindo-Rodríguez 
et al., 2005). Here, independent peristaltic pumps supplied the aqueous and solvent 
phase, which were mixed in a ‘Tee mixer’, where the nanoparticles formed immediately 
after both stream diffuse into each other in the mixer. The system was run at a solvent 
to aqueous ratio of 1:2 at a total flow rate of ca. 190 mL/min, which resulted in a 
difference in particle size of 35 nm from lab scale to pilot-scale process. This difference 
was attributed to changes in the hydrodynamic conditions, where enhanced 
turbulences in the pilot-scale process may have led to enhanced diffusion 
characteristics and reduced particle size, which resulted in a reduced loading efficiency 
(Galindo-Rodríguez et al., 2005).   
 
10.7 The role of process control and modelling  
Within this thesis a range of modelling tools were used to describe the process and aid 
the identification of the design space. This was achieved by design of experiments 
(DoE) and multivariate analysis (MVA) (Eriksson, 2006, 2008). Initially, three 
manufacturing methods, sonication, HSM and microfluidics were investigated in 
relation to the ability for controlling the size of the vesicles in a DoE approach. The 
DDA-TDB liposome formulation was used in the optimisation process as it is a well-
established cationic adjuvant formulation (Christensen et al., 2007b). For the sonication 
method, the sonication amplitude was found as the most important factor controlling 
vesicle size, whereas for the HSM process, the rotational speed was found as the most 
important variable in the process. In the microfluidics method, both factors TFR and 
FRR had a impact on the resulting liposome size, with the ratio between solvent and 
aqueous stream having the most significant impact, emphasised by the quadratic term 
FRR*FRR.  
 
Furthermore, effect of the factors TFR and FRR on liposome size, polydispersity and 
transfection efficiency (luciferase activity) was investigated in a response surface 
model. Model evaluation identified statistical significant models and regression models 
mathematically determined the liposome size, PDI and transfection efficiency as a 
function of the TFR and FRR in the microfluidics-based nanoprecipitation process for 
cationic DOPE-DOTAP lipids. Where the TFR was found less impacting the responses, 
the factor FRR was found significantly affecting the size, PDI and transfection activities. 
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Maximum luciferase activities around 250% were predicted for a FRR of 1:3, 
efficiencies were predicted above 180% for FRR between 1:2 and 1:4, independent of 
the TFR used. Model predictions were validated by direct comparison between 
predicted and experimentally obtained values. The setup was further investigated in a 
MVA approach. Here, the PCA and PLS models were used for cluster analysis and 
outlier detection, regression analysis and predictive modelling (Eriksson, 2006). During 
the cluster analysis, a link between FRR, PDI and size was identified, a similar trend 
seen in above DoE study, where a decrease in liposome size was predicted for an 
increase in FRR along with the increase in PDI. The PLS analysis confirmed the direct 
correlation between FRR and PDI, as well as a direct correlation between the liposome 
size and the transfection efficiency.  The strong link between particle characteristics 
(size, PDI) and FRR was revealed in both scores and loading plots, and confirmed 
above DoE evaluations. Such model analysis verified a mathematical proof that a 
better transfection results may be expected for vesicles with a larger size at a constant 
lipid/DNA ratio (Esposito et al., 2006; Felgner et al., 1987; Kawaura et al., 1998; McNeil 
et al., 2010).  
 
In contrast to OFAT experiments, predictive tools reassure a process or method in 
pharmaceutical development. The process understanding is deepened, and methods 
assist in development work and possible scale-up (Singh et al., 2005) whilst enhancing 
the reproducibility of a process and generating a design space, aligning with recent 
trends in biopharmaceutical and pharmaceutical development (Lawrence, 2008). Such 
MVA tools may accelerate the development process of a vaccine candidate due to 
characterisation by clustering of in-vivo specific immune responses, which generates 
future predictions of vaccine efficiency. A MVA study correlated and analysed in-vivo 
adjuvant activity based on a liposomal adjuvants containing the cationic lipid DDA and 
TDB, with well described adjuvant activity (Christensen et al., 2009; Christensen et al., 
2007b). Increasing levels of the saturated phosphatidylcholine, 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC) were incorporated into the DDA-TDB formulation, at 
a locked DDA-TDB molar ratio of 8:1. The resulting physical adjuvant properties were 
linked to adjuvant activity using a tuberculosis antigen vaccine candidate (H56) in a 
MVA model. Analysis revealed a clustered collectively as Th1-specific immune 
responses, as the responses INF-γ, IL-2 and IL-6 showed coincided coefficient profiles 
for the variables DDA and ZP. Analysis confirmed by statistical insignificance for the 
antibody subtypes, insignificant for the evaluation of vaccine efficacy. 
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10.8 Overall Conclusion 
 
To summarize, in relation to the aims and objectives highlighted in Chapter 1, studies 
within this thesis have shown that: 
 
1. Microfluidics-directed nanoprecipitation was used to formulate stable 
nanoparticles comprised of either lipids (high and low transition temperature), 
cationic amphiphiles with delocalized charge centres or polymers. 
2. The ratio of solvent of aqueous stream was the primary dominant factor for 
controlling the vesicle size. 
3. The total flow rate was the factor primarily dominating the throughput by the 
method for low transition temperature lipids. 
4. Vesicles manufactured with the microfluidics method had good transfection 
rates in standard transfection protocols. 
5. DoE and MVA studies linked the factor FRR to the resulting vesicle size and 
PDI, where the size of the particles was correlated to the transfection efficiency 
of lipoplexes. 
6. The incorporation of a low solubility model drug in the solvent stream lead to 
simultaneous encapsulation of the drug within the lipid bilayer. 
7. Increasing the channel diameter and parallelising the chips in a planar way lead 
to an overall 40-fold increase in throughput in a scale-up and scale-out format. 
8. A tangential flow filtration system based on microfluidics was developed, which 
allowed for continuous manufacturing and purification of liposomal products. 
9. MVA allowed clustering Th1 immune responses whilst relating physicochemical 
adjuvant characteristics to in-vivo derived immune responses upon delivery of a 
tuberculosis antigen. 
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